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CHAPTER I 
 
INTRODUCTION 
 
 
Statement of Problem 
 
 
Cancer affects all populations regardless of race, gender or age. Globally, 
one in four persons will die from cancer (Fearon et al., 2013). This pandemic 
indicates that the physical and psychological sequela of the disease is a common 
occurrence and affects not only the afflicted individual, but also those taking care 
of the patient, whether that is a doctor, nurse or family member (Hopkinson, 
2010) (Huhmann & Cunningham, 2005) (McClement, 2005). One debilitating 
aspect of cancer that affects about half of all cancer patients is cachexia (Suzuki, 
Asakawa, Amitani, Nakamura, & Inui, 2013) (Tisdale, 2009).  
Estimates indicate that up to 80% of all cancer patients experience 
cachexia (Walz, 2010). Cancer cachexia is a complex metabolic condition that is 
characterized by loss of skeletal muscle with or without loss of adipose tissue 
(Dodson et al., 2011) (Fearon et al., 2013). It is a syndrome associated with 
weight loss, lipolysis, muscle wasting, anorexia, chronic nausea, asthenia, with 
resultant changes in body image (Kim et al., 2012). Additionally, about 20%-30% 
of all United States cancer deaths are secondary to the debilitating effects of 
cachexia (Caro et al., 2007)(von Haehling & Anker, 2010) 
 This dissertation research focused on examining the relationship between 
cytokines, red blood cells (RBCs) and albumin in head and neck cancer (HNC) 
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patients and symptoms related to cachexia such as weight loss, fatigue, 
musculoskeletal dysfunction, swallowing, mucositis, anorexia, pain and 
depression.  HNC is defined by the International Agency for Research on Cancer 
as cancer that arises in the head or neck region, which anatomically includes the 
nasal cavity, sinuses, lips, mouth, salivary glands, throat and larynx. (National 
Cancer Institute, 2013). More than 90% of malignant neoplasias of the head and 
neck area are squamous cell carcinomas (Tribius & Hoffmann, 2013). In the 
current Globocan statistic, which ranks the most common cancer diagnosis 
globally, HNC of the lip and oral cavity are in 15th (2.1%), carcinoma of the larynx  
in 20th (1.2%) ,and oropharyngeal cancer in 22nd place (1.1%) (International 
Agency for Research on Cancer, 2008). Combined, HNC is the sixth most 
common cancer worldwide with approximately 650,000 new cases reported 
annually. HNC accounts for approximately 3-5 %of all cancers diagnosed in the 
US.  In 2013, approximately 55,000 new HNC cases were diagnosed in theUS, 
with a projected 30% increase to 80,000 new cases in 2015.(American Cancer 
Society, 2012). Despite treatment advances in multimodality therapy with 
surgery, radiotherapy, and chemotherapy, 5-year survival rate is still poor for 
patients with loco regionally advanced disease (Bonomi, Patsias, Posner, & 
Sikora, 2014). 
Patients with HNC are particularly vulnerable to developing malnutrition 
and anorexia due to tumor of the upper audiodigestive tract such as the oral 
cavity, larynx, pharynx, paranasal sinuses, and salivary glands that makes 
chewing, swallowing and digestion difficult (Vissink, Jansma, Spijkervet, Burlage, 
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& Coppes, 2003) (Larsson, Hedelin, Johansson, & Athlin, 2005) (Jager-Wittenaar 
et al., 2011) (Munshi et al., 2003) (Denis et al., 2004) (Ehrsson et al., 2010). 
Treatment such as radiotherapy and chemotherapy results in symptoms such as 
mucositis, dysphagia, xerostomia, altered taste and smells. (Vissink et al., 2003) 
(Larsson et al., 2005). These symptoms can lead to decreased food intake of 
energy and nutrients can cause anorexia and wasting contributing to cachexia.  
The combination of location and treatment, make patients with HNC particularly 
vulnerable to cachexia.  However, the association between symptoms induced by 
radiation and chemotherapy and the development and consequent progression 
of cachexia is not very well known in patients with HNC. 
As a patient progresses through the continuum of their disease, whether 
or not that is met with remission, spread or recurrence of their cancer, our 
understanding of the many symptoms that a patient experiences and the 
association between those symptoms and cachexia are not fully elucidated. The 
hallmark phenomenon of cachexia is muscle wasting. It would be expected that 
as muscle wasting occurs, that a patient would experience an increased level of 
fatigue, as many studies have demonstrated (Dodson et al., 2011) (Fearon et al., 
2013). However, within the HNC population what is not understood is how 
muscle wasting affects the development of other symptoms such as the ability to 
swallow and consume calories. Furthermore, what is less understood is the 
association between cytokine changes in HNC patients that both affect cachexia 
and symptom development. For example, does an increase in a particular 
cytokine promote muscle wasting that in turn promotes other muscle wasting that 
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increases the symptom burden that HNC patients experiences?  Does this 
muscle wasting have a direct effect on a function such as the ability to swallow, 
to worsening mucositis and depression, which are not necessarily a sequela of 
muscle wasting? Is it the cachexia that makes symptoms worse, or is it possibly 
symptom burden that promotes muscle wasting, or finally, is the relationship a 
combination of these two paradigms? In short, our understanding of the 
relationship between cachexia and symptoms is not understood. This is possible 
because the exact physiological and biological mechanisms that promote 
cachexia are not understood. This makes deciphering the cause and effect of 
symptoms and cachexia difficult to discern.  
As previously stated, the precise cause of cachexia presently remains 
unknown. Cachexia is a type of energy balance disorder, in which energy intake 
is decreased and/or energy expenditure is increased (Argiles, Busquets, 
Stemmler, 2014). A current accepted hypothesis is that the tumor produces 
cytokines, which affects metabolism and cellular respiration. Three physiological 
processes are affected by cytokines in the development of cachexia: 1) 
Cytokines cause an affect that ultimately promotes catabolism, specifically of 
muscle. Furthermore, the body also responds to cancer, possibly mediated by 
cytokines, by slowing the rate at which new muscle is produced. This leads to 
significant muscle wasting; 2) Adipose breakdown is promoted through various 
pathways. This lipolytic degradation promotes the breakdown of triacylglycerol’s 
into glycerol and non-essential fatty acids. Glycerol stimulates liver 
gluconeogenesis. The tumor subsequently uses this additional fuel for growth 
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and production of further cytokines enhancing the effects of cytokines on further 
metabolic alterations. The glucose consumption additionally increases lactic acid, 
which inhibits and stresses other metabolic processes and this process 
independently requires additional energy expenditure by the body for cellular 
respiration; 3) Altered metabolic processes caused by muscle and adipose 
breakdown work in concert to continue the production of “feeding” tumors 
through glucose and non-essential fatty acids which continues to stress the body 
through increasing energy consumption. The body, therefore, responds to the 
tumor by increasing cytokine production, which also contributes to further altered 
metabolic processes experienced in cancer. The exact feedback mechanisms for 
the multiple processes that enhance cachexia are not entirely elucidated 
presently.  
A key concept that appears to contribute to the severity of cachexia is 
cancer type. Cancer by nature is heterogeneous. There seems to be distinct 
differences between the cachexia experienced by different types of cancer. For 
example, it appears that persons with pancreatic cancer experience a greater 
severity of cachexia compared to those with HNC (Fearon et al., 2013). However, 
there are many possibilities of why the difference between different cancers 
occurs. Generally, pancreatic cancer is not diagnosed until the disease has 
progressed to stage IV and subsequently patients are considerably sicker at the 
time of diagnosis and treatment initiation in comparison to the HNC population 
(Bye et al., 2013). When the advanced disease is present, this may alter our 
ability to manage and diagnose the many negative impacts that cachexia 
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presents to the cancer patient in general. Nonetheless, no matter the type of 
cancer, cachexia poses a significant obstacle for the patient and clinician alike 
(Dalal et al., 2012). The greater the weight and muscle loss in cancer patients, 
the worse the outcome is for those patients (Fearon, Arends, & Baracos, 2012a) 
Confounding this problem, is also the variations in symptoms that patients 
experience in different cancers, through either disease progression or secondary 
to the effects of treatment. For example, the treatment modalities of HNC are 
different from those used in the treatment of pancreatic cancer. Therefore, 
symptoms are possibly affected by treatment, as well as by cytokines that are 
mediating the progression of cancer cachexia. Deciphering the noise between 
cytokines, cachexia, treatment and symptom burden is possibly impacted by the 
heterogeneous nature of cancer. Nonetheless, cachexia negatively affects all 
cancers, but what is less known are the different pathways that occur in various 
types of cancer.  
Overall, cachexia is a devastating component of cancer illness for many 
patients. Unequivocally, the greater the severity of cachexia, the worse the 
outcome is for the patient (Steinman & Deboer, 2012). Through the study and 
investigation of cachexia in the HNC patient, it may be possible to find the 
cellular links that perpetuate this process and subsequently enable the 
advancement of treatments for cachexia.  
 
 
 
 7 
Significance of the Issue and the Study 
 
 
 
Significance of the issue to society  
 
HNC, specifically those arising in the oropharyngeal region, are now 
believed to arise from two distinct pathways: one influenced by alcohol and 
tobacco and the other a result of genomic instability induced by human viruses 
such as the human papilloma virus (HPV), specifically HPV 16 (Andl et al., 1998) 
(Gillison et al., 2000) (Gillison et al., 2012) (Weinberger et al., 2006) (Tribius & 
Hoffmann, 2013) (Fakhry, Rosenthal, Clark, & Gillison, 2011) and the Epstein-
Barr Virus (EBV) (Han et al., 2012) (Chai et al., 2012). Currently, alcohol and 
tobacco-associated HNC is decreasing globally while HPV derived HNC is 
increasing (Turi et al., 2013). This trend was demonstrated in a large ten-year 
epidemiological study in Peru where an increase in observed HNC in males aged 
30-44 was 2.5%/ year, in females 15-29 4.2%/year, 30-44 3.4%/year (Walter et 
al., 2013). A similar increase secondary to HPV has also been reported in the 
United States. In 2000-2004 HPV comprised 38% of all HNC diagnosis in the 
United States and by 2009-2010, this increased to 59% of all HNC diagnoses 
(Wang, Thomas, & Zhang, 2012) (Chaturvedi et al., 2011). Other countries such 
as Denmark (Blomberg, Nielsen, Munk, & Kjaer, 2011) Germany (Guntinas-
Lichius, Wendt, & Buentzel, 2010) Sweden (Attner et al., 2010) (Hammarstedt et 
al., 2007), and the United Kingdom (Conway, Stockton, Warnakulasuriya, Ogden, 
& Macpherson, 2006) have also reported significant increases in HPV-associated 
HNC diagnosis. EBV has also been associated with HNC, but this association is 
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seen in more patients who reside in Northern Africa and Southeast Asia. Unlike 
HPV, EBV-associated HNC has not significantly increased within the United 
States (Thompson & Kurzrock, 2004) (Lewis & Chernock, 2014). Within the 
scientific literature, a great deal of information has been garnered in regards to 
the association of HPV and cancer. However, little has changed in terms of our 
understanding of the association between EBV and HNC (Lewis & Chernock, 
2014). 
The consensus is that HNC cancers secondary to viruses have better 
outcomes with tumors more responsive to both surgical and non-surgical 
therapies and a lower risk of dying from the disease. However, the exact 
rationale for this difference is not understood. To confound this thought process 
are research studies recently published indicating that perhaps viral-mediated 
HNC cancers do not convey as much of a survival benefit to those induced by 
alcohol and smoking. Most studies indicate a propensity for increased survival in 
the HPV-positive groups compared to the alcohol and tobacco groups (Ihloff, 
Petersen, Hoffmann, Knecht, & Tribius, 2010). However, other studies challenge 
this notion because they found no statistically significant difference between 
either HNC etiologies (Cerezo et al., 2014) (Sharma et al., 2012) (Stephen et al., 
2012) (Bragelmann et al., 2013). Increased survival has been attributed to the 
younger population of patients diagnosed with cancer and having less pro-
inflammatory exposure than those with a smoking and or high alcohol intake 
history. Overall, a large meta-analysis indicates no survival outcome benefit to 
those HNC patients with a viral etiology (Isayeva, Li, Maswahu, & Brandwein-
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Gensler, 2012). In terms of cachexia, the impact of the virally associated tumor 
on the symptomology and physiology of cachexia has yet to be determined, and 
studies examining this association need to be conducted. Smoking and 
excessive alcohol consumption independently is pro-inflammatory. This constant 
“assault” on the body through continual inflammation may be the reason that 
non-viral mediated cancers have worse outcomes. Nonetheless, whether the 
etiology is viral or non-viral, HNC patients experience anorexia and cachexia. 
The effects of cachexia negatively impact survival in the HNC population. With 
HNC diagnosis continuing to increase, more patients will be susceptible to the 
debilitating effects of cachexia. 
 With the combination of the number of HNC diagnosis increasing along 
with an estimated 15,000 deaths attributed to HNC annually within the United 
States, it is hypothesized that the number of HNC patients with cachexia is 
increasing as the population overall expands. Approximately, 80% of HNC 
patients experience cachexia (Gullett, Mazurak, & Hebbar, 2011)(Gullett et al., 
2011)  (Fearon, Glass, & Guttridge, 2012b) (Siddiqui, Pandya, Harvey, & Zaloga, 
2006)(Gullett et al., 2011). Therefore, it will be significant to understand the role 
of cachexia in weight loss and muscle wasting to combat the profound physical 
and psychological burden of this disease process.  
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Significance of the issue to the patient and caregiver 
 
 
Cachexia is a multidimensional syndrome characterized by involuntary 
weight loss, muscle atrophy, and physiological changes that lead to progressive 
functional impairment. Cachexia has a significant impact on patient morbidity and 
mortality, treatment tolerance, outcomes, and is an extraordinary source of 
psychological distress for patients and their families (Hopkinson, 2010) 
(Huhmann & Cunningham, 2005). Higher levels of depression, pain, decreased 
physical energy, performance and fatigue have been reported in patients with 
cachexia versus those that do not have cachexia (Giannousi, Gioulbasanis, 
Pallis, & Xyrafas, 2012) (Laird et al., 2011b) (Oz, Theilla, & Singer, 2008) 
(Wallengren, Lundholm, & Bosaeus, 2013)(Roberts, Frye, Ahn, Ferreira, & 
Judge, 2013). Overall, cachexia affects the cancer patient negatively and has 
repercussions for many aspects of daily living causing an increased need for 
support on the part of the patient.  
 The physical and psychosocial impact of cachexia on caregivers is 
profound (Longacre, Ridge, Burtness, Galloway, & Fang, 2012; Tamayo, 
Broxson, Munsell, & Cohen, 2010). HNC caregivers often report moderate levels 
of caregiving burden (Donnelly et al., 2008) (Chen et al., 2009; Ross, Mosher, 
Ronis-Tobin, Hermele, & Ostroff, 2010). Caregivers of cancer patients are often 
tasked with providing emotional support, taking patients to frequent clinic 
appointments, cleaning their homes and shopping for the patient (Precious, 
Haran, Lowe, & Rogers, 2012). In a recent HNC pilot study, caregivers (N=23) 
reported at least one neuropsychiatric symptom such as trouble with appetite and 
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eating, altered nighttime behaviors, depression/dysphoria, decreased alertness, 
inattention, apathy/indifference, anxiety, irritability/lability, agitation/aggression, 
and slowed behavior (Bond, Hawkins, & Murphy, 2014).  Delirium is a symptom 
that affects both the patient and caregiver increasing the stress and anxiety of 
the caregiver (Bond, Dietrich, Shuster, & Murphy, 2012). The exact impact of 
these reported neuro-psychiatric symptoms are not fully understood and need 
further study, but it could be hypothesized that the impact upon the caregiver will 
possibly be negative by increasing the psychological distress of the caregiver. 
With increased wasting, specifically of the muscles, patients require support with 
day-to-day activities of daily living. This requires caregivers to spend increased 
time and effort providing care increasing their likelihood of experiencing fatigue 
(Clark et al., 2014). Also, caregivers experience the psychological distress 
associated with witnessing the wasting of their loved one. This may result in 
“helplessness” and “hopelessness” because of the inability to reverse the 
syndrome and to help their loved ones “battle” their cancer.  In one study, 
caregivers reported cachexia, anorexia and fatigue as the three most stressful 
symptoms during the last week of life (Oi-Ling, Man-Wah, & Kam-Hung, 2005). 
Furthermore, loss of weight was associated with increased caregiver distress 
(Rhondali et al., 2012). The reflex reaction of caregivers is to encourage their 
loved one to eat and drink may result in rising interpersonal and familial stress as 
well as the feeling of failure among caregivers as unfortunately, increasing 
calories does not thwart cachexia (Tisdale, 2009). A further discussion on this 
occurs later in this chapter.  
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 Due to the location of the HNC, many patients experience dysphagia and 
this decline in swallowing ability can increase caregiver fatigue through the 
necessity of planning meals and potentially isolating the caregiver from their 
normal social network by preventing the ability to dine at restaurants (Patterson, 
Rapley, Carding, Wilson, & McColl, 2012).  Additionally, many HNC patients 
require insertion of feeding tubes to combat the inability to consume adequate 
calories, and this too requires caregiver management and can cause an increase 
in anxiety among those charged with caring for the patient at home (Penner, 
McClement, Lobchuk, & Daeninck, 2012).  
Overall, the muscle and adipose wasting experienced by cancer patients 
is both distressing to themselves and to those that provide care to them. With 
little evidence-based medicine available to counter this weight loss, distress is 
elevated and therefore finding the associated physiological pathways involved in 
cachexia is paramount to treating this devastating aspect of cancer.  
 
Significance of the issue to healthcare 
  
The National Institutes of Health (NIH) estimated that in 2009 the overall 
annual costs of cancer were as follows: Total Cost- $216.6 billion; Direct medical 
costs (total of all health expenditures): $86.6 billion; Indirect mortality costs (cost 
of total productivity due to premature death): $130 billion (American Cancer 
Society, 2014). Cachexia affects patients’ outcomes by decreasing the ability of 
cancer patients to tolerate therapy as well as decreasing quality of life. A weight 
loss of more than 5% at the time of diagnosis has been associated with 
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decreased response to medical interventions and increased mortality. The direct 
medical costs of cachexia are difficult to tabulate due to a lack of data and to 
date the NIH and the American Cancer Society do not have an estimated 
calculation available. A recent study estimates that in 2009 there were over 
161,000 admissions for cancer cachexia (Arthur et al., 2014). These admissions 
cost on average $4600 more compared to cancer admission for non-cachectic 
reasons. A tabulation of the costs of cachexia includes therapeutic diets, 
nutritional supplements, medications, laboratory tests and other indirect medical 
costs related to the provision of care (Tan & Fearon, 2008). Furthermore, 
involuntary weight loss is associated with anemia, cognitive dysfunction and 
other sequela such as postural hypotension that can lead to an increased risk of 
falls and injury (Knudtson, Klein, Klein, & Shankar, 2005). According to Tan & 
Fearon, 2008, the economic costs of cachexia extend much further than the 
costs of therapeutic diets, nutritional supplements, medications, laboratory tests 
and supplies. The tabulated calculation must also include the provision of 
medical care that is provided by staff, service costs, as well as indirect medical 
costs.  Patients with weight loss, specifically lean body mass, require increased 
attention by either medical professionals or by family members. Each of these 
directly increases the costs of cachexia. Overall, the Arthur et al., (2014) paper is 
the first to begin assessing the costs of cachexia, demonstrating that cachexia 
increases the costs of cancer treatment.  
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Significance to science/discipline of nursing and knowledge gaps 
 
Significant research gaps remain in regards to the underlying biological 
mechanisms surrounding cachexia not only in cancer patients but also within 
chronic disease states such as congestive heart failure, renal failure, and chronic 
obstructive pulmonary disease. Currently, the underlying mechanism of cancer 
cachexia remains to be completely elucidated (Fearon et al., 2012a) (Vaughan, 
Martin, & Lewandowski, 2012) (Argiles et al., 2011) (Blum et al., 2011) (Bennani-
Baiti & Walsh, 2009). Our inability to fully understand the physiological pathways 
of cancer translates into our inability to treat patients who experience cachexia. 
Additionally, cachexia is often not diagnosed until the symptoms are quite severe 
(Fearon et al., 2013). This is primarily in response to a disagreement among 
clinicians about what the diagnosis of cachexia should be currently. A further 
discussion of this issue occurs in chapter 2. This complexity and non-uniformity 
surrounding cachexia as well as our lack of physiological understanding of the 
process, unfortunately leaves the nurse at the forefront of delivering care to 
patients with cachexia with little in their armamentarium to actually treat and 
assuage the tedious progression of cachexia. 
It is possible that our lack of understanding the pathology of cachexia has 
meant an inability to develop evidence-based practice guidelines to assist the 
nurse in their task of caring for the cachectic cancer patient. Once cachexia is 
established in a patient, there are limited therapies that can be initiated, with 
most therapies targeted at palliation of the weight loss. The only possible 
effective treatment has been a combination of delivering adequate dietary protein 
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in combination with progressive resistance exercise. However, even that 
intervention was targeted at sarcopenic patients and not necessarily those with 
confirmed cachexia (Marcell, 2003). With little to offer patients and their families, 
nurses must care for their patient in a holistic non-evidence based directional 
approach to care for the cachectic patient. Without any evidence-based practices 
to guide the nurse, they must provide care that is of the essence of what nurses 
do and that is to place the patient in the best possible position to allow nature to 
heal. Beyond that, the ability to specifically treat cachexia is limited.   
  To date, pharmacological interventions have failed to demonstrate a 
clinically significant impact on cachexia or disease outcomes in patients with 
advanced cachexia. In a recent small study, 62 patients with cancer cachexia 
were placed in a three arm three month study examining 1) megestrol acetate 
(MA) plus meloxicam (n = 23); 2) MA plus meloxicam plus oral eicosapentaenoic 
acid (EPA)-enriched nutritional supplement (n = 21); or 3) meloxicam plus oral 
EPA-enriched nutritional supplement (n = 18) (Kanat et al., 2012). No statistical 
significance were obtained between body weight, lean muscle mass, BMI or 
quality of life. A recent study examining the effects of simvastatin on cachexia 
has been carried out in rats due to the anti-inflammatory properties that statin 
drugs have with a decrease in cachexia symptoms in the treatment group (Palus, 
Haehling, Flach, & Tschirner, 2013). A follow-up study examining statin effects 
on humans with cancer has not been conducted. Again, with no actual definitive 
approaches to treating cachexia, the nurse must rely on fundamental nursing 
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principles to care for their patients. One agent that held promise for use was 
Ghrelin.  
Ghrelin, an endogenous orexigenic hormone, does hold some promise for 
attenuating cachectic symptoms in humans. It is posited that Ghrelin increases 
appetite via melanocortin modulation in conjunction with its anti-inflammatory 
effects, which possibly decreases the effects of cachexia. (Steinman & Deboer, 
2012). Again, Ghrelin effects on humans with cachexia is still largely unknown, 
and the use of Ghrelin has not been uniformly adopted (DeBoer, 2010). The 
short-term use of melatonin has also not demonstrated any benefit in regards to 
reversing cachexia symptoms (Del Fabbro, Dev, Hui, Palmer, & Bruera, 2013). 
Overall, there are no pharmacological interventions that can be used to combat 
cachexia. Rather, treatment must be aimed at reducing the different symptoms of 
cachexia such as fatigue, pain, muscle wasting, decreased ability to tolerate 
treatment, anorexia, malnutrition and an overall decline in the quality of life. 
Nurses, without having specific interventions available for cachexia, must rely on 
their nursing skills to treat the many sequelae of cachexia. One such treatment 
modality that many nurses strive to ensure is that their patients are consuming 
adequate calories. Unfortunately, the effects of cachexia are not assuaged by 
sufficient caloric intake.   
A common hypothesis is that treating cachexia through nutritional 
interventions is the most prudent way to combat the debilitating effects of 
cachexia. However, no single intervention to improve appetite has been able to 
demonstrate a reversal in cachexia (Yavuzsen, Davis, Walsh, LeGrand, & 
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Lagman, 2005). A recent meta-analysis indicates that despite nutritional 
interventions to improve outcomes in patients with cancer and cachexia, reversal 
of cachexia effects could not be achieved and no reduction in mortality has been 
obtained (Baldwin, Spiro, Ahern, & Emery, 2012). Dietary supplementation and 
appetite stimulation alone are inadequate to reverse the underlying metabolic 
abnormalities of cancer cachexia and have limited the long-term impact on 
patient quality of life and survival (Dodson et al., 2011). This is again because 
cachexia is in and of itself is a condition that places the body in a negative caloric 
expenditure. In a study that delivered “adequate” calories through TPN, wasting 
still occurred in patients (Evans et al., 1985). Caloric intake presently is not the 
answer for treating cachexia. The nurse must understand this and must teach 
family members who are watching their loved ones “waste away” that increasing 
caloric intake will not improve cachexia.  
Other factors such as nausea and vomiting decrease the ability of cancer 
patients to tolerate food. However, despite proper nursing and the delivery of 
medicines to decrease nausea and vomiting, cachexia itself will not reverse 
because the patient can increase their food intake. This can be distressing to all 
care providers. While nausea and vomiting needs to be thwarted, there are very 
little evidence-based guidelines to guide medical providers in their ability to 
combat this debilitating process (Laugsand, Kaasa, & Klepstad, 2011; Naeim et 
al., 2008). Prophylactic treatment of nausea and vomiting prior to chemotherapy 
is highly recommended, but the exact guidelines for doing so are not uniform 
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(Vidall et al., 2011; Schulmeister & Gobel, 2008).  Uncontrolled pain can also 
confound nausea and vomiting. 
Nurses handle adequately assessing the pain experienced by their 
patients and to ensure a proper intervention has been conducted to reduce a 
patient’s pain. Ensuring that cancer patients have adequate pain control is 
important in aiding their ability to function and increases their quality of life. Pain 
control in the cachectic patient can inadvertently cause worsening cachectic 
symptoms by causing patients to become somnolent and not eat, as well as 
cause opioid-induced nausea and vomiting. Furthermore, opioids can cause 
gastroparesis causing bloating and often the development of ileus, which 
decreases the bodies’ ability to consume calories due to an improperly 
functioning gut (Mehendale & Yuan, 2006; Kurz & Sessler, 2003). Early 
treatment and prevention of the ill effects of opioids on the gastrointestinal track 
is recommended (Holzer, 2010). With so many symptoms appearing in cancer 
patients such as pain, fatigue, nausea and vomiting there is a possible 
association between the severity of these symptoms, decreased levels of quality 
of life and worse outcomes. However, an exact association is still lacking in the 
HNC population. This lack of association, unfortunately, means that there are 
very few evidence-based approaches that nurses can use to treat cachexia. The 
inability to treat cachexia can decrease a person’s quality of life.  
The quality of life, as sometimes measured by levels of fatigue and pain, 
and its overall association with the severity of cachexia is unknown. It is posited 
that worse QOL indicators would correlate with worse cachexia, but this 
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association has not been fully elucidated though evidence does suggest that 
there is an association between these concepts. Early treatment and intervention 
of cachexia have been demonstrated to improve patient quality of life (Vigano, 
Del Fabbro, Bruera, & Borod, 2012) (Parmar, Swanson, & Jagoe, 2013). 
Whether or not this translates into increased survival and decreased recurrence 
rates is unknown. Nurses, through many of their interventions, can improve the 
quality of life. Understanding these associations is important in the treatment of 
cancer and cachexia.  
Thus far, it has been demonstrated that there are no pharmacological 
interventions that are effective in combatting cachexia.  Furthermore, impacts on 
patient’s quality of life secondary to cachexia are also not fully understood. The 
lack of treatment modalities for cachexia comes from our lack of understanding 
cachexia physiology. The physiological cascade that occurs at the cellular level 
when cancer is present resulting in cachexia is now only starting to be 
illuminated. Cachexia is attributed to tumor and humoral cytokine production, 
which promotes muscle depletion as well as inhibition of new muscle production. 
  Due to the lack of effective interventions, nurses at the front line working 
with patients as they progress in their cancer disease burden must provide 
nursing care, comfort and education to patients with cancer cachexia as well as 
to their caregivers. Nurses handle understanding the many components that 
drive cachexia to help manage and treat the many symptoms of cachexia. To 
continue to help those nurses on the frontline deliver the best care possible 
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continued research into the physiology and targeted treatment modalities must 
continue.  
Overall, there is a significant lack of understanding regarding the 
physiological pathways of cancer cachexia. This absence of data directly 
translates into fewer treatment modalities available for health care professionals 
to provide to their patients. Continued research into the physiology of cachexia is 
paramount to our ability to eventually treat and perhaps thwart this terrible 
sequela of cancer and thereby improve outcomes. 
 
Summary of overall significance 
 
 
 Cachexia affects the majority of cancer patients, including those with HNC 
While it is important to study cachexia about all cancers, it should be noted that 
each cancer presents itself with different obstacles in terms of treatment. HNC 
causes unusual sequela of events for a patient compared to other cancers such 
as primary tumors of the breast, colon or lung. Due to that reason, it is imperative 
that the study of cachexia be investigated in a multitude of different cancers to 
assess the various manifestations of secondary symptoms that accompany the 
disease process. For example, is cachexia different for the lung cancer patient 
who cannot breathe versus the HNC patient who can no longer swallow? Do the 
manifestations of other symptoms, such as depression, fatigue, and social 
isolation affect HNC patients who have cachexia differently than those 
manifested in breast cancer patients? Currently, the state of science cannot 
answer these questions and, therefore, while it will be important to utilize the 
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science of cachexia in other cancers, it will be important to study HNC in its entity 
to define those unique aspects that affect cachexia within this patient population.  
 In addition to studying HNC patients singularly with or without cachexia, it 
should be recognized that any study of cachexia will help move the scientific 
communities understanding of the disease process forward as, overall, there is a 
lack of understanding regarding thee physiology of cachexia itself. Due to this 
lack of physiological understanding, our ability to not only diagnose cachexia is 
affected, but there are limited abilities to actually treat cachexia once it is 
diagnosed aside from palliation. Overall, our understanding of cachexia is limited 
and further studies of this devastating secondary process during cancer are 
necessary in order to improve our physiological underpinnings to cachexia with 
the ultimate goal of being able to treat and possibly thwart the process in its 
entirety in the future. Through this ability, we can save the lives of many cancer 
patients.  
 
Purpose of the Study 
 
 The purposes of this study is to examine the relationship between 
cytokines, red blood cells (RBCs) and albumin in head and neck cancer (HNC) 
patients and symptoms related to cachexia such as weight loss, fatigue, 
musculoskeletal dysfunction, swallowing, mucositis, anorexia, pain and 
depression.  By identifying potential correlatives with different biomarkers, it may 
become possible to develop future treatment modalities aimed at reducing the 
negative cascade that some biomarkers may be initiating. Furthermore, 
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identifying correlatives between symptoms and weight loss with specific 
cytokines can inform future research to both increase our ability to palliate the 
cachectic patients as well as identify further bench science to examine specific 
cytokines and the metabolic processes those identified cytokines promote. 
Specific aims for this study include: 
1. To examine cytokines, red blood cells and albumin in HNC patients.  
2. To examine the role of cytokines, red blood cells and albumin and severity 
of weight loss in HNC patients.  
3. To examine the association between cytokines, red blood cells, and 
albumin and reported symptoms in HNC patients.  
4. To examine the association between cytokines and changes in 
musculoskeletal function in HNC patients. 
 
 
Research Questions 
 
Question 1: Do baseline red blood cells (RBCs) and albumin correlate with 
changes in cytokine levels at 6- and 12-months?  
Question 2a: Are baseline cytokines, red blood cells and albumin correlated with 
weight loss at 6- and 12-months? 
Question 2b: Does a change in cytokine levels from baseline to 6-months 
correlate with weight loss at 12-months?  
Question 3: Are initial cytokines, RBCs and albumin associated with changes in 
reported symptoms such as: depression, nutrition consumption, swallowing 
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difficulties, mucositis, generalized pain, mouth pain, dental discomfort, hearing, 
xerostomia, taste, jaw movement and voice at 6- and 12-months? 
Question 4: Are baseline cytokines associated with musculoskeletal impairment 
(neck and shoulder movement) as measured by shoulder and neck ranges of 
motion, swallowing and neck disability at 12-months? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 24 
CHAPTER II 
 
 
LITERATURE REVIEW 
 
History of the Problem of Interest 
 
In 1980, (Dewys et al., 1980), published the first paper addressing 
outcomes about weight loss within cancer patients. It was demonstrated that a 
>5% unintentional weight loss was able to predict mortality and response to 
treatment. However, a review of human history indicates that people have been 
struggling with cachexia in various forms for centuries. An article by (Ben-Noun, 
2004), demonstrates the biblical description of weight loss and depression 
experienced by King David, who himself may have had cancer. Elizabeth I, 
Queen of England (1533-1603) also indicates depression, altered body image 
and taste changes in her final days (Bennani-Baiti & Walsh, 2009). The term 
cachexia is derived from the Greek word ‘kakos’ (bad) and ‘hexis’ (habit). The 
word anorexia is from the Greek ‘an’ and ‘orexis’, which together mean no 
appetite, i.e. loss of appetite (Ben-Noun, 2004). This wasting and loss of appetite 
is experienced in most cancers.   
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Analysis of Relevant Literature 
 
Head and neck cancer is one of the several types of cancer that causes 
cachexia. As such, while this dissertation will study the HNC population, this 
evaluation of cachexia science in this chapter will analyze the science not only 
specific to HNC, but to other types of cancers. This broad overview of cachexia 
will help guide the physiological and diagnostic principles established through 
scientific research to date and will allow a more comprehensive presentation. 
Furthermore, our understanding of cachexia physiology is promoted through 
research no matter the type of cancer in question. It should be noted that it 
appears that the same mechanisms that cause cachexia in HNC are the same in 
other cancers. 
 
The biology, symptoms and treatment of cancer cachexia 
 
Different mechanisms by which cachexia occur is currently being 
examined. There are three main areas of research that guide cachexia research 
today. They are: 1) the biological processes by which adipose and muscle 
tissues is lost during cancer; 2) the mechanisms that drive those biological 
pathways and 3) the mechanisms by which inflammatory processes affect the 
brain, specifically the hypothalamus, and subsequent anorexia development that 
further potentiates the effects of cachexia. Overall, our knowledge regarding the 
biological process of cachexia is not completely understood.  
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 Cachexia is a relevant comorbid condition of chronic diseases including 
cancer. Inflammation, oxidative stress, autophagy, the ubiquitin-proteasome 
system, nuclear factor (NF)-kappaB, and mitogen-activated protein kinases 
(MAPK) are all involved in the pathophysiology of cancer cachexia (Chacon-
Cabrera et al., 2014). Presently, it is not certain whether the metabolic drivers of 
cachexia, specifically cytokines, are a byproduct of the tumor or a byproduct of 
host inflammatory cells. One hypothesis is that both tumor cell production and 
pro-inflammatory cytokines from the host inflammatory cells respond to tumor 
cells and that this response is the source of an acute phase protein increase 
seen in cachexia (Donohoe, Ryan, & Reynolds, 2011). However, the mechanistic 
physiological steps of subsequent adipose and skeletal muscle are unknown. 
Generally, in humans, the tumor size is less than 1% of an individual’s mass 
when there is profound cachexia suggesting the metabolic demands of the tumor 
are less important than distant metabolic effects induced by the tumor upon the 
host (Fearon et al., 2012a) (Roshani, McCarthy, & Hagemann, 2014). Further 
evidence for this hypothesis is supported by the same tumor burden causing 
different manifestations of cachexia in different persons (Tan & Fearon, 2008). 
These differences are probably based in genetics (Derynck, Akhurst, & Balmain, 
2001) (Saini, Al-Shanti, & Stewart, 2006). 
Different metabolic processes affect the loss of muscle and adipose tissue 
as well as the process by which the human body regulates its diet. These 
metabolic processes are not fully understood negatively impacting the ability to 
develop therapies to counter the devastating effects of cachexia. Thus, our 
 27 
limited understanding of these pathways directly affects our ability to treat 
cachexia. It is imperative that studying of these pathways not only to understand 
cachexia physiology, but also also to develop novel therapies to abate potentially 
the effects of cachexia. Furthermore, cachexia is often not identified and treated 
in late stages of the process are occurring making reversal of cachexia very 
difficult to obtain (Tan, Deans, Skipworth, Ross, & Fearon, 2008).  
 Cytokines are protein molecules released by lymphocytes or monocyte 
macrophages, and in some instances the same cytokine can be released by both 
organelles (Germolec, Frawley, & Evans, 2010). The production of chemical-
mediators associated with cachexia is derived from either the tumor or from 
humoral factors, which are mainly exhibited in the form of cytokines that are 
derived from cellular responses in the tumor microenvironment (Bing & Trayhurn, 
2009) (Bing, 2011). Several cytokines have been linked with cachexia. However, 
one difficulty in the identification of cachexia is that consistent results between 
different cytokines and cachexia development have not been elucidated.  
 Macrophages, dendritic cells, fibroblasts, NK cells, T and B cells, 
keratinocytes and tumor cells produce Tumor Necrosis Factor Alpha (TNF-α). It 
was originally named “cachectin” due to its catabolic nature. At the time of its 
discovery, it was shown to induce cachexia in mice after ovarian cancer was 
transfected with the human gene for TNF-α (Oliff et al., 1987) as well as to slow 
the insulin signaling pathway (Hotamisligil, 1999). However, TNF- alpha has not 
consistently demonstrated a cause and effect of the development of cachexia 
(Maltoni et al., 2001). In a recent study of 32 HNC patients, no association was 
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found between TNF-α levels and weight loss (de Carvalho et al., 2013). 
However, within HNC, a majority of cancer is correlated with alcohol 
consumption, and a significant difference in TNF-α levels between these groups 
has been seen, but these levels did not correlate with weight loss (Heimdal, 
Aarstad, Klementsen, & Olofsson, 1999). 
Multiple animal studies indicate that TNF-α is a cytokine that frequently 
induces cachexia (Tisdale, 2005). In one study of 63 persons with pancreatic 
cancer, only 36.5% of them had detectable levels of TNF-α, with higher levels in 
those with metastatic disease (Karayiannakis et al., 2001). An examination of 
tumor TNF-α production does not demonstrate that tumors are independently the 
source of increased TNF-α in all cases of cachexia (Fearon et al., 2013). 
Unfortunately, while it is known that TNF-α directs catabolism, the exact 
mechanism in vivo remains elusive (Laine, Iyengar, & Pandita, 2013). TNF-α 
appears to be a stimulus for the production of other catabolic cytokines that 
subsequently cause the development of cachexia (Argiles, Busquets, Stemmler, 
& Lopez-Soriano, 2014). This conclusion is further supported by evidence that 
intraperitoneal injection of soluble recombinant human TNF-receptor antagonist 
improved anorexia in tumor-bearing animals (Torelli et al., 1999). 
A recent study also showed a reversal in cachexia in humans with TNF-α 
antibody treatment, but the exact mechanism is not understood (Jatoi et al., 
2010). Further complicating the picture of TNF-α in cancer is the fact that it 
appears to be able to act as both a tumor promoter as well as a tumor inhibitor 
(Balkwill, 2002). Additionally, TNF-α appears to affect the hypothalamus through 
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pro-inflammatory signals that affect neurotransmitters and subsequent hunger 
signaling to patients perpetuating the cycle of cachexia by inducing anorexia 
(Amaral et al., 2006). TNF-α also promotes fat lipolysis and fat depletion (Tsoli & 
Robertson, 2013). TNF-α has also been recently identified to regulate lipolysis 
through the GO/G1 switch gene 2 (GOS2). By inhibiting the expression of GOS2, 
an increased level of lipolysis occurs (Yang, Zhang, Heckmann, Lu, & Liu, 2011). 
Presently, it appears that TNF-α directly relates to adipose tissue loss, but not 
directly to the loss of muscle protein (van Hall, 2012). 
 A closely related member of TNF-α is the TNF-like weak inducer of 
apoptosis (TWEAK). It is a regulator of inflammation and skeletal muscle mass 
and works through binding to Fn14 (fibroblast growth factor-inducible receptor 
14), which is a cell-surface receptor that is linked to various intracellular signaling 
pathways. The TWEAK-Fn14 axis handles the promotion of tissue repair 
following an acute injury. It is now recognized as a novel inducer of skeletal 
muscle wasting (Kumar, Bhatnagar, & Paul, 2012). The TWEAK-Fn14 can 
contribute to starvation-induced muscle atrophy (Penna et al., 2013). Genetic 
ablation of TWEAK in a murine model has demonstrated a decrease in the loss 
of muscle mass (Mittal et al., 2010).  
 TWEAK suppresses satellite cell self-renewal reciprocally regulating 
NOTCH and NF-ΚB  and P38 mitogen-activated protein kinase (MAPK) 
pathways. In short, TWEAK up-regulates NF-ΚB  levels, which have been linked 
to the progression of cancer-related symptoms including cachexia (Gupta et al., 
2011) (Cleeland et al., 2003; Myers, 2008) (Rhoads, Kandarian, Pacelli, 
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Doglietto, & Bossola, 2010). Interleukin-1 can also activate the NF-KB  pathway 
(Johns, Stephens, & Fearon, 2013). NF-KB is a protein complex that controls 
transcription of DNA and is found in almost all animal cell types. In regards to 
cachexia, NF-ΚB has been linked to muscle-protein breakdown and wasting (Op 
den Kamp et al., 2013). This muscle wasting appears to be regulated by the 
ability of NF-ΚB to increase Pax7 expression, which inhibits myofiber 
regeneration leading to muscle wasting (He et al., 2013). Additionally, TWEAK 
handle up-regulation of the E3 ubiquitin ligases MuRF1 (muscle ring finger 1) 
through NF-ΚB signaling. The ubiquitin-proteasome pathway/ubiquitin-mediated 
proteolytic (UPP) system is involved in the disease-related hyper catabolism 
(Mitch & Goldberg, 1996). The UPP handles protein catabolism at the 
mammalian cytosol and nucleus. MuRF1 participates in the regulation of amino 
acid metabolism, including the control of free amino acids and their supply to 
other organs under catabolic conditions and in the regulation of ATP synthesis 
under metabolic stress conditions where MuRF1 expression is induced (Koyama 
et al., 2008). This up-regulation results in the loss of myosin heavy chain (MyHC) 
and other thick filament components (Cohen et al., 2009). The inhibition of the 
NF-ΚB  induced MuRF1 pathway has demonstrated the decrease of muscle 
wasting in mice (Moore-Carrasco et al., 2007). Further studies surrounding the 
regulation of P38 MAPK needs be conducted to identify the exact mechanism 
through which protein synthesis is decreased (Wing, 2013). Presently, strong 
evidence exists that tumors directly induce signaling pathways that upregulate 
enzymes that induce skeletal muscle breakdown. However, in the absence of 
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these pathways, such as MuRF1, muscle breakdown does not occur despite 
tumor burden, further indicating that genetics possibly dictate the 
microenvironment response to the tumor..  
 However, conflicting evidence has recently been reported in regards to 
both serum TWEAK levels and tumor TWEAK levels in HNC patients (Aviles-
Jurado et al., 2014). Study participants who had lower TWEAK serum levels had 
significantly increased recurrence of disease (N=37). Furthermore, higher 
TWEAK levels within the tumor were correlated with worse prognosis. However, 
an examination of these levels and weight loss was not conducted in this study. It 
can be speculated that elevated TWEAK levels hinder tissue repair through the 
promotion of catabolism, which enhances cachexia. Further studies examining 
this association will need to be conducted in a large RCT.  
 TNF-α and TWEAK appear to work in concert with the cytokine interleukin 
6 (IL-6) in the progression of cachexia. IL-6 stimulates the liver to induce an 
acute phase response. However, unlike TNF-α, circulating levels of IL-6 have 
been shown to correlate with weight loss and survival in cancer patients, (Scott, 
McMillan, Crilly, McArdle, & Milroy, 1996) (Moses, Maingay, Sangster, Fearon, & 
Ross, 2009) as well as a predictor of survival in patients with advanced cancer 
(Suh et al., 2013). Macrophages, dendritic cells and T and B cells produce IL-6. 
IL-6 levels have been shown to increase significantly in head and neck cancer 
patients (Pries & Wollenberg, 2006) (Richey et al., 2007). In a large prospective 
cohort study of HNC patients, higher IL-6 levels were significantly associated with 
worse overall prognosis (n-444) (Duffy et al., 2008). However, in a recent study 
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of lung and colorectal cancer patients, elevated IL-6 levels did not significantly 
correlate with weight loss until after 6-months duration (Kim et al., 2012). 
However, in an attempt to understand the association between levels of IL-6 and 
muscle wasting, only supra-physiological levels of IL-6 when administered to 
healthy animals, in the absence of disease, was sufficient to initiate muscle 
wasting and subsequent loss (Baltgalvis et al., 2008). Additionally, a recent trial 
of IL-6 monoclonal antibody in weight losing lung cancer patients has shown 
reversal of anorexia, fatigue and anemia, but not of muscle atrophy (Bayliss, 
Smith, Schuster, Dragnev, & Rigas, 2011). IL-6 has also been shown to stop 
muscle catabolism but was unable to reverse the depression of muscle synthesis 
(White et al., 2012). From a prognosis perspective, it appears that IL-6 rises in 
the final week before death (Martin et al., 1999). IL-6 seems to elevate slowly at 
the initial onset of cachexia and increase exponentially at the end of life (Tisdale, 
2009).  
 IL-6 has been additionally linked to cachexia within the concept of fat-
muscle crosstalk, specifically in the setting of the C26 tumor (Das et al., 2011). 
Physiological important crosstalk between adipose tissue and skeletal muscle 
exists in the context of cancer cachexia (Zechner et al., 2012). In a recent study, 
autophagy was shown to increase in mice implanted with C26 tumor (Penna et 
al., 2013). Ablation of the adipose triglyceride lipase, also known as hormone-
sensitive lipase, (Das et al., 2011), was able to preserve muscle mass. This data 
suggests that the tissue cross-talk between tumor, fat and muscle is important to 
our understanding of the cachectic process.  
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 C26 abundantly secretes myostatin, which is a member of the 
transforming growth factor-beta family. Myostatin regulates the glucose 
metabolism of muscle cells while deregulated myostatin activity is associated 
with some metabolic disorders, including muscle cachexia, obesity and type II 
diabetes (Liu et al., 2013). Through the activation of the UPP, myostatin has 
been shown to upregulate MuRF1 and NF-κB . Myostatin also inhibits the activity 
of IGF-1. The skeletal muscle cells further secrete myostatin and first signals 
through the activin type II receptor, which then recruits Akt family kinase resulting 
in the activation of SMAD2 and SMAD3 transcription factor complexes. Akt, in 
conjunction with TORC1, is down-regulated resulting in a decrease in muscle 
protein production (Thomas & Mitch, 2013). By inhibiting myostatin, a reduction 
in muscle wasting has been accomplished. Within a mouse model, myostatin 
antagonism demonstrated the ability to prevent cachexia (Benny Klimek et al., 
2010). Furthermore, in a separate mouse model, the utilization of actRIIB 
antagonism inhibited myostatin thus blocking MuRF1 and improving muscle 
mass and weight (Busquets et al., 2012). Furthermore, inhibition of the FoxO 
transcriptional factor also blocked MuRF1 and prevented muscle atrophy (Reed, 
Sandesara, Senf, & Judge, 2012). The recent successes in mouse models 
regarding myostatin holds promising leads into the quest to reverse and prevent 
cachexia. The muscle weakness produced by myostatin has also been linked to 
increased diaphragmatic weakness in patients leading to profound respiratory 
failure and intubation (Roberts et al., 2013). 
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 Three major proteolytic pathways responsible for the degradation of 
proteins in skeletal muscle exist. These are 1) the lysosomal system including 
the cysteine proteases cathepsins B, H and L as well as the aspartate protease 
cathepsin D (Tisdale, 2009). When myostatin was inhibited causing a decrease 
in MuRF1 up-regulation, there was also a subsequent decrease in cathepsins L 
(Busquets et al., 2012). 2) Protein degradation through the UPP. This pathway is 
the main driver behind the degradation of myofibrillar proteins, especially in 
patients with a weight loss of greater than 10% (Khal, Hine, Fearon, Dejong, & 
Tisdale, 2005) (Smith, Khal, & Tisdale, 2005). The exact process by which the 
UPP promotes protein degradation is not known but is possibly associated with a 
genetic component that takes its initiation from cytokine mediators (Bhattacharya 
et al., 2014)  3) The calcium-activated system. Research suggests that 
myofilaments are released from the sarcomere by the action of calcium-activated 
calpains followed by the degradation of the myofilaments by the ubiquitin-
proteasome system (Adams, Anker, & Schuler, 2011). This process in 
conjunction with the UPP drives muscle degradation further.  
 Further muscle breakdown can be initiated by the tumor itself through the 
production of proteolysis-inducing factor (PIF). The action of PIF is mediated 
through a high-affinity membrane receptor in muscle (Mirza, Wyke, & Tisdale, 
2011). PIF has been shown to increase directly the activity of the UPP (Russell, 
Siren, Siren, & Tisdale, 2010). The exact role of PIF is not entirely understood. 
Several studies have correlated a presence of PIF in the urine of cachectic 
patients that was related to weight loss (Wang et al., 2003) (Williams et al., 
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2004), while other studies have questioned this association (Jatoi et al., 2010) 
(Whitehouse, Smith, Drake, & Tisdale, 2001). 
 The human stress response to disease is often linked to an increase in the 
readily available release of glucose into the blood stream. Furthermore, many 
patients today have increased insulin resistance either from metabolic syndrome 
or diabetes. Insulin resistance has been linked to cancer progression in several 
cancers (Hursting & Berger, 2010). However, in relation to cachexia, the 
increased insulin resistance is problematic in that it potentiates several pathways 
that have been linked to adipose and muscle mass loss. The binding of insulin, or 
insulin growth factor-1 (IGF-1) to cell surface receptors on tumors activates the 
PI3K/Akt  (phosphoinositide-3-kinase/Akt) and glycogen synthase kinase (GSK-
3beta) pathways leading to the activation of the mammalian target of rapamycin 
(mTOR) (Pollak, 2008). This activation triggers muscle growth. However, under 
catabolism, IGF-1 ability to function appropriately is altered. Increased 
metabolically altered IGF-1 levels directly enhance the role of myostatin 
potentiating cachexia (Bonetto et al., 2013). Evidence suggests that IGF-1 and 
insulin are impaired under catabolic stress conditions, potentiating the production 
of these factors and driving cachexia. Perhaps what is altered at the cellular level 
is the IGF-1 and insulin receptors. The IGF-1 administration failed to reverse the 
muscle atrophy in experimental mouse models (Costelli et al., 2006). Remodeled 
post-receptor insulin, GH, and IGF-1 pathways constitute a potential target for 
pharmacological treatment in the setting of body wasting and cachexia (Trobec, 
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von Haehling, Anker, & Lainscak, 2011). It should also be noted that IGF-1 
studies in HNC patients in regards to cachexia have not occurred.  
 Standard treatments in the cachectic patients such as glucocorticoids to 
stimulate appetite and food intake may be promoting further muscle loss. 
Glucocorticoids (GC) promote muscle atrophy through enhancement of the UPP 
(Schakman, Kalista, Barbe, Loumaye, & Thissen, 2013), specifically through the 
FOX-O transcription factor (Sandri et al., 2004). FOX-O3 deletion results in 
protection against muscle wasting (Zhao et al., 2007). The inhibitory effect of GC 
on muscle protein synthesis is thought to result mainly from the inhibition of the 
mTOR/S6 kinase-1 pathway (Schakman et al., 2013). These changes in muscle 
protein turnover could be explained by changes in the muscle production of two 
growth factors, namely IGF-1, a muscle anabolic growth factor and myostatin, a 
muscle catabolic growth factor (Schakman et al., 2013). Research has indicated 
that by suppressing myostatin, this also reduces the metabolic derangements 
IGF-1 and insulin receptors experience under stress, thus enhancing muscle 
growth (Han & Mitch, 2011). 
 Conversely, data indicates that IGF-1 is not necessarily negative in the 
promotion of cachexia. Under normal physiological conditions, IGF-1 promotes 
muscle growth. High levels of Angiotensin II can affect IGF-1. Angiotensin II is 
produced through the renin-angiotensin system and has been associated with 
weight loss (Tisdale, 2009). The idea that angiotensin II could promote weight 
loss was first discovered in heart failure patients who began taking angiotensin 
converting enzyme inhibitors. Subsequent mouse studies have shown that 
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injection of angiotensin II promoted muscle and adipose tissue loss (Brink et al., 
2001). Angiotensin II infusion induces skeletal muscle atrophy in rodents and 
mechanisms include increased expression of the E3 ligases atrogin-1/MuRF-1, 
an elevated rate of ubiquitin-proteasome mediated proteolysis and increased 
reactive oxygen species (ROS) levels, closely mimicking conditions of human 
cachexia (Sukhanov et al., 2011). 
 Single polymorphisms of IL-1, IL-6 and IL-10 have also been implicated in 
the development of cachexia (Fearon et al., 2012a) (Tan & Fearon, 2008). In a 
large study of 203 patients examining multiple cytokine polymorphisms, only IL-
10-1082 polymorphism was linked to the development of cachexia in gastric 
cancer (Deans et al., 2009). Increased IL-10 serum expression was significantly 
associated with worse survival in early stage oral squamous cell carcinoma 
(Chen et al., 2013). However, this same association was not witnessed in 
myelofibrosis (Tefferi et al., 2011). An affirmative association with circulating IL-
10 levels and cachexia is currently lacking.  Nonetheless, various cytokines have 
been linked to the process of cachexia through both down-regulation and up-
regulation of metabolic processes. Furthermore, cytokines are also responsible 
for metabolic processes within the brain.  
 Various circulating levels of cytokines affect brain neuropeptides. Many 
cytokines have an impact on appetite such as IL-1α, IL-1β, IL-6, TNF-α and 
interferon-gamma (Patra & Arora, 2012). These cytokines transport across the 
blood-brain barrier and interact on the luminal surface of brain endothelial cells 
and release substances driving or hindering appetite (Banks, 2001). Cytokines 
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modulate the activity of neuropeptides and hormones that control energy 
homeostasis and/or illness behaviors (Krasnow & Marks, 2010). Cytokines seem 
to play a fundamental role in energy balance through persistent activation of the 
melanocortin system and inhibition of the central neuropeptide Y and agouti-
related protein (AgRP) pathways (Patra & Arora, 2012). Under normal 
physiological conditions, activation of neuronal nitric oxide synthase results in 
increased adenosine monophosphate kinase and a decrease in malonyl-
coenzyme-A, leading to increased food intake (Morley & Farr, 2008). However, 
under various disease states, these processes can be altered leading to an 
imbalance in anorexigenic and orexigenic peptides which can result in 
suppression of appetite and increased satiety ultimately leading to weight loss 
(Perboni & Inui, 2006). The pathophysiological role of cytokines in the 
hypothalamic accurate nucleus is not yet fully understood, but the evidence 
suggests a strong association between cytokines and the brain, which in turn can 
promote cachexia, and symptoms, such as depression and anorexia during 
cancer. Complicating this notion are two studies. In a mouse model, 
intracerebroventricular injection of inflammatory cytokines reduced food intake 
indicating that the brain can directly respond to inflammatory messages (Braun & 
Marks, 2010). However, in a separate study a negative association was reported 
between food intake and IL-1 (Braun & Marks, 2010). A recent study also 
indicated that association between glucocorticoid levels and CNS activation of 
muscle catabolism (Braun et al., 2011). While it is agreed that the hypothalamus 
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responds to cytokines, the exact pathological path is not clearly identified further 
complicating the treatment of cachexia. 
 One such cytokine recently implicated in the regulation of appetite on the 
hypothalamus was the TGF-beta cytokine MIC-1/GDF 15 (Tsai, 2012). Evidence 
for this has been demonstrated in a mouse model where tumors overexpressing 
MIC-1/GDF15 are present, a decrease in food intake and loss of lean body mass 
occurs (Johnen et al., 2007). Additionally, in humans with heart failure, those with 
the highest MIC-1/GDF levels had the lowest BMI (Kempf et al., 2007). This MIC-
1/GDF15 association is possibly a factor in HNC cachexia, but presently no such 
examination to date has been conducted. In regards to symptoms such as 
anorexia, there appears to be an association with cytokine levels and symptoms. 
However, the association with cytokines and other symptoms is not fully 
understood. 
Recent scientific research suggests that some of the most common 
symptoms reported by oncology patients are associated with changes in the 
levels of pro and anti-inflammatory cytokines (Miaskowski & Aouizerat, 2012) 
(Serugua, et al., 2008). Despite this increased association, there is mixed data 
regarding the development of symptoms, such as pain, anorexia and lethargy 
that occur in cancer patients and the association between these symptoms and 
cachexia. This is partially because there appears to be a lag between an 
elevation of cytokines and subsequent symptom development (Lucia, Esposito, 
Fanelli, & Muscaritoli, 2012). Also, there is an indication that symptoms can be 
present, such as pain, lethargy, depression, prior to muscle and adipose wasting 
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(Laird et al., 2011b). This is a classic conundrum of trying to decipher what 
occurs first in patients. Do symptoms predicate the development of cachexia, or 
is it cachexia that predicates the development of symptoms? Alternatively, is it a 
combination of both? What is hypothesized is that cytokine dysregulation caused 
by tumor burden begins to have a cascade effect on the physiological processes 
of the body. This cascade is possibly regulated by tumor burden and location. In 
one study of breast cancer patients, it was found that increased cytokine 
dysregulation with IL-6 correlated to worse symptoms of pain, fatigue, sleep 
disturbance and depression (Doong, et al., 2014). Further complicating the 
dysregulation of the cytokine is the additional dysregulation that can be caused 
by treatment modalities such as chemotherapy, radiation and medications 
(Cheung, et al., 2013). Many studies do not follow patients over a long enough 
period to demonstrate how inflammatory cytokines correlate with future 
developments of symptoms and wasting associated with cachexia (Fearon et al., 
2012a). Further explorations between symptoms and cachexia must occur in 
order to provide better treatment options for patients with cachexia and other 
symptom burdens.   
 
Summary of the biology, symptoms and treatment of cancer cachexia 
 
Overall, our knowledge in regards to cancer cachexia continues to 
accelerate. In regards to HNC, fewer studies have been conducted in regards to 
specific pathways, such as IGF-1, MIC-1/GDF15 and E3 ligases atrogin-1/MuRF-
1. Furthermore, contradictory evidence has been shown in HNC patients with 
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more established cytokines such as IL-6. To improve our understanding of HNC 
cachexia, further large prospective studies will need to be conducted  to improve 
our understanding of the many complex mechanisms involved in cachexia. The 
effects of cytokines and associations with symptoms such as depression, 
appetite suppression and anorexia development have only recently begun to be 
understood.  
 The association between cytokines and other symptom development such 
as mucositis and fatigue are less known. In regards to fatigue, the association 
between cytokines and development of lethargy has not been fully elucidated. 
Fatigue is possibly due to a conglomeration of processes from the disease 
process itself and treatment. Additionally, the role of cytokines in cancer and the 
associations with musculoskeletal dysfunction and cytokines is also not 
understood. However, muscle dysfunction is possibly related to the progression 
of tumor burden and the subsequent inhibition of new muscle production as well 
as degradation of muscle previously discussed in this chapter.  Overall, the 
association between cytokines, symptoms and cachexia experienced by cancer 
patients is not understood, but it is agreed that these three principles make the 
experience of cancer patients difficult.  
 
Definition of Terms 
 
 
A major impediment to research in cachexia has been the lack of a 
consensus clinical definition and diagnostic criteria to help design and interpret 
clinical studies, and appraise the relevance of findings from animal tumor models 
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of cachexia (Tsoli & Robertson, 2013). Historically, cachexia has generally been 
defined as involuntary weight loss of >5% from baseline, a body mass index 
(BMI) <20kg/m2 with any degree of weight loss (Vaughan et al., 2012). However, 
this vague definition does not take into account severity of illness, and other 
measurable factors such as cytokine levels, inflammation, treatment toxicity and 
impact on quality of life (von Haehling & Anker, 2010). 
In 2010, key individuals identified as experts in cancer cachexia and 
members from the European Palliative Care Research Collaborative, the Society 
on Cachexia and Wasting Disorders, the National Cancer Research Institute, 
Palliative Care Clinical Studies Group and the European Society for Clinical 
Nutrition Metabolism Special Interest Group on Cachexia participated in focus 
groups and two Delphi rounds to identify a working definition of cancer cachexia 
that could be applied to future research.  The working group published the 
following consensus: 
 Cancer cachexia was defined as a multifactorial syndrome defined by an 
ongoing loss of skeletal muscle mass (with or without loss of fat mass) 
that cannot be fully reversed by conventional nutritional support and leads 
to progressive functional impairment. Its pathophysiology is characterized 
by a negative protein and energy balance driven by a variable combination 
of reduced food intake and abnormal metabolism. The agreed diagnostic 
criterion for cachexia was weight loss greater than 5%, or weight loss 
greater than 2% in individuals already showing depletion according to 
current bodyweight and height (body-mass index [BMI] <20 kg/m(2)) or 
skeletal muscle mass (sarcopenia). An agreement was made that the 
cachexia syndrome can develop progressively through various stages--
precachexia to cachexia to refractory cachexia. Severity can be classified 
according to degree of depletion of energy stores and body protein (BMI) 
in combination with degree of ongoing weight loss. Assessment for 
classification and clinical management should include the following 
domains: anorexia or reduced food intake, catabolic drive, muscle mass 
and strength, functional and psychosocial impairment. Consensus exists 
on a framework for the definition and classification of cancer cachexia. 
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After validation, this should aid clinical trial design, development of 
practice guidelines, and, eventually, routine clinical management. 
    (Fearon, Strasser, Anker, Bosaeus, & Bruera, 2011) 
 
Cachexia is a multi-organ syndrome, characterized by weight loss (at least 
5%), muscle and adipose tissue wasting and inflammation. Metabolic 
abnormalities, carbohydrate levels, lipid and protein metabolism are thought to 
be caused by the tumor-induced production of humoral inflammatory mediators 
or other mediators produced directly by the tumor (Fearon et al., 2011). In 2013, 
cachexia was classified into three distinct areas: 
1. Pre-cachexia: when a patient has weight loss <5%, but has not yet 
developed serious complications. 
2. Cachexia: where the syndrome is progressing, with weight loss 
exceeding the parameters mentioned above, but still potentially able to 
be treated. 
3. Refractory cachexia: the point at which the disease is no longer 
responsive to treatment or when treatment benefits are outweighed by 
burden and risk.  
(Vaughan et al., 2012) 
 
 However, while an acceptable definition of cancer cachexia can be agreed 
upon, translating this definition into the clinical diagnosis of cachexia will still be 
difficult despite the identification of the five domains of cachexia. The key 
concept from the group’s consensus is identification that lean muscle mass loss 
is the greatest link with poor outcomes in cancer patients.  However cachexia 
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itself appears to be affected by a host of mediators that affect both the adipose 
and skeletal muscle simultaneously, suggesting that multiple pathways are 
occurring that can lead to cachexia (Dalamaga, 2013). 
 
Key concepts in head and neck cancer cachexia 
 
Within the following section, there are three separate tables for 
identification of key concepts relating to cachexia. They are general definitions, 
cytokines/chemokine’s, and symptoms. Cytokines are important physiological 
agents that handle the regulation of cellular functioning and human stress 
response. They are molecular messengers that assist in coordinating the 
interplay of the human immune system. The half-life of cytokines are relatively 
short and therefore have limited biological importance under normal conditions. 
However, during acute and chronic illnesses, the production of cytokines 
increases and often remains elevated. Cytokine elevation leads to inflammation 
and disease. The cytokines IL-1,2,6, TNF-a, INF-y have consistently been shown 
to correlate with cancer cachexia (Tisdale, 2009). (Antoun et al., 2010) (Bye et 
al., 2013). 
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Table 1: Cancer Cachexia General Definitions 
Acute phase 
reactants 
APR- during any inflammatory response, production of 
these reactants by the liver ensues. These reactants 
consume albumin. The body does not increase its 
production of albumin. Hypoalbuminanemia is due to 
increased trans capillary escape and increased albumin 
degradation by the APR (Fearon et al., 2012a) 
Body Mass Index Body Mass Index (BMI): the current standard for 
measuring weight and obesity and is a number 
calculated from a person's weight and height. BMI is a 
fairly reliable indicator of body fatness for most people. 
BMI does not measure body fat directly, but research has 
shown that BMI correlates to direct measures of body fat, 
such as underwater weighing and dual energy x-ray 
absorptiometry (DXA) 
 
BMI = weight (lb.) / [height (in)] 2 x 703 (English 
measurements) 
BMI = weight (kg) / [height (m)]2 (metric measurements) 
• Less than 18.5 = underweight 
• 18.5 to 24.9 = normal weight 
• 25 to 29.9 = overweight 
• 30 and above = obesity 
o 30-34.9 (class 1 obesity) 
o 35-39.9 (class 2 obesity) 
o 40 and above = morbid obesity 
 (Martin et al., 2013)  
Cachexia Diagnosis Cachexia can be diagnosed in the following way: a 
weight loss of at least 5% or more in 12-months or less in 
the presence of underlying illness, plus three of the 
following criteria: decreased muscle strength, fatigue, 
anorexia, low fat-free mass index, abnormal biochemistry 
(increased inflammatory markers (C-reactive protein 
>5.0 mg/l), IL-6 >4.0 pg/ml),  
However, other diagnostic tools should not be discarded, 
such as decreased physical performance (total activity, 
handgrip strength, stairs climb, or 6-min walk distance) or 
biochemical tissue analysis (activation of proteolysis or 
apoptosis in skeletal muscle biopsies (Couch et al., 
2014) 
Cachectic Syndrome A complex metabolic syndrome associated with 
underlying illness and characterized by loss of muscle 
with or without loss of fat mass. The prominent clinical 
feature of cachexia is weight loss in adults (corrected for 
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fluid retention) or growth failure in children (excluding 
endocrine disorders) (Fearon et al., 2011) 
CASCO Cachexia Score: a numerical scale, classifies cachexia 
into mild (0–25), moderate (26–50), severe (51–75), and 
terminal (76–100). The higher the score, the worst the 
syndrome (Argiles et al., 2011). 
C-reactive protein 
(CRP) 
C-reactive protein (CRP) is a nonspecific but sensitive 
marker of inflammation. Interleukin-6 (IL-6), IL-1, and 
tumor necrosis factor alpha induce the synthesis of CRP 
in hepatocytes. It is positively correlated with weight loss, 
anorexia-cachexia syndrome, the extent of disease, and 
recurrence in advanced cancer. (Mahmoud & Rivera, 
2002). However, its uses as a prognostic indicator in 
cancer are controversial (Chung & Chang, 2003). 
Decreased quality of life scores have been associated 
with increased CRP (Imayama et al., 2013) (Wallengren 
et al., 2013). Reducing CRP levels has helped patients 
increase their energy levels and improve their quality of 
life (Kamath, 2012). Elevated levels have been 
associated with increased depression levels in cancer 
patients (Archer, Hutchison, Dorudi, Stansfeld, & 
Korszun, 2012). CRP levels have also been correlated 
with cancer pain (Laird et al., 2011a).  
Cytokine Any of a class of immunoregulatory proteins (as 
interleukin, tumor necrosis factor, and interferon) that are 
secreted by cells especially of the immune system 
(Bennani-Baiti & Walsh, 2009). 
Muscle Atrophy The involuntary wasting or loss of muscle tissue 
(Whitehouse et al., 2001). 
Obesity Paradox The concept that obese persons have a decreased 
mortality rate from certain cancers compared to normal 
and underweight persons (Gonzalez, Pastore, Orlandi, & 
Heymsfield, 2014) 
Pro-Inflammatory Any substance that causes inflammation. Chronic 
inflammation plays a major role in carcinogenesis, and 
cancer cells potentially rely on production of 
proinflammatory mediators for growth, protection from 
apoptosis, and promotion of angiogenesis/metastasis 
(Donohoe et al., 2011) 
Total Energy 
Expenditure 
TEE is divided into resting energy expenditure (REE), 
diet-induced energy expenditure (DEE) and the energy 
cost of physical activity (AEE). A majority of cancer 
patients are hyper metabolic (Solheim et al., 2014). 
Tumorkine Tumor derived factors and cytokines that directly affect 
the bodies’ metabolism, lipogenesis, lipolysis, 
myogenesis, myolysis, and neuroendocrine control of 
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appetite and production of acute phase proteins. 
Cytokines derived from tumors appear to be the key 
agent in causing cachexia, rather than those from human 
innate immunity (Cahlin et al., 2000). 
 
Table 2: Cytokines Relating to Cachexia 
Cytokine Definition 
Tumor Necrosis 
Factor- alpha (TNF-α) 
Synthesized by activated macrophages. Originally called 
cachectin due to its relation to weight loss in rabbits 
(Beutler & Cerami, 1986). Later demonstrated to 
correlate with weight loss in (Oliff et al., 1987). 
Contributes to insulin resistance by degrading the 
insulin-signaling pathway (Hotamisligil, 2000). Promotes 
atrophy through the induction of E3 ligase genes that 
mediate the breakdown of myofibrillar proteins by the 
ubiquitin-proteasome pathway (Sishi & Engelbrecht, 
2011). However, systemically it is unclear as to its 
relevance in the development of human cachexia 
(Fearon et al., 2013) 
Interleukin-6 Appears to works in synergy with TNF-a and other 
cytokines. Circulating levels of IL-6 have been shown to 
correlate with weight loss and increased mortality in 
cancer patients (Scott et al., 2002). IL-6 receptor 
antibody blocked cachexia progression via suppression 
of muscle protein degradation, while not rescuing the 
suppression of synthesis (White et al., 2011). IL-6 is an 
acute phase reactant, but will remain at elevated levels 
during a chronic illness. Causes a reduction in 
erythropoietin production by the kidneys and can 
contribute to the anemia of chronic illness. Also 
promotes erythrophagocytosis by macrophages and in 
conjunction with IL- β1 and IFN-y decreases erythroid 
progenitor proliferation.  
Interleukin-1 Responsible for activating T and B-lymphocytes. Is an 
acute phase responder and is responsible for the 
production of other cytokines. IL-1 levels have been 
attributed to muscle wasting and the development of 
cachexia in cancer patients (Patra & Arora, 2012).   
Interleukin-2 Are produced by T and B-lymphocytes. Augments NK 
cell activity (Tefferi et al., 2011). 
Interleukin-8 IL-8 is a designated chemokine. Its role in cachexia is 
unclear presently; however, levels have been correlated 
with the nutritional status of cancer patients suggesting 
a role in driving muscle wasting (Gioulbasanis, 
Patrikidou, & Kitikidou, 2012). 
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Interleukin-10 Considered an anti-inflammatory cytokine the can down-
regulate TNF-α. (Mydlarz et al., 2014). 
Interferon-y A type II interferon that is part of human adaptive 
immunity against viral, bacterial and tumor regulation. 
Activates macrophages and stimulates the production of 
IL-1 and TNF-α. The essential role of IFN-γ in the 
pathogenesis of cachexia was confirmed by the 
demonstration that monoclonal antibodies (MAbs) 
against IFN-γ, given prior to injection of the tumor cells 
in mice, prevented cachexia (Matthys et al., 1991). 
MIC-1/GDF-15 MIC-1/GDF15 is a transforming growth factor beta 
(TGF-β) family cytokine. In experimental animals, serum 
MIC-1/GDF15 levels at the lower end of this range 
induce anorexia by direct actions of the circulating 
cytokine on feeding centers in the brain (Tsai, et al., 
2012). 
Transforming Growth 
Factor B 
TGF-β assists in the regulation of tissue repair and 
regeneration following an injury. Released from platelets 
at the time of tissue injury, it handles regulating TNF-α, 
IL-2. MIC-1/GDF15 is a TGF-β  family cytokine that is 
found in the serum of all normal individuals at an 
average concentration of about 0.6 ng/ml. Its increased 
expression in both cancers and other diseases can 
result in 10-100-fold or more elevation of its serum 
levels. In experimental animals, serum MIC-1/GDF15 
levels at the lower end of this range induce anorexia by 
direct actions of the circulating cytokine on feeding 
centers in the brain (Tsai et al., 2012). 
Nuclear Factor-kB  NF-κB  has been called a master transcriptional switch 
in inflammation that regulates dozens of targets involved 
in inflammation and other biochemical processes. IL-1, 6 
and TNF-a enhance NF-κB  and mediates muscle loss 
and dysfunction (Wysong et al., 2011).  
MMP2A/9A Biological important in terms of tissue remodeling. 
Possibly contributes to tumorgenesis (Nagase & 
Woessner, 1999).   
TWEAK TWEAK has multiple biological activities, including 
stimulation of cell growth and angiogenesis, induction of 
inflammatory cytokines, and under some experimental 
conditions, stimulation of apoptosis (Wiley & Winkles, 
2003). 
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Table 3: Symptoms affecting Quality of Life that may or may not impact 
Cachexia  
Symptom Definition 
Anorexia Unintentional weight loss and non-reversible despite 
adequate nutritional support (Fearon et al., 2011)  
Body Image 
Disturbance 
Alteration in body image perception secondary to highly 
visible disfigurement resulting from primary cancer and 
its treatment (Rhoten, Murphy, & Ridner, 2013). Can 
also be from resultant changes from weight loss. 
Depression Major depressive disorder, or major depression, is 
characterized by a combination of symptoms that 
interfere with a person's ability to work, sleep, study, eat, 
and enjoy once pleasurable activities. Major depression 
is disabling and prevents a person from functioning 
normally. Minor depression is characterized by having 
symptoms for 2 weeks or longer that do not meet full 
criteria for major depression. Without treatment, people 
with minor depression are at high risk of developing the 
major depressive disorder (Health, 2013). 
Dyspnea Shortness of breath, the inability to catch one’s breath 
(Landis et al., 2014). 
Dysphagia Difficulty or the inability to swallow content into the 
esophagus (Raber-Durlacher et al., 2012). 
Dysphonia Hoarse voice, inability to phonate 
Fatigue Cancer-related fatigue (CRF - sometimes simply called 
"cancer fatigue") is one of the most common side effects 
of cancer and its treatments. It is often described as 
"paralyzing." Usually, it comes on suddenly, does not 
result from activity or exertion, and is not relieved by rest 
or sleep. It may not end - even when treatment is 
complete. The exact reason for cancer fatigue is 
unknown. CRF may be related to both the disease 
process and treatments, including surgery, 
chemotherapy, and radiation therapy (Moubayed et al., 
2014). 
Insomnia Trouble falling asleep or staying asleep through the 
night(Oi-Ling et al., 2005) 
Malnutrition Occurs when the body does not get enough nutrients for 
proper metabolic functioning (O’Neill & Shaha, 2011). 
Mucositis Cytokine-induced inflammation of the mucosal lining of 
the mouth and esophagus usually caused by treatment 
modalities (Nicolatou-Galitis et al., 2013).  
Otalgia Pain in the ear  
Pain The International Association for the Study of Pain says 
it is "an unpleasant sensory and emotional experience in 
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association with actual or potential tissue damage, or 
described in terms of such damage." (Cancer-Pain.Org, 
2014, #25133) 
Rhinorrhea Mucous discharge from the nose that has increased 
secondary to tumor burden and treatment (Dallapiazza 
et al., 2014) 
Shoulder and Neck 
Dysfunction 
Alterations in the ability to use either or both the neck 
and shoulder following surgical resection of HNC and or 
secondary to tumor or lymphadenopathy (Patterson et 
al., 2012). 
Social Isolation Refers to a complete or near-complete lack of contact 
with people and society for members of a social species 
(Rhoten et al., 2013)  
 
 
Theoretical Framework 
  
As presented previously, cachexia is a conglomeration of metabolic 
derangements that occur as a result of tumor-derived signals as well as altered 
metabolism occurring in the host microenvironment. There are several 
conceptual models that have been proposed regarding the development of 
cachexia. Due to the heterogeneity of cancer, the heterogeneity of humans, and 
our limited knowledge of the physiology that is occurring during cancer and the 
subsequent development of cachexia, a precise model does not exist. However, 
several models help to inform the current state of cachexia science. Many are 
overlapping in their context, but each has its variations.  
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Figure 1: The Tsoli and Robertson Model of Cachexia Physiology  
  
This model highlights the involvement of tumor and the production of 
tumor-derived cytokines. These cytokines have an impact on the brain, muscle, 
liver and adipose tissue. In regards to the brain, the tumor itself in conjunction 
with tumor produced cytokines causes anorexia due to decreased caloric intake 
because the neuroendocrine system is negatively altered by the cytokines 
causing a reduction in caloric intake (Laviano, Seelaender, Rianda, Silverio, & 
Rossi Fanelli, 2012). The model indicates that decreased muscle mass 
secondary to muscle wasting results in increased fatigue. In regards to 
impairment in hepatic function, a decrease in drug clearance is experienced 
secondary to the tumor kind increasing the likelihood of drug toxicity (Prado, 
Antoun, Sawyer, & Baracos, 2011). The model also demonstrates that lipolysis is 
increased in both brown and white adipose tissue. While the model identifies a 
very good overall synopsis of cachexia, it does not fully highlight the many 
different pathophysiology’s that are potentially occurring at the cellular level in the 
brain, liver, fat and muscle tissue. However, this is not necessarily a negative as 
the process of cachexia is very complex, and this model is very basic allowing for 
further in-detail analysis to occur. Overall, the model is very accurate in its 
current format.  
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(Tsoli & Robertson, 2013) 
 
 
 
 
 
 
 
 
Figure 2: The Dodson Model of Cancer Cachexia Physiology  
 
 
 This model is more detailed than the Tsoli and Robertson model in terms 
of cachectic effects on the patient and the symptoms that they experience. The 
premise of this model is that there is a definitive cancer diagnosis, which then 
leads to a progression in cancer cachexia. This progression of cancer cachexia 
leads to inflammatory cytokines to cause an increase in protein catabolism, 
insulin resistance, lipolysis and resting energy expenditure as well as a decrease 
in protein anabolism and caloric intake (Evans et al., 2008)These changes lead 
to a loss of muscle mass and strength, loss of whole body fat, increased fatigue 
and a decline in a patient’s immune system (Dillon et al., 2012). From these 
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changes, the patient experiences a decrease in physical function and the ability 
to perform activities of daily living, a decreased response to therapy and quality 
of life (Barrera & Norton, 2009). The patient furthermore experiences an increase 
in hospitalizations and drug toxicity. The positives, in regards to this model, are 
the association between a progression of cachexia and changes in a patient’s 
symptom presentation. Additionally, the model is not very detailed in the exact 
process by which these symptoms develop, but this is not necessarily a negative 
in that it allows for the recognition that we do not fully understood the exact 
pathways yet between cachexia and symptoms. Furthermore, the model begins 
with a cancer diagnosis and a secondary progression of cachexia. Research 
clearly indicates that a patient is possibly experiencing cachexia even before a 
diagnosis is made (Citrin et al., 2012). However, without a diagnosis of cancer, 
there would be no diagnosis of cancer cachexia. Additionally, the model states 
that a progression of cachexia occurs, and then inflammatory cytokines begin to 
increase. Most likely, both are occurring simultaneously because cytokines 
increase systemically at the very start of cancer (Lucia et al., 2012). The models 
insinuation that the progression of cachexia is occurring before the inflammatory 
cytokines begin to increase, or perhaps even circulate, is very misleading and not 
an accurate representation of the progression of cachexia. The model would 
have been better had arrows been included highlighting the feedback loop of 
cachexia progression, cytokines, and symptoms.  
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(Dodson et al., 2011) 
 
 
 
 
 
 
 
Figure 3: The Fearon Model of Cancer Cachexia Physiology 
 
  
 This model highlights the involvement of tumor and the production of 
cytokines. However, this model is unique In that it demonstrates a feedback 
mechanism from the cytokines produced by the tumor itself and the cytokines 
produced in the microenvironment secondary to the tumor. This model also takes 
into consideration the effects of hypogonadism, which is a very common 
occurrence in persons with cachexia as well as the Cori cycle which is affected 
by the development of acute phase reactants (APRs) secondary to cytokines. 
The alteration in the CORI cycle increases lactate as well as increases the 
production of glucose by the Liver (Trendelenburg, Meyer, Jacobi, Feige, & 
Glass, 2012).This in turn helps to feed the tumor itself with sustenance for its 
 55 
growth potential. The model also takes into consideration both the effects of 
insulin resistance and the increasing occurrence of nitrogen loss. Insulin 
resistance is an important component of increased muscle catabolism. This 
increased catabolism increases the amount of circulating amino acids, which 
increases the APRs from the liver (Trendelenburg et al., 2012). The effects of 
increased free fatty acids are also linked to muscle breakdown. Overall, the 
model is one of the better models demonstrating the physiological loop of 
cachexia. It demonstrates the plethora of biological processes that are altered in 
cachexia.  
 
 
(Fearon et al., 2012) 
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Figure 4: The Argiles, Busquents, Felipe and Lopez-Soriano Model of Cancer 
Cachexia  
 
 This model of cachexia is unique in that it presents cachexia in a pyramid 
rather than a loop mechanism like the previous three models. The model is a 
progression of processes that occur from top to bottom with the tumor at the top. 
The tumor causes a change in food intake and metabolic abnormalities (Siddiqui 
et al., 2006). These changes interplay with tumor factors, cytokines and 
hormones (Bosaeus, Daneryd, Svanberg, & Lundholm, 2001). As these 
biological factors increase, the brain, immune system, Liver, skeletal muscle, 
adipose tissue, blood and gastrointestinal system are altered which leads to 
immobility, quality of life issues, weight loss, anemia, edema and weakness 
(Laviano et al., 2012). The pyramid attempts to capture the various sequela of 
cancer as it causes cachexia. What is excellent about this model is the fact that it 
attempts to have a foundational effect of the tumor on the many processes that 
promote cachexia. As cachexia progresses, a change and increase in symptom 
burden is finally achieved. The model captures the areas within the body that are 
affected by metabolic abnormalities, the increase in cytokines and the 
progression of cachexia. The cytokines affect multiple organs, and the 
penultimate development of symptoms. 
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(Argiles et al., 2005) 
 
 
 
 
Conceptual and Theoretical Limitations 
 
 
 
One of the limiting factors in the development of a precise cachexia model 
is our limited knowledge regarding the role of neuroinflammation in muscle and 
adipose tissue wasting. What is known is that the brain responds to tumor-
generated cytokines negatively in that it causes anorexia. The precise biological 
pathway(s) involved in this process is still limited, but overall the role of the 
hypothalamic arcuate nucleus in food intake appears to be a central component 
that can impact cachexia (Laviano et al., 2012). None of the models incorporate 
the role of neuropeptide Y (NPY) and agouti-related protein (AgRP), which are 
both potent stimulators of food intake as well as proopiomelanocortin (POMC) 
and cocaine and amphetamine-regulated transcript (CART) which are both 
appetite suppressants (Trivedi, 2014). While it is assumed that the tumor impacts 
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these biochemical agents, the precise role is not fully understood. Hence, most 
models in regards to cachexia are at this point vague in their association 
between neuroinflammation and the perpetuation of cachexia. Exacerbating this 
lack of understanding is also the unknown role of different tumors and the 
enhancement of appetite suppressant within the brain (Fearon et al., 2012b). The 
role of different cytokines and their levels in this process is also not understood. 
Therefore, cachexia models that are incorporating the role of neuroinflammation 
are at this point limited by the current knowledge.  
 In regards to the brain during cachexia, what is also lacking in terms of our 
understanding is the role in which other attributed sequela of cachexia affects the 
brain and appetite regulation (Perboni & Inui, 2006). Symptoms such as 
mucositis, nausea, lethargy, insomnia, depression, pancytopenia and 
leukocytosis impact the overall state of health in cancer patients (Laird et al., 
2011b) (Oi-Ling et al., 2005). What are not understood is how these symptoms 
affect the brain and how those impacts are manifested in terms of cachexia 
(Grossberg, Scarlett, & Marks, 2010). Presently, the role of the brain in 
relationship to tumor-induced regulation of neuropeptides as well as the brain's 
response to various symptoms commonly associated with cancer is not fully 
understood (Johnen et al., 2007). This lack of understanding presently limits the 
ability to capture fully the role of neuroinflammation precisely in a cachexia model 
unfortunately leaving many models significantly shallow in their ability to capture 
this process.   
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 In addition to the many components of cachexia, that may or may not be 
impacted by the brain, is the lack of understanding of cytokine levels and 
cachexia. For example, in some studies, cachexia appears to be strongly 
correlated with certain cytokines, but in other studies this association is not 
statistically significant (Bennani-Baiti & Walsh, 2009) (Dodson et al., 2011). 
Therefore, the different models that utilize various cytokines do so with the 
understanding that different levels of individual cytokines may or may not be 
involved in the cachectic process. This variation in the association between 
cytokines and cachexia is possibly rooted in the overall heterogeneity of cancer 
(Fearon et al., 2012b). Every type of cancer appears to cause different outcomes 
and processes in humans. Why this is the case is possibly attributed to the 
location of the tumor and the impairment that various organ dysfunction can also 
cause upon the body. Even within the HNC population different studies have 
demonstrated mixed results in terms of correlating cytokines with outcomes 
(Duffy et al., 2008) (Heimdal, Kross, Klementsen, Olofsson, & Aarstad, 
2008).The various cachexia models do not adequately depict this variation. 
However, the models do serve as a starting point for developing an 
understanding of cachexia as well as formulating studies that can help 
investigate these associations.   
 The heterogeneity of cancer is also possibly confounded by the lack of 
understanding regarding the role of genetics within the development of cachexia 
(Fearon, 2012) The process by which myosin and adipose degradation occurs is 
in response to tumor mediated inflammatory markers is possibly affected by the 
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individual’s genetic make-up (Whitehouse et al., 2001). Additionally, the 
relationship is further confounded by our lack of understanding regarding the role 
of demographics and other factors such as pre-diagnosis state of health. For 
example, men overall have worse cachexia as determined by muscle wasting 
(Marcell, 2003). This is likely due to the fact that men typically have larger muscle 
stores compared to women. Presently, the models do not take into consideration 
these other factors that possibly affect cachexia.  
 
Summary of conceptual and theoretical limitations 
 
There are significant factors that appear to affect the brain during cancer 
and the subsequent development of cachexia. However, to date the precise 
sequence of these mechanisms have not been fully elucidated. In regards to 
HNC patients, the disease process itself may affect the brain and thus alter the 
neurochemical balance of the brain negatively. Symptoms such as lethargy, 
insomnia, mucositis, xerostomia and dysphagia possibly affect the ability to eat, 
but the exact associational effects of these symptoms on the brain are unknown. 
The probable hypothesis is that these symptoms negatively influence the brain 
through depression and likely cause a decline in appetite. However, the role of 
these symptoms in the brain and secondary cachexia development and 
promotion remains unclear. Further studies of these symptoms and their effects 
on the brain and cachexia in the HNC population are needed. 
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Discussion of Theoretical Knowledge 
 
 
 Despite the discussed shortcomings of the current state of cachexia 
models, the models that have been presented are robust in the synthesis of the 
present state of cachexia research. Due to the heterogeneity of cancer, the 
models represent all cancers and cachexia. There are no specific cachexia 
models for a single type of cancer such as HNC.   
Presently, all models indicate a role of the cytokine. While the precise 
function of a single or group of cytokines has not been elucidated presently, what 
is known is that the cytokines participate in the ignition switch that starts and then 
perpetuates muscle and adipose tissue wasting. The models are adequate for 
their presentation for why cachexia occurs. As cytokines increase, whether from 
the tumor itself, or cell mediates pathways distal to the actual tumor, a 
progression of events occur in various organs, such as the liver and brain that 
potentiates cachexia through muscle and adipose breakdown. Furthermore, the 
regeneration of muscle and adipose tissue is severely limited placing the person 
in a negative net balance, which ultimately leads to weight loss. The models 
present this progression of events very well. What is limited in our understanding 
is why in certain cases this does not occur.  
 Not all cancer patients experience cachexia. The models do not 
necessarily account for this discrepancy. Presently it is unknown why some 
persons with cancer do not develop cachexia despite having identical cancers. 
However, even persons without a profound experience of weight loss, muscle 
wasting appears to occur in every patient (Argiles et al., 2014). The difference 
 62 
between severe muscle and mild muscle wasting has not been elucidated 
presently. However, the models do indicate the various molecular pathways for 
this process, even though a person may not experience a significant loss of 
muscle. Therefore, our models capture the overall process of muscle wasting. 
What they do not capture presently are the inhibitory factors that prevent an 
extraordinary loss of muscle. This is significantly in part secondary to the lack of 
understanding of what these inhibitory processes are and the fact that the 
molecular pathway for cachexia is only slowly being pieced together. Thus, the 
development of the many pathways secondary to cytokine production that 
induces cachexia are still be identified and until this process can be elucidated in 
may be difficult to determine the mechanisms that actually inhibit muscle wasting 
in general. The processes by which cachexia is occurring is not entirely 
identified. 
 A question that cannot be answered presently is, do all cancers produce 
cachexia through the same pathways? In regards to HNC, do the symptoms 
experiences of HNC patients differ compared to those of lung or breast cancer? 
The answer is yes. Therefore, is it possible that the specific symptoms that are 
associated with HNC negatively or positively affect cachexia? Is there a 
difference between patients who cannot swallow from HNC tumor burden verses 
that patient who cannot swallow due to shortness of breath from lung cancer? In 
a recent study examining symptom clusters and various cancers such as lung, 
gastrointestinal, genitourinary, breast and HNC, it was found that now significant 
difference in symptoms were reported between the lung and gastrointestinal 
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cancers (Jimenez et al., 2011). An analysis of HNC in this study was not 
conducted due to sample size. Nonetheless, the study indicates that various 
symptoms are universal to all cancers. Currently what is unknown is how these 
symptoms potentially affect cachexia. However, if symptoms are equally shared 
between cancers, the symptoms affecting cachexia in HNC patients may be 
similar to those of other cancers. It will be important for future research to 
examine these symptoms and their neurological impacts and subsequent 
cachexia development.  
 
 
Theoretical Framework for Study 
 
Currently, there is not one universal model that precisely describes the 
physiology of cancer cachexia. However, given the strengths and limitations of 
the available models, the best framework to guide this dissertation research is 
the Model of Cancer Cachexia proposed by Argiles, Busquents, Felipe and 
Lopez-Soriano. In this model, the tumor produces metabolic abnormalities that 
promote cytokine production, causing muscle wasting, and other symptoms 
ultimately leading to cachexia. As this dissertation research is focused on 
examining the association between cachexia, symptoms and cytokines, this 
model best fits the research questions proposed.  
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CHAPTER III 
 
METHODOLOGY 
 
Research Design 
 
This dissertation is a secondary analysis of data from a four-year 
prospective longitudinal, descriptive study that was recently completed. The 
following assumptions guided this study: 1) many patients with HNC develop 
cachexia; 2) the physiological underpinnings of cachexia in this population are 
not well articulated; 3) inflammatory processes contribute to cachexia; 4) other 
symptoms besides weight loss can accompany cachexia such as depression, 
fatigue and pain; and 5) long-term associations between baseline cytokines and 
symptoms progression are not well understood. To examine these assumptions, 
this secondary analysis examined cytokines, red blood cells (RBCs), albumin and 
changes in symptoms and weight over a 12-month period post treatment. It 
assessed how changes in cytokines over time correlated with variables of 
cachexia and cancer symptoms as well as changes in musculoskeletal 
functioning over the 12-month period. Data values were collected on the patients 
at the initiation and conclusion of treatment as well as at 6, 12, 24, 30, 36, 42 and 
48 weeks. This data analysis only included individuals who completed their 48-
week assessment.  
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Description of Research Setting 
 
 Recruitment, as well as all study visits, took place in private clinic rooms at 
Vanderbilt-Ingram Cancer Center (VICC) in Nashville, TN. The VICC was 
established in 1993 and integrates the cancer-related expertise and resources of 
the School of Medicine, School of Nursing, School of Arts and Sciences, School 
of Engineering and the Peabody School of Education as well as the fully 
integrated Veterans Administration Medical Center. The VICC is a National 
Cancer Institute designated Comprehensive Cancer Center.  
 
Sample and Sampling Plan 
 
Inclusion and exclusion criteria  
 
The targeted population for the parent study consisted of patients with 
carcinoma of the head and neck. Eligibility criteria included: a) newly diagnosed, 
histologically proven carcinoma involving the head and neck; b) Stage II or 
greater; c) age of 21 or over; d) willing and able to undergo baseline and follow-
up assessment at the VICC; and e) the ability to speak English. Patients were 
excluded if a) they had medical record documentation of cognitive impairment 
that would preclude the capacity to provide informed consent; b) were unwilling 
to undergo routine follow-up at the VICC; or c) had recurrent cancer. No 
restriction was placed on the type of treatment; however, treatment parameters 
were meticulously documented. To accomplish the aims of this study, which was 
to examine the association between baseline inflammatory markers and 
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symptoms one year later, only persons completing the 48-week assessment 
were included in this analysis. Some patients had their 48-week assessment 
prior to and after the precise 48-week mark. Therefore, persons completing their 
48-week assessment 6 weeks prior to and after 48 weeks, giving a range of 42-
54 weeks, were included in this analysis.  
 
Recruitment 
 
 For the primary study, one hundred subjects were recruited over 25 
months from newly diagnosed patients with carcinoma of the head and neck 
undergoing treatment at the Vanderbilt-Ingram Cancer Center. Study staff met 
with individuals who were interested in participating in the study and reviewed the 
informed consent document with potential participants. Individuals who selected 
to participate in the study signed an informed consent document. For this 
secondary analysis, only those individuals who completed their week 48 
assessment were included.  
 
Retention 
 
 The study was designed to place as minimal amount of burden on study 
participants as possible. Study visits were scheduled to take placed shortly 
before or after a participant’s regularly scheduled visit. The study sessions took 
more than 60 minutes. Participants received U.S. postal reminders of their study 
visits and were additionally thanked during that time. Patients were incentivized 
with increasing amounts of money for each assessment that they completed 
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ranging from $15 to $25. Of the 96 individuals who enrolled in the study, 56 
persons finished the week 48 assessment.  
 
Protection of Human Subjects 
 
The data from the parent study was obtained through IRB approved procedures 
at Vanderbilt University Medical Center and the VICC Scientific Review 
Committee. All participants gave informed consent. The data analysis conducted 
for this research was void of name and other identifiable characteristics.  
 
Data Collection Methods 
 
The timeline for data that was collected for this secondary analysis is included in 
Table 4.   Trained research individuals collected data. 
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Table 4: Data Collection Timeline 
Task BL EoT Wk 
6 
Wk 
12 
Wk 
18 
Wk 
24 
Wk 
30 
Wk 
36 
Wk 
42 
Wk 
48 
Med. Hx1 X          
Weight & 
Height3 
X X X X X X X X X X 
Red Blood Cell 
Count3 
X          
Albumin3 X          
Demographics2,3 X          
VHNSS2 X X X X X X X X X X 
Cytokines3 X X X X X X X X X X 
CROM3 X X X X X X X X X X 
NDI2 X X X X X X X X X X 
CESD2 X X X X X X X X X X 
BL= Baseline, EoT= End of Treatment, VHNSS= Vanderbilt Head and Neck 
Symptom Survey, CROM= Cervical Range of Motion, NDI= Neck Disability 
Index, CESD= Center for Epidemiological Studies Depression 
1= interview, 2= patient completed, 3= physicians or study staff/completed task 
 
Instruments 
 
The following data collection instruments were used for each aim:  
 
AIM 1: To examine cytokines, RBCs and albumin in HNC patients.  The 
Vanderbilt Flow Cytometry and Human Immunology Core handled all storage, 
processing and analyzes of the cytokines, red blood cells and albumin used in 
this study. IL-1β, IL-6, IL-8, IL-10, IL-12p70, TNF-α, IFN-γ, MMP2A, and MMP9A 
were measured using a sensitive flow cytometric bead array (CBA; Becton 
Dickinson) assay that allows multiple cytokine analyses of a single sample 
(American Cancer Society, 2006). Two-color flow cytometric analysis was 
performed using an LSRII flow cytometer (Becton Dickinson). Data was acquired 
and analyzed using Becton Dickinson CBA software. Forward-scatter versus side 
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scatter gating was used, to exclude any sample particles other than the 7.5-mm 
polystyrene beads. CRP and TGF-β1, TGF-β2, TGF-β3 were measured using 
electro- chemiluminescence multiplex array technology from Meso-Scale 
Discovery (Gaithersburg, MD) according to manufacturer’s instructions. Data 
were acquired using Sector 2400 imager. Red blood cells were measured using 
a hemacytometer and reported in million cells per microliter (cells/mcl). Albumin 
was measured using the Beckman UniCell DxC800 Synchron method. Results 
were reported in grams per deciliter (g/dL). 
AIM 2: To examine the role of cytokines, RBCs, albumin and severity of 
weight loss in HNC patients.  The cytokines, red blood cells and albumin 
analyzed for AIM 1 were used for this aim. Weights, measured in kilograms that 
were collected/obtained at the time of visit, were used for this analysis. Heights 
were also collected on all patients at the start of the study. BMIs were calculated 
using the original weight and height with the following formula (weight (kg) / 
[height (m)]2 ). 
AIM 3: To examine the association between cytokines, RBCs, albumin 
and reported symptoms in HNC patients. In regards to cytokines, red blood cells, 
and albumin, using the specimens collected as described in Aim 1 completed this 
objective. Additionally, the following tools were utilized for this study: 
Vanderbilt Head and Neck Symptom Survey (VHNSS) version 2.0. The 
Vanderbilt Head and Neck Symptom Survey (VHNSS) 2.0 is a 50-item patient 
reported outcome measure that identifies and quantitates acute and late 
symptom burden and functional deficits experienced by HNC patients. The 
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VHNSS has 13 domains including nutrition, swallowing, xerostomia, mucositis, 
excess mucous, speech, hearing, taste change, smell, dental health, Furl 
sensitivity, a range of motion and pain. Items are scored on a Likert scale rating 
the severity of the symptom from 0 (none) to 10 (severe). The Vanderbilt Head 
and Neck Symptom Survey version 2.0 was designed to provide an expanded 
inventory of symptoms that an included an emphasis on oral health outcomes 
and was an expansion of version 1.0 (Cooperstein, et al., 2012) (Murphy, et al, 
2010). Within version 2.0 the internal consistency of the ten clusters was good to 
excellent, with Cronbach’s alpha coefficient above 0.90 in 6 symptom clusters 
and above 0.70 in four remaining clusters (ranges 0.74 to 0.95).  The Cronbach’s 
alpha for each domain are as follows: nutrition (0.83), swallowing solids (0.92), 
swallowing liquids (0.74), xerostomia (0.92), mucous (0.95), voice (0.89), 
taste/smell (0.91), dental health (0.75), mouth pain (0.89), general pain (0.94). 
Within this study, the internal reliability of the VHNSS version 2.0 ranged from 
0.82-0.86 for Cronbach’s alpha. The Cronbach’s alpha for each domain in this 
study are as follows: nutrition (0.82), swallowing solids (0.82), swallowing liquids 
(0.84), xerostomia (0.83), mucous (0.84), voice (0.83), taste/smell (0.85), dental 
health (0.85), mouth pain (0.82), general pain (0.84). 
Center for Epidemiological Studies Depression Scale (CESD; Depressive 
symptomatology). The CESD is a 20 item self-report measure that assesses the 
presence and severity of depressive symptoms occurring over the past week 
from the patient’s perspective (Ridner & Dietrich, 2008). All items are rated on a 
4-point scale. Psychometric properties of the CESD have been extensively 
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examined and the scale has been used widely in cancer research. In breast 
cancer survivors, it has reported Cronbach’s alpha of .89 (Ridner & Dietrich, 
2008). Within this study, the internal reliability ranged from 0.81-0.86 for 
Cronbach’s alpha.  
AIM 4. To examine the association between cytokines and changes in 
musculoskeletal function in HNC patients.  
Cervical Range of Motion. Cervical Range of Motion Kit. The Dynatronics CROM-
D (Litchfield, Minnesota) was used to measure CROM in all planes of movement.  
The CROM-D measures cervical flexion and extension, lateral extension, and 
cervical motion. (Youdas, Carey, Garrett, 1991) (Jordan, 2000) (Dynatronics, 
2014). This instrument was utilized to determine if there was any association with 
increasing symptoms of cachexia and a decreased ability for the patient to move 
their neck. It has demonstrated the clinical validity and reliability (ICC= .89-.98) 
when compared with other measures of cervical range of motion (r=.93-98) 
(Audette, Dumas, Cote, De Serres, 2010).  The CROM measures 6 movements: 
1) head and forward neck flexion, 2) head and neck extension, 3) left lateral 
flexion, 4) right lateral flexion, 5) left lateral rotation and 6) right lateral rotation.  
Within this study, the internal reliability of the CROM ranged from 0.72 to 0.80 for 
Cronbach’s alpha.  
Neck Disability Index (NDI). This 10-item instrument taps components of daily life 
that may be affected by neck pain and dysfunction. Items include pain, personal 
care, lifting, reaching, headache, concentration, work, driving, sleeping, and 
recreation. A Gutman-style response format is used, with 6 possible responses 
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reflecting increasing degrees of disability. Items are summed to provide a total 
score. The NDI categorizes levels of disability through percentage. The 
questionnaire consists of 10 items, each scored from 0-5. The maximum score 
that can be obtained is fifty. The score is multiplied by 2 to and divided by 100 to 
compute the percentage. A raw score of 0-4 indicates no disability, 5-14 mild 
disability, 15-24 moderate disability, 25-34 severe disability, and 35 or greater 
complete disability. Internal consistency of the 10-item scale has been adequate 
in previous research (α= .89 - .92) (Vernon & Mior, 1991) (Hains, Waalen, & 
Mior, 1998). Factor analysis identified 1 dimension. Stability of the instrument 
also was adequate (r = .89). For this study, internal reliability for the NDI was 
0.89 for Cronbach’s alpha.  
 
Other data collection instruments 
Demographic variables (age, race/ethnicity, marital status, employment, 
insurance, and education) were collected through self-report in the primary study. 
Clinical variables (date of cancer diagnosis, treatment received/planned, 
radiation dose, radiation schedule, stage, and medications taken) were obtained 
from participant medical records and collected at the start of the primary study. 
 
General Data Analysis and Sample 
 
Ninety-six individuals originally enrolled in the parent study. Cases with 
data assessments within plus or minus 6 weeks of 12-months post-treatment 
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persons. Randomly missing responses to items within the self-report assessment 
tools (e.g., CESD, VHNSS, NDI) were handled via protocols specified by the 
instrument developers. Within this sample, randomly missing values occurred for 
baseline, 6-months and 12-months post-treatment lab and self-report measures 
resulting in minimally differing samples size for specific analyses.  
Data were analyzed using SPSS Version 22 (Chicago, IL). Descriptive 
statistics were used to summarize all of the variables used in this study. 
Frequency distributions were used to summarize and evaluate nominal and 
ordinal data values. Information from these summaries was also used to inform 
whether specific categories contained sufficient cases to conduct analysis or if 
categories needed to be combined into clinically appropriate larger categories. 
Due to extreme skewness, common to symptom data, cytokine distributions and 
outlying values, all of the continuous data were summarized using median, 25th-
75th inter-quartile range (IQR, minimum, and maximum values). Distributions 
were rank transformed for use in parametric statistical methods.  
Chi-Square Tests of Independence (nominal, ordinal) and Mann-Whitney 
tests were used to test for differences between the samples of 56 individuals 
from the parent study that were included in this study to the remaining 40 
individuals from the parent study that was not included. There was no correction 
to the Type I error rate for any of the statistical tests conducted in this study. An 
alpha of 0.05 was used for each test. Many statistical tests were conducted in 
this study therefore results were interpreted with extreme caution. Accordingly, 
effect sizes were the primary focus.  
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Analysis of Specific Aims 
 
AIM 1: To examine concentration of red blood cells and serum cytokines 
and albumin in HNC patients.  
Question 1: Do baseline red blood cells and baseline albumin levels correlate 
with changes in cytokine levels at 6- and 12-months?  
Method of analysis: The operationalization of “change” in cytokines was 
accomplished by subtracting baseline cytokines values from respective values at 
6-months and 12-months post-treatment. A multiple linear regression of baseline 
red blood cell count on each of the resulting change values was conducted that 
included the respective cytokine’s baseline value. Another set of such 
regressions was conducted for the baseline albumin levels.  
AIM 2: To examine the role of cytokines, red blood cells, albumin and 
severity of weight loss in HNC patients. 
Question 2a: Are baseline cytokines, baseline red blood cells and baseline 
albumin levels correlated with weight loss at 6- and 12-months? 
Question 2b: Does a change in cytokine levels from baseline to 6-months 
correlate with weight loss at 12-months?  
Method of analysis: For question 2a, the operationalization of “change” in weight 
was accomplished by subtracting baseline weight values from respective values 
at 6-months and 12-months post-treatment. A multiple linear regression of 
baseline cytokines, red blood cells and albumin levels on each of the resulting 
weight change values was conducted. For question 2b, the operationalization of 
“change” in cytokines values was accomplished by subtracting baseline 
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cytokines values from respective values at 6-months. A multiple linear regression 
of 6-month cytokine values was conducted on 12-month weight changes 
calculated for question 2a. 
AIM 3: To examine the association between cytokines, red blood cells, 
and albumin and reported symptoms in HNC patients.  
Question3: Are initial cytokines, RBCs and albumin associated with changes in 
reported symptoms such as: depression, swallowing difficulties, mucositis, 
generalized pain, mouth pain, nutrition consumption, dental discomfort, hearing, 
xerostomia, taste, jaw movement and voice at 6- and 12-months? 
Instrument: Vanderbilt Head and Neck Symptom Survey (VHNSS). 
Method of analysis:  The operationalization of “change” in symptoms was 
accomplished by subtracting baseline symptoms scores from respective values 
at 6-months and 12-months post-treatment. A multiple linear regression of 
baseline cytokines, red blood cells and albumin on each of the resulting symptom 
change values was conducted. 
Descriptive statistical summaries of cytokines and nutritional biomarkers 
prior to treatment and summaries of symptoms 12-months after enrollment were 
obtained and analyzed. To ensure that parametric statistical methods were used 
appropriately, the distributions and shapes of the continuous measures were 
evaluated to determine if any violations of parametric statistical assumptions 
such as normality exist.  Multiple linear regressions were performed on the 
pretreatment cytokine values, and one-year symptom measurements obtained 
from the VHNSS. Each variable prior to analysis was ranked and transformed  
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AIM 4: To examine the association between cytokines and changes in 
musculoskeletal function in HNC patients. 
Question 4: Are baseline cytokines associated with musculoskeletal impairment 
(neck and shoulder movement) as measured by shoulder and neck ranges of 
motion and neck disability at 12-months? 
Instrument: Neck Disability Index (NDI), Cervical Range of Motion (CROM),  
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CHAPTER IV 
 
RESULTS 
 
Sample 
 
 The demographic characteristics of all participants in the parent study 
(N=96), the subsample included in this study (N=56) and those not included 
(N=40) are summarized in Table 5. There were no statistically significant 
differences in demographic characteristics between those included in this study 
and those not included. The majority of participants in this secondary analysis 
were male (N=40, 71.4%). Most persons in the analysis were White (N=51, 
91.1%). A majority of patients were married (N=42, 75.0%), resided in the 
country (N=31, 55.4%) and had at least finished high school (N=52, 92.9%). The 
group was evenly distributed between currently employed (N=27, 48.2%) and not 
employed (N=29, 51.8%) as well as between those who currently consume 
alcohol (N=15, 48.4%) and those who do not (N=16, 51.6%). The average age of 
those in this study was 57.7 years. The minimum age was 29 and the maximum 
age was 80.  Most persons indicated that they resided in homes where the 
income level was less than $50,000 annually (N=37, 48.2%).  
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Table 5: Demographic Characteristics 
 
 
 
 
Parent 
Study 
 
Not in 
Current 
Study 
In Current 
Study 
p-
value 
 Total (%) 
N=96 
Total (%) 
N=40 
Total (%) 
N=56 
 
Gender    .698 
Male 70 (72.9) 30 (75.0) 40 (71.4)  
Female 26 (27.1) 10 (25.0) 16 (28.6)  
Race    .314 
White 86 (89.6) 35 (87.5) 51 (91.1)  
Black or African American 7 (7.3) 4 (10.0) 3 (5.4)  
Other 3 (3.1) 1(2.5) 2 (3.6)  
Marital Status    .952 
Single/Widowed 21 (21.9) 9 (22.5) 12 (21.4)  
Married/Partnered 72 (75.0) 30 (75.0) 42 (75.0)  
Other 3 (3.1) 1 (3.6) 2 (3.6)  
Employment    .492 
Full & Part Time 42 (43.8) 15 (37.5) 27 (48.2)  
Unemployed/Retired/Home- 
maker/Other 
54 (56.2) 25 (62.5) 29 (51.8)  
Location of Residence    .130 
City 42 (43.8) 22 (55.0) 20 (35.7)  
Country 45 (46.9) 14 (35.0) 31 (55.4)  
Other 9 (9.4) 4 (10.0) 5 (8.9)  
Smoking (now or past use)    .448 
Yes 68 (70.8) 30 (75.0) 38 (67.9)  
No 28 (29.2) 10 (25.0) 18 (32.1)  
Alcohol History (now or past 
use) 
   .972 
Yes 55 (57.3) 23 (57.5) 32 (57.1)  
No 41 (42.7) 17 (42.5) 24 (42.9)  
Current Alcohol intake    .309 
Yes 27 (54.0) 12 (63.3) 15 (48.4)  
No 23 (46.0) 7 (36.8) 16 (51.6)  
Income per year    .496 
<$50,000 51 (53.1) 24 (60.0) 27 (48.2)  
>50,000 28 (29.2) 10 (25.0) 18 (32.1)  
Did not care to respond 17 (17.7) 6 (15.0) 11 (19.6)  
Education    .258 
< High School 9 (9.4) 4 (10.0) 4 (7.1)  
> High School 85 (88.5) 30 (90.0) 52 (92.9)  
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The disease and treatment characteristics of all participants in the parent 
study (N=96), the subsample included in this study (N=56) and those not 
included (N=40) are summarized in Table 6. The most common type of cancer 
diagnosis in the current study sample was squamous cell carcinoma (N=48, 
84.9%). The predominant location of the cancer was in the oropharynx (N=28, 
50.0%). Additionally, most patients underwent chemotherapy (N= 54, 96.4%)  
There was a statistically significant difference in the rates of viral etiology within 
the set of patients in the current study and those not in this study (p=0.038). This 
rate was higher in the study sample (N=30 of 56, 53.8%) than it was in the 
sample not included (N=15 of 40, 37.5%). There were no other statistically 
significant differences in disease and treatment characteristics between the 
groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 80 
Table 6: Description of Disease and Treatment 
 
 
 
 
Parent Study 
 
Not in Current 
Study 
In Current 
Study 
p-
value 
 Total (%) 
N=96 
Total (%) 
N=40 
Total (%) 
N=56 
 
Type of Cancer    .517 
Squamous Cell Carcinoma 81 (84.4) 33 (82.5) 48 (84.9)  
Other 15 (15.6) 7 (17.5) 8(14.3)  
Location of Cancer    .427 
Oral Cavity 20 (20.8) 9 (22.5) 11 (19.6)  
Oropharynx 41 (42.7) 13 (32.5) 28 (50.0)  
Larynx 13 (13.5) 8 (20.0) 5 (8.9)  
Other 22 (22.9) 10 (25.0) 9 (16.1)  
Known Viral Etiology    .039 
None 51 (53.1) 25 (62.5) 26 (46.4)  
HPV 28 (29.2) 5 (12.5) 23 (41.1)  
Other 17 (17.7) 10 (25.0) 7 (12.5)  
Surgery    .422 
Yes 41 (42.7) 19 (47.5) 22 (39.4)  
No 55 (57.3) 21 (52.5) 34 (60.7)  
Chemotherapy    .227 
Yes 94 (97.9) 40 (100) 54 (96.4)  
No 2 (2.1) 0 (0) 2 (3.6)  
Type of Surgery (N=41) (N=19) (N=22) .764 
RND 2 (4.9) 1 (5.3) 1 (4.6)  
Modified ND 25 (61.0) 10 (52.6) 15 (68.2)  
Total/Partial Laryngectomy 4 (9.8) 3 (15.8) 1 (4.6)  
Other 10 (24.4) 5 (26.3) 5 (22.7)  
Concurrent Radiation    .239 
Yes (97.9) 38 (100) 54 (96.4)  
No 2 (2.1) 0 (0) 2 (3.6)  
PEG    .078 
Yes 49 (52.1) 24 (63.2) 25 (44.6)  
No 45 (47.9) 14 (36.8) 31 (55.4)  
Type of Treatment    .380 
Chemo XRT 15 (16.0) 7 (18.4) 8 (14.3)  
Induction + ChemoXRT 42 (44.7) 14 (36.8) 28 (50.0)  
Surgery + ChemoXRT 25 (26.6) 11 (28.9) 14 (25.0)  
Surgery + Radiotherapy 2 (2.1) 0 (0) 2 (2.1)  
Induction + Chemo XRT+Surgery 10 (10.6) 6 (15.8) 4 (7.1)  
Distant Metastasis    .445 
Yes 5 (5.2) 3 (7.5) 2 (3.6)  
No 91 (94.8) 37 (92.5) 54 (96.4)  
Tumor TNM Stage    .317 
Stage 0-3 45 (46.9) 20 (50.0) 25 (44.6)  
Stage 2a,2b,2c, 3b 51 (53.1) 20 (50.0) 31 (55.4)  
Stage of Tumor    .849 
Stage 1-3 26 (27.1) 11 (27.5) 15 (26.8)  
Stage 4a and 4b 70 (72.9) 29 (72.5) 41 (73.2)  
Size of the Tumor    .259 
3 or less 67 (68.8) 23 (57.5) 44 (76.8)  
4 12 (12.5) 9 (22.5) 3 (5.4)  
4a/b 11 (11.4) 5 (12.5) 6 (10.7)  
X 6 (6.3) 3 (7.5) 3 (5.4)  
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Results for each AIM 
 
AIM 1: To examine cytokines, RBCS and albumin in HNC patients.  
 
Question: Do baseline red blood cells and baseline albumin levels correlate with 
changes in cytokines at 6- and 12-months? 
 
RBCs in this study were measured in million cells per microliter 
(cells/mcL). The normal range for an adult male is 4.7 to 6.1 cells/mcL and for an 
adult female is 4.2 to 5.4cells/mcl. However, variations within these ranges can 
occur for several reasons (NIH, 2015). The median for males and females in this 
study (4.51) were within their respective normal ranges (Table 7). The median for 
females (4.28) and males (4.73) are within the normal range for both sexes. 
Normal albumin level is approximately 4m/dL. The median and IQR albumin 
values for the sample in this study were slightly higher than that norm.  
Table 7: Description of Red Blood Cells and Albumin at Baseline 
 Red Blood 
Cells Entire 
Study Group 
Red Blood 
Cells Male 
Red Blood 
Cells Female 
Albumin 
N 55 39 16 53 
Median 4.51 4.73 4.28 4.20 
IQR 4.21, 4.87 4.37, 4.96 3.63, 4.46 4.05, 4.40 
Min, Max 3.08, 5.56 3.62, 5.56 3.08, 5.44 3.10, 4.70 
 
Descriptive summaries of the cytokines assessed in this study at baseline 
and the changes in those cytokines from baseline at 6-months and 12-months 
post treatment are summarized in Tables 8-11. The interleukins assessed 
included IL-1β, IL-6, IL-8, IL-10, and IL-12p70. As shown in Table 8, there was a 
high degree of variability among the interleukins at baseline and changes in 
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those interleukins throughout the first year. Furthermore, it was not uncommon to 
see many patients with zero detectable IL-1β and IL-12p70 at baseline and little 
change in values throughout the study period. In contrast to, IL-6, IL-8 and IL-10, 
a majority of patients had detectable levels of those cytokines at baseline and 
varying levels of change during the study period.  
 
Table 8: Interleukins at Baseline and Changes from Baseline at 6- and 12-
months 
IL-1β    
 BL 6 Month Change 12 Month Change 
N 56 54 56 
Median 0.03 -0.02 0.00 
IQR 0.00, 0.18 -0.10, 0.00 -0.14, 0.01 
Min, Max 0.00, 6.51 -6.48, 1.09 -6.51, 0.14 
IL-6    
 BL 6 Month Change 12 Month Change 
N 56 54 56 
Median 1.37 -0.03 -0.08 
IQR 0.65, 3.01 -1.04, 0.43 -0.89, 0.44 
Min, Max 0.10, 28.30 -27.63, 9.37 -9.65, 463.70 
IL-8    
 BL 6 Month Change 12 Month Change 
N 56 54 56 
Median 12.35 -0.84 -2.27 
IQR 8.64, 17.18 -6.12, 2.89 -7.13, 1.44 
Min, Max 2.27, 6845.00 -6833.70,  
671.30 
-6836.89 
32,140.50 
IL-10    
 BL 6 Month Change 12 Month Change 
N 56 54 56 
Median 0.44 -0.06 -0.07 
IQR 0.26, 2.06 -0.61, 0.16 -0.44, 0.54 
Min, Max 0.07, 852.00 -851.87, 2.92 -851.80, 4.07 
IL-12p70    
 BL 6 Month Change 12 Month Change 
N 56 54 56 
Median 0.07 -0.002 0.00 
IQR 0, 0.18 -0.11, 0.4 -0.08, 0.05 
Min, Max 0, 0.57 -0.48, 1.26 -0.57, 1.14 
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The matrix metalloproteinases assessed in this study included MMP2A 
and MMP9A in this study. There was high variability amongst MMP2A and 
MMP9A (see Table 9). Both cytokines trended downward over the one-year of 
the study. 
Table 9: Matrix Metalloproteinases at Baseline and Changes from Baseline  
    at 6- and 12-months. 
MMP2A    
 BL 6 Month Change 12 Month Change 
N 56 54 56 
Median 1.1 x 104 8187.50 5820.00 
IQR 9.2 x105  
3.4 x105 
-5477.00,  
2.8 x104 
-3898.50,  
1.8 x 104 
Min, Max 5.5 x104 4.5 x105 -3.2 x105,  
1.2 x 104 
-4.7 x104,   
1.8 x 104 
MMP9A    
 BL 6 Month Change 12 Month Change 
N 56 54 56 
Median 1.5 x105 -5.3 x104 -4.5 x104 
IQR 1.1 x 105,   
1.5 x 105 
-1.6 x105, 
8030.50 
-1.4 x 105, 
-1704.00 
Min, Max 5.3 x 105,  
6.0 x 105 
-4.2 x 10 x105, 
8030.50 
-1.4 x105, 
-1704.00 
 
 The tumor growth factor families measured in this study included TGF-β1, 
TGF-β2 and TGF-β3.  As shown in Table 11, a general decrease in these 
cytokines occurred over the one-year study period. It should be noted that lab 
analyses of TGF-β3 at the three times of assessment was available for less than 
half of the participants in the study (25 of 56). 
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Table 10: Transforming Growth Factors (TGF-β1, TGF-β2 and TGF-β3) at 
Baseline and Changes from Baseline at 6- and 12-months.  
TGF-β1    
 BL 6 Month Change 12 Month Change 
N 56 54 56 
Median 3.3 X104 -6500.00 -5127.00 
IQR 2.4 X 104,  
4.1 X 104 
-1.6 x104, 530.25 -1.0 X 104, 437.50 
Min, Max 2399, 4.1 X104 -2.8 x 104,  
1.6 X 104  
-4.3 x 104,  
3.1 x104 
TGF-β2    
 BL 6 Month Change 12 Month Change 
N 54 53 54 
Median 1637.50 -280.00 -283.00 
IQR 1080.00 
2164.25 
-692.25, 191.75 -592.25, 130.50 
Min, Max 560.00, 4842.00 -2587.00, 1511.00 
  
-2556.00, 1272.00 
TGF-β3    
 BL 6 Month Change 12 Month Change 
N 24 25 26 
Median 85.00 6.50 -37.05 
IQR 30.32, 142.75 -17.38, 31.93 -81.78, 31.58 
Min, Max 9.00, 416.00 -69.30, 133.90 -347.70, 85.00 
 
 There was very little variability in IFN-γ during the study, but overall the 
median level trended downward over one-year (see Table 11). TNF-α also had 
very little variability over one year and overall had a slight decrease over the one-
year study period. CRP levels had great variability over the one-year period. CRP 
also decreased over the one-year study period. 
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Table 11: Description of TNF-α, IFN-γ & CRP at Baseline and Changes from 
Baseline at 6- and 12-months. 
TNF-α    
 BL 6 Month Change 12 Month Change 
N 56 54 56 
Median 2.59 -0.31 -0.25 
IQR 1.82, 3.72 -0.93, 0.13 -1.07, 0.08 
Min, Max 0.36, 69.8 -65.23, 0.97 -52.00, 2.30 
IFN-γ    
 BL 6 Month Change 12 Month Change 
N 56 54 56 
Median 3.69 -0.09 -0.19 
IQR 0.80, 7.79 -2.12, 1.43 -2.36, 1.00 
Min, Max 0.00, 32.90 -26.70, 19.00 -23.51, 24.71 
CRP    
 BL 6 Month Change 12 Month Change 
N 56 54 56 
Median 1.60 x 106 -7815.00 -2.2 x 105 
IQR 0.2x105 6.5x106 -1.1 x 106, 5.8 x 
104 
-2.3 x106, 1584.50 
Min, Max 817, 1.1 x106 -1.8 x 106, 2.1 x 
107 
-1.1 x 108, 1,8 x 
107 
 
 
Associations of baseline red blood cells (RBCs) with changes in cytokines 
from baseline to 6- and 12-months are shown in Table 12. Associations of pre-
treatment albumin levels with the same cytokine changes are shown in Table 13. 
After controlling for respective pre-treatment cytokine levels, there were 
statistically significant inverse associations of pretreatment RBCs levels changes 
from pre-treatment in MMP9-A and TNF-α (MMP9-A: beta= -0.22, p=0.018; TNF-
α: beta= -0.24, p=0.045). Patients with higher RBCs at baseline had less 
increase or greater decrease in both MMP9-A and TNF-α through the study 
period. A similar pattern of association was found between pre-treatment levels 
of albumin and changes in IL-1β from pre-treatment to 12-months post-treatment 
(beta= -0.22, p=0.027, see Table 13). 
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Table 12: Association with Red Blood Cells at Baseline and 6- and 12-
Month Changes in Cytokines from Baseline  
Cytokines 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 -0.12 0.120 -0.14 0.169 
IL-6 0.03 0.835 -0.07 0.574 
IL-8 0.05 0.675 -0.03 0.755 
IL-10 -0.05 0.690 -.15 0.183 
IL-12p70 <0.01 0.987 -0.06 0.616 
MMP2A 0.20 0.157 <0.01 0.993 
MMP9A -0.16 0.065 -0.22 0.018 
TGF-β1 -0.02 0.813 0.06 0.592 
TGF-β2 -0.12 0.310 -0.07 0.546 
TGF-β3* 0.15 0.576 -0.41 0.055 
TNF-α -0.09 0.501 -0.24 0.046 
IFN-y 0.23 0.090 0.05 0.675 
CRP 0.10 0.419 0.17 0.126 
* N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 
 
 
Table 13: Association with Albumin at Baseline and 6- and 12-months 
Changes in Cytokines from Baseline  
Cytokines 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 -0.15 0.055 -0.22 0.027 
IL-6 0.03 0.852 -0.11 0.439 
IL-8 0.07 0.524 -0.08 0.374 
IL-10 -0.10 0.424 -0.22 0.073 
IL-12p70 -0.07 0.550 -0.15 0.226 
MMP2A 0.19 0.190 -0.05 0.751 
MMP9A <0.01 0.993 -0.06 0.570 
TGF-β1 0.11 0.260 -0.06 0.637 
TGF-β2 0.15 0.177 0.04 0.757 
TGF-β3* -0.11 0.691 -0.04 0.861 
TNF-α -0.05 0.685 -0.06 0.647 
IFN-y -0.03 0.839 -0.03 0.820 
CRP 0.13 0.348 0.15 0.203 
* N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 	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AIM 2: To examine the role of cytokines, RBCs, albumin and severity of 
weight loss in HNC patients. 
 
Question 2a: Are baseline cytokines, RBCs and Albumin correlated with weight 
loss at 6- and 12-months? 
 
Weight (kg) and BMI measured at baseline, and changes from baseline 
BMI and weight at 6-months and 12-months post treatment are shown in Table 
14. The median baseline BMI of 28.82 is above 25. A BMI > 25 is considered 
overweight. The 25% IQR at baseline is also above 25 indicating that a majority 
of patients were overweight at the time of enrollment. While the median BMI does 
decrease from baseline at both 6- and 12-months, a majority of patients 
remained overweight. At 12-months, the median change in BMI was slightly less 
than 6-months. This indicates that the group as a whole remained stable with 
their weight after approximately 6-months.  
Table 14: Description of Weight and BMI at Baseline and Changes from 
Baseline at 6- and 12-months 
Weight (kg)    
 BL 6 Month Change 12 Month Change 
N 56 53 53 
Median 86.00 -9.10 -6.84 
IQR 78.12, 99.55 -14.26, -2.20 -12.22, 3.00 
Min, Max 48.10, 151.40 -32.41, 10.54 -31.69, 12.62 
BMI    
 BL 6 Month Change 12 Month Change 
N 56 53 53 
Median 28.82 -2.86 -2.20 
IQR 25.81, 32.15 -4.67, -0.67 -4.23, 1.00 
Min, Max 18.20, 41.72 -11.53, 3.15 -8.50, 5.62 
 
Associations of pre-treatment cytokine levels with changes in weight and 
BMI from pre-treatment to 6- and 12-months post-treatment are shown in Tables 
15 (weight) and 16 (BMI). Pre-treatment levels of IL-6 provided the single 
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statistically significant pattern of associations with changes in weight at 6-months 
post-treatment (beta= -0.23, p=0.045). Patients with higher IL-6 levels at baseline 
had greater decrease in weight through the study period than patients with lower 
IL-6 pre-treatment values. By 12-months post-treatment a similar direction yet 
slightly smaller coefficient and no longer statistically significant coefficient was 
demonstrated (beta= -0.23, p=0.045). 
Table 15: Association of Pre-Treatment Cytokine Levels, RBC, and Albumin 
with Change in Weight from Pre-Treatment to 6- and 12-months Post-
Treatment 
Biomarker 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 -0.12 0.324 -0.03 0.826 
IL-6 -0.23 0.045 -0.21 0.082 
IL-8 0.06 0.606 0.03 0.820 
IL-10 -0.04 0.760 0.03 0.811 
IL-12p70 0.03 0.784 0.01 0.944 
MMP2A 0.05 0.655 <0.01 0.974 
MMP9A <0.01 0.983 0.14 0.264 
TGF-β1 0.13 0.275 0.20 0.096 
TGF-β2 -0.12 0.321 -0.14 0.285 
TGF-β3* -0.12 0.559 -0.09 0.680 
TNF-α 0.01 0.914 -0.01 0.970 
IFN-y -0.10 0.427 -0.06 0.617 
CRP -0.03 0.817 -0.02 0.863 
RBC 0.16 0.230 0.17 0.267 
Albumin 0.22 0.082 0.21 0.119 
* N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 
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Table 16: Associations of Pre-Treatment Cytokines Levels, RBC, and 
Albumin with Change in BMI from Pre-Treatment to 6- and 12-months Post-
Treatment 
Biomarker 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 -0.07 0.522 0.02 0.861 
IL-6 -0.18 0.101 -0.16 0.199 
IL-8 0.07 0.516 0.02 0.849 
IL-10 -0.01 0.933 0.06 0.631 
IL-12p70 -0.03 0.785 -0.03 0.819 
MMP2A 0.03 0.768 <0.01 0.972 
MMP9A 0.01 0.915 0.15 0.230 
TGF-β1 0.10 0.369 0.19 0.110 
TGF-β2 -0.09 0.438 -0.08 0.509 
TGF-β3* -0.19 0.908 -0.04 0.851 
TNF-α 0.03 0.758 0.03 0.806 
IFN-y -0.11 0.337 -0.09 0.482 
CRP <0.01 0.990 -0.01 0.955 
RBC 0.09 0.434 0.10 0.431 
Albumin 0.21 0.078 0.19 0.128 
* N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 
 
Question 2b: Does a change in cytokine levels from baseline to 6-months 
correlate with weight loss at 6- and 12-months?  
 
Correlations of changes in cytokine levels from pre-treatment to 6-months 
and 12-months post-treatment with respective changes in weight and in BMI are 
summarized in Tables 17 and 18. Similar patterns of associations resulted. 
During the early post-treatment period the strongest and only statistically 
significant association was an inverse association of changes in IL-10 with weight 
and BMI changes over the same period (weight: beta= -0.36, p=0.012; BMI: 
beta=-0.31, p=0.025). In other words increasing IL-10 levels were associated 
with decreasing weight and/or BMI over the same time period. For the longer 
post-treatment period (12-months), the strongest associations and statistically 
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significant associations with changes in weight/BMI from pre-treatment were with 
changes in IFN-y and TGF-β1.Contrary to the pattern seen with IL-10 during the 
short-term, decreasing levels of both of these cytokines were associated with 
decreasing weight and/or BMI (see Tables 17 and 18). 
Table 17:  6-Month Change in Cytokines, RBC, and Albumin with Change in 
Weight from Baseline at 6- and 12-months	  
Biomarker 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 -0.31 0.157 -0.14 0.435 
IL-6 0.10 0.484 0.25 0.112 
IL-8 0.21 0.190 0.20 0.309 
IL-10 -0.36 0.012 -0.18 0.241 
IL-12p70 <0.01 0.983 -0.22 0.141 
MMP2A 0.19 0.114 -0.05 0.734 
MMP9A 0.15 0.441 0.09 0.653 
TGF-β1 0.20 0.256 0.32 0.033 
TGF-β2 0.21 0.200 -0.05 0.743 
TGF-β3* 0.30 0.351 -0.35 0.361 
TNF-α 0.10 0.474 0.18 0.220 
IFN-y -0.01 0.971 0.32 0.019 
CRP -0.03 0.797 0.10 0.562 
RBC 0.47 0.088 0.71 0.356 
Albumin -0.51 0.117 -0.10 0.753 
* N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 
 
 
 
 
 
 
 
 
 
 
 91 
Table 18:  6-Month Change in Cytokines, RBC, and Albumin with Change in 
BMI from Baseline at 6- and 12-months 
Biomarker 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 -0.19 0.360 -0.10 0.581 
IL-6 0.11 0.409 0.26 0.087 
IL-8 0.19 0.200 0.11 0.578 
IL-10 -0.31 0.025 -0.21 0.158 
IL-12p70 <0.01 0.985 -0.20 0.162 
MMP2A 0.17 0.118 -0.07 0.549 
MMP9A 0.26 0.149 0.14 0.451 
TGF-β1 0.10 0.559 0.29 0.047 
TGF-β2 0.09 0.596 -0.06 0.729 
TGF-β3* 0.29 0.331 -0.33 0.287 
TNF-α 0.10 0.435 0.19 0.193 
IFN-y 0.03 0.785 0.31 0.020 
CRP -0.08 0.549 0.05 0.768 
RBC 0.28 0.070 0.31 0.666 
Albumin -0.36 0.268 0.02 0.949 
*  N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 
 
AIM 3: To examine the association between cytokines, RBCs, albumin and 
reported symptoms in HNC patients? 
 
Question 3: Are initial cytokines, RBCs and albumin associated with changes in 
reported symptoms such as: depression, nutrition consumption, swallowing 
difficulties, mucositis, generalized pain, mouth pain, dental discomfort, hearing, 
xerostomia, taste, jaw movement and voice at 6- and 12-months. 
 
Depressive Symptoms 
Descriptions of the CESD measured at baseline, and changes in that 
measure at 6-months and 12-months is provided in Table 19. There was 
considerable variability in self-reported CESD scores over the duration of this 
study. This variability likely made it possible to identify associations with other 
variables such as cytokines.  
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Table 19: Description of Depressive Symptoms as Measured by CESD at 
Baseline and Changes from Baseline at 6- and 12-Months 
 BL 6 Month Change 12 Month Change 
N 56 54 54 
Median 12.00 -3.50 -4.00 
IQR 7.00, 21.75 -10.00, 1.00 -10.00, 1.00 
Min, Max 0.0, 39.00 -34.00, 16.00 -34.00, 15.00 
 
 
Associations of initial levels of cytokines with changes in levels of 
depression over 6- and 12-months post treatment are presented in Table 20. 
Lower levels (relative to higher levels) of TGF-β2 prior to treatment were 
statistically significantly associated with greater increases in CESD scores from 
prior to treatment to 12-months post treatment (beta= -0.41, p=0.002). In 
addition, a positive association with pre-treatment CRP levels was observed 
(beta= 0.28, p=0.035) indicating the patients with higher CRP levels pre-
treatment tended to have greater increases in depressive symptoms in the 12-
months post-treatment (relative to their symptoms prior to treatment) than did 
patients with lower pre-treatment CRP levels.   
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Table 20: Initial Biomarker Levels and Changes in Depression from 
Baseline at 6- and 12-months 
Biomarker 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 <0.01 0.987 -0.01 0.957 
IL-6 0.22 0.079 0.04 0.750 
IL-8 0.17 0.184 0.20 0.139 
IL-10 0.08 0.543 -0.13 0.347 
IL-12p70 -0.08 0.511 0.12 0.362 
MMP2A -0.08 0.545 -0.15 0.255 
MMP9A -0.19 0.129 -0.10 0.445 
TGF-β1 -0.21 0.099 0.07 0.584 
TGF-β2 -0.21 0.119 -0.41 0.002 
TGF-β3* 0.12 0.443 -0.02 0.902 
TNF-α 0.16 0.207 -0.07 0.599 
IFN-y 0.14 0.270 0.20 0.125 
CRP 0.17 0.168 0.28 0.035 
RBC -0.20 0.112 0.01 0.966 
Albumin 0.01 0.941 -0.03 0.857 
* N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 
 
Nutrition-Related Symptoms 	  
Descriptions of the VHNSS Nutrition cluster scores at baseline and 
changes from baseline at 6-months and 12-months post treatment are presented 
in Table 21. The median baseline score was <0.3 on a 0-10 scale. Fifty percent 
of patients demonstrated no change from baseline to 6- or 12-months; 75% did 
not increase more than 0.75 over the course of the study period.   
Table 21: Reported Difficulties with Consuming Nutrition at Baseline and 
Changes from Baseline at 6- and 12-Months 
 BL 6 Month Change 12 Month Change 
N 56 54 54 
Median 0.25 0.00 0.00 
IQR 0.00, 1.50 -0.50, 0.75 -1.00, 0.25 
Min, Max 0.00, 7.00 -5.25, 7.75 -7.00, 3.75 
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Associations of initial levels of cytokines and changes in the VHNSS 
Nutrition cluster scores from baseline at 6- and 12-months post treatment are 
presented in Table 22. Higher levels of IL-6, IL-10 and MMP2a at baseline were 
associated with worsening nutrition consumption at 6-months (IL-6: beta= 0.35, 
p=0.006; IL-10: beta= 0.33, p=0.008; MMP2A: beta= 0.27, p=0.035). Lower 
levels of TGF-β1 and IFN-y at baseline were associated with worsening nutrition 
symptoms at 6-months: (TGF-β1: beta= -0.31, p= 0.014; IFN-y: beta= -0.25, p= 
0.048). IL-6 was the only biomarker with short-term effects that remained at a 
statistically significant level over the longer 12-month post-treatment period 
(beta= 0.21, p=0.041).  
Table 22: Initial Biomarker Levels and Changes in Nutrition-Related 
Symptoms from Baseline at 6- and 12-Months 
Biomarker 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 0.06 0.660 0.06 0.592 
IL-6 0.35 0.006 0.21 0.041 
IL-8 -0.06 0.641 0.06 0.568 
IL-10 0.33 0.008 0.12 0.237 
IL-12p70 -0.06 0.631 -0.03 0.764 
MMP2A 0.27 0.035 0.11 0.297 
MMP9A -0.17 0.202 0.03 0.765 
TGF-β1 -0.31 0.014 -0.06 0.600 
TGF-β2 0.12 0.359 -0.14 0.201 
TGF-β3* -0.04 0.854 -0.36 0.096 
TNF-α 0.18 0.155 0.17 0.112 
IFN-y -0.25 0.048 -0.03 0.807 
CRP -0.24 0.064 -0.03 0.789 
RBC -0.13 0.321 -0.04 0.727 
Albumin -0.01 0.930 -0.10 0.369 
* N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 
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Swallowing  	  
Descriptions of patients’ self-reported difficulties with swallowing solids as 
assessed by the VHNSS Swallowing Solids cluster score at baseline and 
changes from baseline at 6-months and 12-months post treatment are presented 
in Table 23.  There was considerable variability in reported difficulties with 
swallowing solids over the duration of this study. This variability likely made it 
possible to identify associations with other variables such as cytokines.   
  
Table 23: Reported Difficulties with Swallowing Solids from Baseline and 
Changes from Baseline at 6- and 12-Months 
 BL 6 Month Change 12 Month Change 
N 56 54 54 
Median 0.63 0.63 0.38 
IQR 0.03, 2.63 -0.38, 2.91 -0.38, 1.16 
Min, Max 0.00, 8.00 -3.50, 5.63 -4.63, 6.13 
 
Associations of initial levels of cytokines with changes in symptoms 
related to swallowing solids between pre-treatment and 6- and 12-months post 
treatment are presented in Table 24. Higher initial levels of IL-6, IL-10 and TNF-α 
were associated with an increase in difficulty swallowing solids from baseline to 
6- and 12-months post-treatment. [IL-6: (6-months: beta= 0.34, p=0.009; 12-
months: beta= 0.36, p=0.006), IL-10: (6-months: beta= 0.31, p=0.023; 12-
months: beta= 0.39, p=0.003), and TNF-α: (6-months: beta= 0.31, p= 0.019)]. 
Lower levels of albumin pre-treatment were both associated with increased 
difficulty swallowing solids one-year later (beta= -0.27, p=0.048).  
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Table 24: Initial Biomarker Levels and Changes in Swallowing Solids from 
Baseline at 6- and 12-Months 
Biomarker 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 0.26 0.057 0.25 0.060 
IL-6 0.34 0.009 0.36 0.006 
IL-8 0.22 0.107 0.21 0.116 
IL-10 0.31 0.023 0.39 0.003 
IL-12p70 -0.04 0.770 -0.11 0.394 
MMP2A 0.03 0.828 0.16 0.233 
MMP9A 0.16 0.262 0.11 0.416 
TGF-β1 -0.17 0.223 -0.11 0.445 
TGF-β2 -0.12 0.399 -0.14 0.303 
TGF-β3* -0.17 0.448 -0.10 0.628 
TNF-α 0.31 0.019 0.23 0.091 
IFN-y -0.07 0.625 -0.05 0.711 
CRP -0.09 0.509 -0.15 0.253 
RBC 0.18 0.198 0.24 0.085 
Albumin -0.15 0.292 -0.27 0.048 
* N=~25 with data for TGF-β3 pre-treat, 6- and 12-months post 
 
 
Summaries of patient-reported VHNSS Swallowing Liquids cluster scores 
at baseline and changes in that score from baseline to 6- and 12-months post 
treatment are presented in Table 25. The median score was 0 at baseline and 
the median IQR change values also indicated was also 0 or less than 0.5 point 
change on a scale of 0-10 from baseline to 6- and 12-months post treatment.  
 
Table 25: Reported Difficulties with Swallowing Liquids from Baseline and 
Changes from Baseline at 6- and 12-Months 
 BL 6 Month Change 12 Month Change 
N 56 54 54 
Median 0.00 0.00 0.00 
IQR 0.00, 0.38 0.00, 0.13 0.00, 0.00 
Min, max 0.00, 9.00 -9.00, 6.00 -8.50, 10.00 
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Associations of initial levels of biomarkers with changes in the patient-
reports of changes in difficulty with swallowing liquids from baseline to 6- and 12-
months post treatment were considerably weaker than those observed for 
swallowing solids (see Table 26).  A single inverse association was statistically 
significant (IL-12p70: beta= -0.27, p=0.025).   
Table 26: Initial Biomarker Levels and Changes in Swallowing Liquids from 
Baseline at 6- and 12-Months 
Biomarker 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 0.24 0.058 0.15 0.221 
IL-6 0.09 0.483 0.03 0.822 
IL-8 0.09 0.507 -0.12 0.349 
IL-10 <0.01 0.989 0.15 0.231 
IL-12p70 -0.01 0.948 -0.27 0.025 
MMP2A -0.12 0.347 0.01 0.928 
MMP9A 0.20 0.114 0.05 0.682 
TGF-β1 -0.23 0.078 -0.16 0.201 
TGF-β2 -0.11 0.413 -0.14 0.297 
TGF-β3* -0.31 0.171 -0.04 0.865 
TNF-α 0.11 0.411 <0.01 0.990 
IFN-y -0.20 0.132 -0.15 0.221 
CRP -0.01 0.936 -0.13 0.282 
RBC 0.13 0.330 0.15 0.249 
Albumin 0.10 0.465 -0.02 0.889 
* N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 
 
Mucositis 
 
Descriptions of the patient-reported VHNSS Mucositis cluster scores at 
baseline and changes from baseline at 6- and 12-months post treatment are 
presented in Table 27. The median baseline score was <0.2 on a 0-10 scale and 
there was no change in the median score over the duration of the study. 
Additionally, 75% of the participants did not increase more than 0.50 over the 
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course of this study period. Due to the limited variability in mucositis self-reported 
scores, detecting any associations with cytokines and mucositis will be difficult.   
Table 27: Reported Difficulties with Mucositis Symptoms at Baseline and 
Changes from Baseline at 6- and 12-Months 
 BL 6 Month Change 12 Month Change 
N 56 54 54 
Median 0.13 0.00 0.00 
IQR 0.00, 1.00 -0.25, 0.50 -0.75, 0.50 
Min, Max 0.00, 10.00 -10.00, 9.75 -10.00, 7.00 
 
Associations of initial levels of biomarkers with changes from baseline to 
6- and 12-months post treatment in patient-reported mucous symptoms are 
summarized in Table 28.  Initial levels of IL-1β indicated a statistically significant 
positive association with increases in such symptoms 6-months post-treatment 
(beta= 0.26, p=0.035). 
Table 28: Initial Biomarker Levels and Changes in Mucous Symptoms from 
Baseline at 6- and 12-Months 
Biomarker 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 0.26 0.035 0.11 0.333 
IL-6 0.21 0.097 0.02 0.861 
IL-8 0.12 0.322 0.02 0.834 
IL-10 0.08 0.540 0.08 0.501 
IL-12p70 0.10 0.405 -0.01 0.968 
MMP2A 0.04 0.762 0.09 0.446 
MMP9A 0.10 0.409 0.05 0.698 
TGF-β1 -0.14 0.277 -0.10 0.370 
TGF-β2 -0.04 0.783 -0.18 0.122 
TGF-β3* -0.25 0.244 -0.29 0.153 
TNF-α 0.14 0.257 -0.02 0.880 
IFN-y -0.09 0.487 0.06 0.600 
CRP -0.06 0.612 -0.07 0.535 
RBC 0.21 0.093 0.20 0.081 
Albumin -0.13 0.328 0.05 0.683 
* N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 
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Generalized Pain 	  
Descriptions of the patient-reported VHNSS generalized pain cluster 
scores at baseline and changes from baseline at 6- and 12-months post 
treatment are presented in Table 29. Due to the limited variability in generalized 
pain self-reported scores, detecting any associations with cytokines and 
generalized pain scores will be difficult. 
 
Table 29: Reported Difficulties with Generalized Pain at Baseline and 
Change from Baseline at 6- and 12-Months 
 BL 6 Month Change 12 Month Change 
N 56 54 54 
Median 0.83 0.00 0.00 
IQR 0.00, 4.67 -2.08, 0.21 -3.00, 0.33 
Min, Max 0.00, 9.00 -9.33, 2.33 -9.33, 6.67 
 
Associations of initial levels of cytokines with changes in patient-reports of 
pain levels from baseline to 6-and 12-months post treatment are presented in 
Table 30. Higher levels of IL-1β and RBC pre-treatment were associated with 
greater increases in pain symptoms from pre-treatment to 6-months post-
treatment (IL-β1: beta= 0.25, p=0.031, RBC: beta= 0.23 p=0.048). 
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Table 30: Initial Biomarker Levels and Changes in General Pain Symptoms 
from Baseline at 6- and 12-Months 
Biomarker 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 0.25 0.031 0.07 0.585 
IL-6 0.20 0.094 -0.12 0.345 
IL-8 0.21 0.078 0.16 0.198 
IL-10 0.20 0.092 0.07 0.613 
IL-12p70 -0.02 0.873 -0.11 0.355 
MMP2A 0.07 0.592 0.04 0.742 
MMP9A 0.11 0.342 -0.06 0.617 
TGF-β1 -0.01 0.964 0.10 0.420 
TGF-β2 0.02 0.854 -0.13 0.306 
TGF-β3* -0.19 0.370 -0.23 0.217 
TNF-α 0.16 0.169 0.07 0.583 
IFN-y -0.07 0.555 0.16 0.198 
CRP -0.10 0.429 -0.16 0.210 
RBC 0.23 0.048 0.20 0.105 
Albumin -0.01 0.930 0.13 0.293 
* N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 
 
Mouth Pain 
 
Descriptions of the patient-reported VHNSS mouth pain cluster scores at 
baseline and changes from baseline at 6- and 12-months post treatment are 
presented in Table 31. At baseline, the overall median was <0.3 on a scale 
where 10 indicates severe pain and 1 indicates mild discomfort. There was no 
change in the median pain score from baseline at both 6- and 12-months. Due to 
the limited variability in mouth pain self-reported scores, detecting any 
associations with cytokines and mouth pain will be difficult.  Similar patterns of 
association for pre-treatment IL-1β and RBCs as that found for general pain were 
observed for changes in mouth pain symptoms from pre- to 6-months post (IL-β1: 
beta= 0.30, p=0.021; RBC: beta= 0.30, p=0.027, see Table 32). 
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Table 31: Reported Difficulties with Mouth Pain at Baseline and Change 
from Baseline at 6- and 12-Months 
 BL 6 Month Change 12 Month Change 
N 56 54 54 
Median 0.25 0.00 0.00 
IQR 0.00, 1.63 -0.21, 1.13 -0.33, 0.42 
Min, Max 0.00, 10.00 -10.00, 8.83 -8.33, 6.00 
 
 
 
Table 32: Initial Biomarker Levels and Changes in Mouth Pain Symptoms 
from Baseline at 6- and 12-Months 
Biomarker 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 0.30 0.021 0.14 0.260 
IL-6 0.22 0.093 0.15 0.233 
IL-8 0.15 0.260 0.13 0.296 
IL-10 0.17 0.201 0.14 0.261 
IL-12p70 0.07 0.631 0.01 0.961 
MMP2A 0.09 0.496 0.09 0.453 
MMP9A 0.17 0.193 -0.01 0.925 
TGF-β1 -0.04 0.789 -0.06 0.662 
TGF-β2 0.11 0.470 -0.05 0.686 
TGF-β3* -0.18 0.356 -0.21 0.203 
TNF-α 0.08 0.541 0.02 0.865 
IFN-y -0.15 0.254 0.02 0.899 
CRP -0.15 0.270 -0.13 0.307 
RBC 0.30 0.027 0.25 0.051 
Albumin -0.05 0.697 -0.18 0.164 
* N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 
Dental Discomfort 
 
Descriptions of the VHNSS Dental cluster scores at baseline and changes 
from baseline at 6- and 12-Months post treatment are presented in Table 33. The 
baseline median score was 0 on a 0-10 scale and there was little to no change 
from this level over the course of the study. No statistically significant 
 102 
associations of pre-treatment biomarker levels with changes in dental symptoms 
were observed (see Table 34). 
Table 33: Reported Difficulties with Dental Discomfort at Baseline and 
Change from Baseline at 6- and 12-Months 
 BL 6 Month Change 12 Month Change 
N 44 43 44 
Median 0.00 0.00 0.00 
IQR 0.00, 0.50 0.00, 0.75 0.00, 1.25 
Min, Max 0.00, 5.00 0.00, 6.00 0.00, 5.00 
 
Table 34: Initial Biomarker Levels and Changes in Dental Discomfort 
Symptoms from Baseline at 6- and 12-Months 
Biomarker 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 0.13 0.426 -0.01 0.935 
IL-6 0.17 0.280 0.13 0.423 
IL-8 0.07 0.648 0.08 0.620 
IL-10 0.12 0.437 0.04 0.795 
IL-12p70 -0.22 0.167 -0.15 0.350 
MMP2A 0.09 0.581 -0.12 0.499 
MMP9A 0.21 0.189 -0.21 0.192 
TGF-β1 0.10 0.551 0.12 0.472 
TGF-β2 -0.28 0.082 -0.26 0.126 
TGF-β3* -0.12 0.652 0.29 0.256 
TNF-α 0.01 0.952 -0.08 0.629 
IFN-y -0.14 0.388 0.17 0.274 
CRP -0.09 0.592 0.10 0.534 
RBC 0.11 0.508 -0.06 0.718 
Albumin -0.22 0.196 0.05 0.749 
* N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 
 
Hearing 
 
Descriptions of the VHNSS Hearing cluster scores at baseline and 
changes from baseline at 6-months and 12-months post treatment are presented 
in Table 35. The baseline median score was 0 on a 0-10 scale and again there 
was little to no change from this level over the course of the study. A single 
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statistically significant inverse association of pre-treatment TGF-β2 levels with 
the amount of change in hearing symptoms from pre-treatment to 6-months post-
treatment was observed (beta= -0.23, p=0.028, see Table 36). 
Table 35: Reported Difficulties with Hearing at Baseline, and Changes from 
Baseline at 6- and 12-Months 
 BL 6 Month Change 12 Month Change 
N 56 54 54 
Median 0.00 0.00 0.00 
IQR 0.00, 3.00 -2.00, 0.00 -1.25, 0.00 
Min, Max 0.00, 10.00 -6.00, 6.00 -8.00, 8.00 
 
 
Table 36: Initial Biomarker Levels and Changes in Hearing from Baseline at 
6- and 12-Months 
Biomarker 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 -0.02 0.876 0.05 0.670 
IL-6 0.06 0.616 0.24 0.071 
IL-8 0.14 0.208 0.11 0.368 
IL-10 0.10 0.362 0.21 0.084 
IL-12p70 -0.15 0.165 -0.15 0.235 
MMP2A -0.09 0.425 0.01 0.969 
MMP9A -0.10 0.366 0.06 0.656 
TGF-β1 -0.10 0.325 0.11 0.358 
TGF-β2 -0.23 0.028 0.02 0.877 
TGF-β3* 0.09 0.566 0.04 0.822 
TNF-α 0.06 0.577 0.18 0.144 
IFN-y 0.13 0.231 0.04 0.741 
CRP 0.05 0.664 <0.01 0.985 
RBC -0.08 0.479 -0.14 0.263 
Albumin -0.17 0.171 -0.04 0.769 
* N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 
 
Xerostomia 	  
Descriptions of the VHNSS Dry Mouth (Xerostomia) cluster scores at 
baseline and change from baseline at 6 and 12-month are presented in Table 37. 
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There was considerable variation in xerostomia scores over the duration of the 
study. This variation is important for the detection of associations with other 
variables.    
Table 37: Reported Difficulties with Xerostomia at Baseline and Change 
from Baseline at 6- and 12-Months 
 BL 6 Month Change 12 Month Change 
N 56 54 54 
Median 0.40 1.10 0.80 
IQR 0.00, 1.75 0.15, 3.20 0.00, 2.20 
Min, Max 0.00, 10.00 -2.60, 7.80 -6.00, 8.00 
 
Associations of initial levels of cytokines and changes in xerostomia 
symptoms as assessed by the VHNSS Dry Mouth cluster scores from baseline to 
6- and 12-months post treatment are presented in Table 38. Statistically 
significant associations of higher initial IL-6, IL-10, and RBCs with worsening 
xerostomia were found at 6-months (IL-6: beta= 0.28, p=0.042; IL-10: beta=0.32, 
p=0.021; RBCs: beta= 0.28, p= 0.042).  Of those, only baseline IL-10 levels 
remained statistically significantly associated with the amount of increase in 
VHNSS Dry Mouth (xerostomia) scores at 12-months relative to baseline 
(beta=0.31, p=0.024). 
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Table 38: Initial Biomarker Levels and Changes in Xerostomia Symptoms 
from Baseline at 6- and 12-Months 
Biomarker 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 0.10 0.458 0.05 0.716 
IL-6 0.28 0.042 0.14 0.298 
IL-8 0.08 0.550 0.04 0.802 
IL-10 0.32 0.021 0.31 0.024 
IL-12p70 -0.15 0.280 -0.23 0.094 
MMP2A -0.10 0.499 0.04 0.773 
MMP9A 0.04 0.756 -0.04 0.778 
TGF-β1 -0.08 0.551 -0.07 0.622 
TGF-β2 -0.18 0.194 -0.20 0.152 
TGF-β3* 0.04 0.865 0.05 0.842 
TNF-α <0.01 0.998 -0.07 0.613 
IFN-y -0.09 0.510 -0.03 0.815 
CRP 0.09 0.521 0.01 0.946 
RBC 0.28 0.042 0.08 0.576 
Albumin <0.01 0.989 0.02 0.868 
* N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 
 
Taste-Smell 
 
Descriptions of the VHNSS Taste/Smell cluster scores at baseline and 
changes from baseline to 6-months and 12-months post treatment are presented 
in Table 39. The median baseline score was 0 on a 0-10 scale and did not 
change more than a point over the course of the study. There was moderate 
variability in self-reported taste/smell scores throughout the duration of the study. 
As shown in Table 40, higher baseline levels of IL-1β and IL-6 were associated 
with worsening taste/smell symptoms at 6- and 12-months post-treatment (all 
betas > 0.30, p < 0.05). 
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Table 39: Reported Changes in Taste/Smell from Baseline and Changes 
from Baseline at 6- and 12-Months 
 BL 6 Month Change 12 Month Change 
N 56 53 54 
Median 0.00 0.67 0.00 
IQR 0.00, 1.33 0.00, 2.33 -0.42, 1.00 
Min, Max 0.00, 8.00 -5.50, 7.00 -5.17, 6.50 
 
 
Table 40: Initial Biomarker Levels and Changes in Taste/Smell Symptoms 
from Baseline at 6- and 12-Months 
Biomarker 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 0.37 0.005 0.32 0.003 
IL-6 0.31 0.022 0.36 0.001 
IL-8 0.02 0.897 0.16 0.148 
IL-10 0.26 0.055 0.16 0.154 
IL-12p70 0.02 0.867 0.05 0.680 
MMP2A 0.14 0.312 0.04 0.719 
MMP9A 0.04 0.749 0.16 0.148 
TGF-β1 -0.24 0.079 -0.06 0.563 
TGF-β2 0.19 0.169 -0.02 0.870 
TGF-β3* -0.02 0.946 0.30 0.149 
TNF-α 0.20 0.150 0.19 0.088 
IFN-y -0.27 0.050 -0.14 0.217 
CRP -0.17 0.209 0.01 0.904 
RBC -0.03 0.811 -0.07 0.512 
Albumin 0.17 0.221 -0.05 0.685 
* N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 
 
Jaw Movement / Trismus 
 
Descriptions of the VHNSS Jaw Movement cluster scores at baseline, and 
changes from baseline to 6-months and 12-months post treatment are presented 
in Table 41. There was limited variability in reported difficulties with opening and 
moving the jaw over the duration of this study. This lack of variability makes it 
difficult to identify associations with other variables such as cytokines. A single 
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statistically significant inverse association of pre-treatment IL-12p70 levels with 
the amount of change in jaw/trismus symptoms from pre-treatment to 6-months 
post-treatment was observed (beta= -0.23, p=0.049, see Table 42). 
Table 41: Reported Difficulties with Opening and Movement of the Jaw at 
Baseline and Change from Baseline at 6- and 12-Months 
 BL 6 Month Change 12 Month Change 
N 56 54 54 
Median 0.00 0.00 0.00 
IQR 0.00, 2.00 0.00, 1.00 -1.00, 0.00 
Min, Max 0.00, 10.00 -8.00, 10.00 -10.00, 7.00 
 
Table 42: Initial Biomarker Levels and Changes in Jaw/Trismus Function 
from Baseline at 6- and 12-Months 
Biomarker 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 0.05 0.647 0.02 0.875 
IL-6 0.10 0.375 0.01 0.964 
IL-8 0.12 0.315 0.14 0.174 
IL-10 0.15 0.206 0.12 0.216 
IL-12p70 -0.23 0.049 -0.12 0.232 
MMP2A 0.04 0.766 <0.01 0.994 
MMP9A 0.05 0.696 0.02 0.884 
TGF-β1 0.07 0.526 0.13 0.197 
TGF-β2 -0.11 0.346 -0.17 0.085 
TGF-β3* 0.19 0.277 0.15 0.362 
TNF-α 0.20 0.080 0.16 0.108 
IFN-y 0.06 0.618 0.16 0.112 
CRP -0.02 0.852 -0.01 0.935 
RBC 0.05 0.701 -0.06 0.578 
Albumin 0.07 0.566 -0.01 0.962 
* N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 
Voice 	  
Descriptions of the VHNSS Voice cluster scores at baseline and changes 
in those scores from baseline at 6-months and 12-months post treatment are 
presented in Table 43.  The median baseline score was <0.7 on a 0-10 scale 
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There was limited variability in reported difficulties with voice over the duration of 
this study. This lack of variability makes it difficult to identify associations with 
other variables such as cytokines. No statistically significant associations of pre-
treatment biomarker levels with changes in dental symptoms were observed (see 
Table 44). 
Table 43: Reported Difficulties with Voice from the VHNSS at Baseline and 
Changes from Baseline at 6- and 12-Months 
 BL 6 Month Change 12 Month Change 
N 56 54 54 
Median 0.67 0.00 0.00 
IQR 0.00, 2.25 -1.00, 1.33 -1.00, 0.33 
Min, Max 0.00, 10.00 -8.67, 7.00 -9.00, 7.00 
 
Table 44: Initial Biomarker Levels and Changes in Voice Function from 
Baseline at 6- and 12-Months  
Biomarker 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 0.21 0.086 0.04 0.771 
IL-6 0.10 0.423 0.09 0.452 
IL-8 0.12 0.331 0.15 0.205 
IL-10 0.05 0.700 0.07 0.544 
IL-12p70 -0.18 0.134 -0.19 0.112 
MMP2A -0.09 0.493 0.08 0.488 
MMP9A 0.13 0.301 -0.02 0.894 
TGF-β1 -0.09 0.507 -0.09 0.473 
TGF-β2 -0.16 0.219 -0.21 0.097 
TGF-β3* 0.02 0.920 0.04 0.833 
TNF-α 0.14 0.262 0.14 0.248 
IFN-y -0.01 0.965 -0.01 0.932 
CRP -0.01 0.946 -0.08 0.533 
RBC 0.24 0.059 0.10 0.427 
Albumin -0.08 0.521 -0.10 0.402 
* N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 
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AIM 4. To examine the association between cytokines and changes in 
musculoskeletal function in HNC patients.  
 
Question 4: Are baseline cytokines associated with musculoskeletal impairment 
(neck and shoulder movement) as measured by shoulder and neck ranges of 
motion and neck disability at 12-months?  
 
 
Descriptions of the Neck Disability Index values (NDI) values at baseline 
and changes from baseline at 6- and 12-months post treatment are presented in 
Table 45. The median score at baseline was 10 on a scale of 0-50. There was 
significant variability of the data over the 12-month time period of the study. 
While the median score did not change throughout the study period, there was 
variation within the IQR.  
Table 45: Neck Disability Index as Reported at Baseline and Changes from 
Pre-Treatment to 6- and 12-Months Post-Treatment 
 BL 6 Month Change 12 Month Change 
N 56 54 54 
Median 10.00 0.00 0.00 
IQR 2.50, 22.00 -8.50, 6.50 -10.00, 4.00 
Min, Max 0.00, 59.00 -43.11, 42.00 -38.00, 44.00 
 
Associations of pre-treatment biomarker levels with changes in scores on 
the neck disability index are presented in Table 46. As shown, higher pre-
treatment levels of IL-β1, IL-6, IL-8, MMP9A, and TNF-α were statistically 
significantly associated with increasing disability at 6-months relative to pre-
treatment. Those patterns of association remained statistically significant with 
more long-term increasing disability for IL-8 and MMP9A. Lower pre-treatment 
TGF-β2 levels were statistically associated with greater increases in disability at 
12-months relative to levels of disability pre-treatment (beta= -0.26, p=0.035, see 
Table 46). 
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Table 46: Initial Biomarker Levels with Changes in NDI from Pre-Treatment 
to 6- and 12-Months Post-Treatment 
Cytokines 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 0.22 0.048 0.16 0.170 
IL-6 0.26 0.019 0.18 0.118 
IL-8 0.27 0.015 0.24 0.040 
IL-10 0.12 0.286 0.07 0.564 
IL-12p70 0.03 0.789 0.07 0.587 
MMP2A 0.12 0.296 0.13 0.270 
MMP9A 0.23 0.044 0.25 0.030 
TGF-β1 0.10 0.399 0.13 0.279 
TGF-β2 -0.20 0.093 -0.26 0.035 
TGF-β3* -0.19 0.304 -0.29 0.143 
TNF-α 0.24 0.036 0.17 0.144 
IFN-y 0.07 0.516 0.03 0.823 
CRP <0.01 0.983 -0.07 0.573 
RBC 0.12 0.314 0.12 0.358 
Albumin -0.22 0.053 -0.20 0.089 
* N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 
 
Descriptive statistics for the Cervical Range of Motion (CROM) scores at 
baseline and changes in those scores from baseline to 6- and 12-months for all 
areas of measurement (flexion, extension, left lateral, right lateral, left lateral 
rotation and right lateral rotation) are presented in Table 47. There was not a 
high degree of variability among neck movement throughout the first year with 
the exception of neck flexion.  It was not uncommon to see many patients with 
zero detectable neck measurements for right lateral neck movement throughout 
the study. 
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Table 47: Neck-related Function Measured by Cervical Range of Motion at 
Baseline and Changes from Baseline at 6- and 12-Months (CROM) 
Flexion    
 BL 6 Month Change 12 Month Change 
N 56 54 54 
Median 47.0 -1.0 1.5 
IQR 37.1, 52.8 -9.0, 8.1 -4.3, 9.0 
Min, Max 19.0, 74.0 -23.1, 32.0 -33.0, 32.0 
Extension    
 BL 6 Month Change 12 Month Change 
N 56 54 54 
Median 50.0 -3.0 -3.8 
IQR 44.0, 62.8 -9.3, 1.5 -10.1, 5.3 
Min, Max 19.0, 80.0 -33.0, 18.0 -29.0, 34.0 
Left Lateral    
 BL 6 Month Change 12 Month Change 
N 56 54 54 
Median 33.5 -1.0 0.0 
IQR 30.0, 42.8 -6.0, 7.3 -8.6, 5.0 
Min, Max 13.0, 54.0 -23.0, 17.0 -28.0, 23.0 
Right Lateral    
 BL 6 Month Change 12 Month Change 
N 56 54 54 
Median 33.0 -1.5 -2.0 
IQR 27.4, 41.8 -6.3, 2.6 -7.0, 4.0 
Min, Max 9.0, 60.0 -28.0, 23.0 -30.0, 30.0 
Left Lateral Rotation   
 BL 6 Month Change 12 Month Change 
N 56 54 54 
Median 53.5 1.5 1.8 
IQR 46.3, 61.0 -5.5, 10.0 -4.9, 9.6 
Min, Max 29.0, 71.0 -45.0, 26.0 -40.0, 35.0 
Right Lateral Rotation   
 BL 6 Month Change 12 Month Change 
N 56 54 54 
Median 57.0 0.0 0.0 
IQR 47.3, 63.0 -7.3, 8.0 -8.0, 6.0 
Min, Max 12.0, 75.0 -29.0, 58.0 -20.0, 60.0 
 
 
Associations of pre-treatment biomarker levels with changes in CROM 
scores from baseline to 6- and 12-months post treatment are summarized in 
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Tables 48 to 53.  No clear patterns of associations were observed. The only 
biomarker with more than one statistically significant association among the 6 
CROM measures was MMP2A. Higher pre-treatment levels of the cytokine was 
associated with greater decreases (relative to pre-treatment) in extension (beta= 
-0.31, p=0.020) and left lateral movement (beta= -0.28, p=0.032) at 6-months 
post-treatment (see Tables 48 to 53). 
 
 
Table 48: Initial Biomarker Levels and Changes in Forward Flexion from 
Pre-Treatment to 6- and 12-Months Post-Treatment 
Biomarker 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 -0.13 0.240 -0.03 0.793 
IL-6 -0.10 0.344 -0.07 0.525 
IL-8 -0.11 0.315 0.09 0.460 
IL-10 -0.08 0.452 -0.14 0.204 
IL-12p70 -0.10 0.364 -0.10 0.396 
MMP2A -0.07 0.546 -0.17 0.140 
MMP9A -0.07 0.533 0.11 0.347 
TGF-β1 0.21 0.056 0.09 0.408 
TGF-β2 0.12 0.290 -0.18 0.125 
TGF-β3 0.14 0.405 0.21 0.297 
TNF-α -0.18 0.108 -0.16 0.148 
IFN-y 0.12 0.264 0.14 0.229 
CRP 0.03 0.762 0.10 0.384 
RBC 0.01 0.903 0.09 0.457 
Albumin -0.15 0.186 <0.01 0.993 
* N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 	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Table 49 : Initial Biomarker Levels and Changes in Extension from Pre-
Treatment to 6- and 12-Months Post-Treatment 
Biomarker 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 0.02 0.892 0.07 0.571 
IL-6 -0.13 0.354 -0.12 0.364 
IL-8 -0.08 0.531 0.01 0.919 
IL-10 -0.20 0.133 0.01 0.954 
IL-12p70 0.15 0.263 0.01 0.940 
MMP2A -0.31 0.020 -0.06 0.646 
MMP9A 0.04 0.766 0.06 0.646 
TGF-β1 0.04 0.773 <0.01 0.974 
TGF-β2 -0.20 0.141 -0.05 0.717 
TGF-β3 0.13 0.495 0.07 0.736 
TNF-α -0.07 0.620 -0.05 0.731 
IFN-y 0.14 0.304 -0.04 0.750 
CRP 0.20 0.122 0.04 0.770 
RBC -0.14 0.300 -0.05 0.726 
Albumin 0.18 0.186 0.11 0.433 
* N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 	  	  
Table 50: Initial Biomarker Levels and Changes in Left Lateral Flexion from 
Pre-Treatment to 6- and 12-Months Post-Treatment 
Biomarker 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 0.09 0.518 -0.09 0.483 
IL-6 0.03 0.823 -0.05 0.715 
IL-8 -0.04 0.774 -0.05 0.696 
IL-10 0.03 0.822 -0.11 0.425 
IL-12p70 0.26 0.058 0.20 0.127 
MMP2A -0.07 0.586 -0.13 0.325 
MMP9A <0.01 0.974 -0.12 0.366 
TGF-β1 0.10 0.490 0.06 0.645 
TGF-β2 0.06 0.689 -0.09 0.527 
TGF-β3 -0.05 0.800 -0.05 0.812 
TNF-α -0.08 0.562 -0.23 0.083 
IFN-y -0.05 0.706 -0.04 0.780 
CRP -0.02 0.870 0.15 0.268 
RBC 0.14 0.298 0.14 0.286 
Albumin 0.02 0.915 0.14 0.307 
* N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 
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Table 51: Initial Biomarker Levels and Changes in Right Lateral Flexion 
from Pre-Treatment to 6- and 12-Months Post-Treatment 
Biomarker 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 -0.02 0.882 -0.05 0.713 
IL-6 -0.22 0.096 0.04 0.737 
IL-8 -0.01 0.948 0.13 0.282 
IL-10 -0.11 0.409 -0.08 0.529 
IL-12p70 0.03 0.844 0.14 0.282 
MMP2A -0.06 0.646 -0.11 0.371 
MMP9A -0.21 0.114 -0.06 0.622 
TGF-β1 -0.08 0.563 0.04 0.740 
TGF-β2 -0.26 0.059 -0.09 0.508 
TGF-β3 0.02 0.917 0.02 0.912 
TNF-α -0.17 0.190 -0.13 0.290 
IFN-y 0.14 0.310 0.16 0.200 
CRP 0.04 0.770 0.25 0.040 
RBC 0.03 0.819 0.04 0.744 
Albumin 0.15 0.279 -0.13 0.326 
* N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 	  
Table 52: Initial Biomarker Levels and Changes in Left Lateral Rotation 
from Pre-Treatment to 6- and 12-Months Post-Treatment 
Biomarker 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 -0.05 0.723 -0.21 0.100 
IL-6 -0.02 0.903 -0.11 0.409 
IL-8 -0.05 0.715 0.08 0.507 
IL-10 -0.06 0.665 -0.06 0.636 
IL-12p70 0.15 0.227 -0.07 0.592 
MMP2A -0.28 0.032 -0.15 0.263 
MMP9A 0.08 0.530 -0.08 0.515 
TGF-β1 0.06 0.670 -0.01 0.934 
TGF-β2 -0.09 0.483 -0.20 0.115 
TGF-β3 0.34 0.104 0.11 0.602 
TNF-α -0.23 0.079 -0.20 0.120 
IFN-y -0.16 0.218 -0.07 0.584 
CRP 0.14 0.284 0.15 0.228 
RBC <0.01 0.999 -0.09 0.480 
Albumin 0.25 0.057 0.12 0.342 
* N=~25 with data for TGF-β3 pre-treatment, 6- and 12-months post-treatment 
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Table 53: Initial Biomarker Levels and Changes in Right Lateral Rotation 
from Pre-Treatment to 6- and 12-Months Post-Treatment 
Biomarker 6 Month 
Change 
 12 Month 
Change 
 
 Beta p-value Beta p-value 
IL-β1 -0.10 0.449 -0.21 0.099 
IL-6 -0.04 0.780 -0.14 0.319 
IL-8 -0.19 0.157 -0.13 0.297 
IL-10 -0.05 0.707 0.06 0.659 
IL-12p70 0.05 0.722 0.17 0.190 
MMP2A -0.18 0.197 0.11 0.435 
MMP9A 0.06 0.658 -0.04 0.780 
TGF-β1 -0.06 0.679 -0.21 0.106 
TGF-β2 -0.10 0.452 -0.28 0.029 
TGF-β3 0.07 0.752 0.12 0.575 
TNF-α -0.24 0.084 -0.14 0.316 
IFN-y -0.07 0.582 -0.12 0.346 
CRP 0.13 0.330 0.03 0.838 
RBC -0.25 0.065 -0.23 0.074 
Albumin 0.02 0.902 0.01 0.915 
* N=~25 with data for TGF-β3 pre-treat, 6- and 12-months post 
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CHAPTER V 
 
DISCUSSION 
 
 
This chapter presents a summary and discussion of the study finding in 
the following five sections: (a) sample characteristics, (b) aims and questions, (c) 
study strengths and limitations, (d) implications, and (e) recommendations for 
future research.  
 
 
Sample Characteristics 
 
 
Due to the complexity of the original study requiring several blood draws 
and patient self-reporting on tools such as the VHNSS, CESD and NDI, a 
completion total of 56 patients is similar in size compared with other HNC studies 
where frequent blood draws and multiple cytokine analysis were conducted 
(Jager-Wittenaar et al., 2011) (Liu et al., 2010) (Heimdal et al., 2008) (Druzgal et 
al., 2005). Larger studies have occurred, but have primarily focused on fewer 
cytokines and fewer symptoms (Duffy et al., 2008) (Pai et al., 2012) (Shen et al., 
2012). The average age of persons completing one-year of this study was 57.8 
(N=56). The average age for a HNC patient is between 50-70 years (American 
Cancer Society, 2012). The mean age within this study is similar to the mean 
ages in other studies such as 59 in Duffy et al., (2008) and 60 in Jager-Wittenaar 
et al., (2011) study.  Globally, there is a trend with younger persons more 
commonly being afflicted with HNC (Wang et al., 2012), primarily due to an 
increase in HPV and other viral mediated factors. Statistically, there was a 
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difference between the 56 individuals analyzed within this study compared to the 
parent study. This difference was in the context of more persons with a viral 
etiology causing their HNC completing one-year of the study and thus viral HNC 
was more represented in the secondary analysis group. This is perhaps why the 
mean age was slightly lower than the parent study (although not statistically 
significant). Having more patients with viral mediated HNC does correlate with 
current trends in the HNC literature. Studies have indicated a survival advantage 
for those individuals with a viral mediated HNC compared to smoking and alcohol 
linked HNC (Ihloff et al., 2010).  
The majority of participants enrolled in the study were male 72.9% as well 
as those who completed one year of the study (71.4%). The predominance of 
males in this study is similar to other studies such as (Liu et al., 2010) (70.7%) 
and (Ehrsson et al., 2010) (70.3%). This is consistent with the national 3:1, male 
to female, ratio of HNC diagnosis (American Cancer Society, 2012). Most 
participants who completed one-year of the study were either married or 
partnered at the time of their enrollment (75.0%). Additionally, a majority of those 
in the study identified as White (N=51, 91.1%). According to the US Census 
bureau, the average race in the United States is White (77.7%)(2014). The 
average person diagnosed with HNC is White. Additionally, there is also a higher 
rate of HPV associated HNC in White males compared to White females and 
Black males and females (American Cancer Society, 2015). However, Blacks 
have a higher rate of mortality from the disease (Gourin & Podolsky, 2006). This 
study adequately reflected the racial differences seen in HNC diagnosis.   
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Within Tennessee, the median income in 2013 was $42,764 (City-
data.com, 2015). Within this study, there was a higher propensity for individuals 
to have a higher income compared to the parent study, but this difference was 
not statistically significant. In total 28 (29.2%) of enrollees at the start of the 
parent study made less than $30,000 annually. Of this original group only 13 
people completed their 48-week assessment. Similarly, 28 people (29.2%) of 
enrollees at the start of the parent study made greater than $50,000 annually. Of 
this group, 18 persons finished one-year of the study. It is interesting to note that 
the median income in the United States for the 55-64 year old group in 2013 was 
$57,538, which is slightly higher than the national median of $51,758 (US 
Census Bureau, 2014).  
Overall, there was no statistical difference between the parent and 
secondary analysis groups in terms of income. Within this study a majority had a 
history of smoking (N=38, 67.9%). Slightly fewer persons had a history of alcohol 
intake (N=32, 57.1%). The majority of persons also indicated that they lived in the 
country as opposed to the city (N=31, 55.4%). The demographics of the study 
participants within this secondary analysis resemble other HNC studies (Liu et 
al., 2010).  
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Aims and Research Questions 
 
 
Aim 1. To examine cytokines, RBCs and albumin in HNC patients.  
 
Question: Do baseline RBCs and albumin correlate with changes in 
cytokines at 6- and 12-months? 
 
 Within this study, higher baseline levels of RBCs associated with 
decreased MMP9A over a 6- and 12-month period and TNF-α over a 12-month 
period. Higher MMP-9 levels are linked with increased inflammation, diabetic 
micro-vascular complications, extracellular matrix degradation and synthesis, and 
cardiac dysfunction (Halade, Jin & Lindsey, 2013). The association between 
higher levels of RBCs at baseline and long-term levels of MMP9A could 
theoretically be associated with the possibility that persons with higher RBCs 
were less sick at the time of their enrollment in the study and perhaps had less 
long-term inflammation. However, if this were the precise reason, one would 
expect to see this association at 6-months. Further studies examining MMP9A 
levels in head and neck cancer patients will need to be conducted to examine 
this association.  
In regards to TNF-α, there was no association between TNF-α and RBCs 
at 6-months with a p-value of 0.501. The statistically significant association at 12-
months is likely spurious.  TNF-α was one of the first cytokines that was 
associated with cancer cachexia (Oliff et al., 1987). However, TNF-α has not 
consistently demonstrated a cause and effect on the development and severity of 
cachexia (Maltoni et al., 2001). TNF-α appears to be a stimulus for the production 
of other catabolic cytokines that subsequently cause the development of 
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cachexia (Argiles et al., 2014). The Association between RBCs and decreased 
TNF-α level over time is intriguing. There are several possibilities for why this 
may be the case.  
 Higher levels of RBCs may be associated with healthier individuals at the 
time of enrollment in the study. It is a possibility that persons with higher RBCs 
were less sick at baseline, had less inflammation and subsequently had lower 
TNF-α. Overtime, these healthier individuals with higher red blood cells may have 
experienced less overall systemic inflammation and therefore incurred a 
decrease in TNF-α production. If these patients were healthier at the time of 
enrollment in the study, it may have conferred a benefit to them post-treatment, 
allowing for quicker healing time due to less generalized inflammation. However, 
further studies of this association must occur, as blood delivery of oxygen under 
certain conditions can be toxic secondary to free radical production such as 
acute illness, sepsis and cardiogenic shock.   
Higher albumin levels in general are associated with healthier individuals. 
It has traditionally been a marker of long-term nutrition, with higher levels 
indicating better overall nourishment. Lower albumin levels at the time of 
admission to the hospital have been associated with worse prognosis (Ferguson 
et al., 1993) (Baltazar et al., 2015). Within this study, lower levels of IL-1β at 12-
months was associated with higher baseline levels of albumin at baseline. IL-1β 
is associated with inflammatory pain responses in the central nervous system as 
well as cellular matrix formation. It is generally considered a pro-inflammatory 
cytokine.  
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Perhaps, overtime, patients with higher albumin levels have the reserves 
to mount a better immunological response compared to individuals with lower 
albumin levels because they are overall healthier due to their nutritional status. 
Subsequently their IL-1β levels begin to decrease. However, if this were 
completely true, one would expect that persons with higher albumin levels should 
have other cytokines decrease proportionally. Potentially, there is a metabolic 
process that influences IL-β1, but not such physiological process has yet been 
identified. A further exploration of the association between increased RBCs and 
albumin levels will need to occur to elucidate what these findings mean in the 
HNC population. 
Aim 2: To examine the role of cytokines, RBCs, albumin and severity of 
weight loss in HNC patients.  
 
Question 2a: Are baseline cytokines, RBCs and albumin correlated with 
weight loss at 6- and 12-months? 
  
 
 There was only one statistically significant finding when examining for an 
association between baseline cytokines, RBCs and albumin with weight loss. 
Patients with higher IL-6 levels at baseline had greater decrease in weight 
through the study period than patients with lower IL-6 pre-treatment values. By 
12-months post-treatment a similar direction yet slightly smaller coefficient and 
no longer statistically significant coefficient was demonstrated. IL-6 levels have 
been correlated with cachexia in patients in several studies (Duffy, et al, 2008) 
(Bayliss, et al., 2011). IL-6 is an acute phase protein that is associated with 
inflammation during cancer and increased tumor genesis (Taniguchi & Karin, 
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2014). Within HNC patients, higher circulating levels of IL-6 has been 
significantly associated with muscle wasting, weight loss and higher mortality 
(Duffy et al., 2008) (Moses et al., 2009). The findings within this study reflect 
other findings regarding higher levels of IL-6 and weight loss.  
In regards to IL-6, at 12-months, as IL-6 levels decreased it appears that 
individuals weight increased. Several smaller HNC studies have also 
demonstrated this trend, but it was not until Duffy et al., (2008), had a large 
enough sample size to demonstrate that there was a statistical difference 
between levels of IL-6 and weight loss. Within this study, no other cytokine 
demonstrated any close relation to weight loss at 6- and 12-months. This is 
perhaps due to the significant variability in cytokine levels for individuals as well 
as due to the small sample size used in this study.  
 Initial cytokines may not have any association with long-term weight loss 
and what may be more important is the overall trend of these cytokines as 
demonstrated by Duffy et al., (2008). Additionally, the study group as a whole 
had a BMI median >25kg/m2. Studies have suggested that patients with HNC 
and BMIs > 25kg/m2 are associated with improved outcomes and better long-
term survival (Gaudet et al., 2012). Perhaps the lack of significance with other 
cytokines in these findings is suggestive of the obesity paradox conferring a 
benefit to the overall progression of disease in the study patients (Gonzalez et 
al., 2014).  Future studies examining the obesity paradox in HNC patients should 
occur.  
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Question 2b: Does a change in cytokine levels, RBCs and albumin from 
baseline to 6-months correlate with weight loss at 6- and 12-months?  
 
Increasing IL-10 levels were associated with decreasing weight and BMI 
over the same time period. This correlates with similar results found at 15 months 
by Mydlarz et al., (2014). IL-10 is involved in the regulation of the JAK-STAT 
signaling pathway. Through inhibition of this pathway, the body increases its 
consumption of muscle protein while at the same time begins to decrease muscle 
production through increased release of myostatin.  The question and answer 
that is unknown is why would IL-10 remain elevated in some individuals? It is 
possible that there may be an unknown genetic component influencing IL-10 
production. Certain IL-10 genotypes appear to contribute to oral cancer 
susceptibility (Tsai, et al., 2014). What is less clear is what the IL-10 elevation 
means beyond the 12-month period of this study. The same questions can be 
posited for TGF-β2 and TFN-y. 
   Patients’, who had lower levels of TGF-β1 overtime, appear to have 
experienced increased weight loss. This may be attributed to the transforming 
growth factor ability to promote tissue repair. Perhaps in persons with higher 
TGF-β1 there is a propensity for improved tissue repair thereby decreasing an 
individual’s overall inflammatory status?  The ability to promote tissue repair may 
decrease the metabolic demands of the body. The loss of TGF-β1 signaling has 
been associated with worse outcomes for patients with HNC (Bian et al., 2012). 
Overall, as a whole, patients within this study lost the most weight between 
baseline and 6-months and then in fact began to increase their weight by the 12th 
month.  The reasons for this increase are presently unclear. However, it is likely 
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indicative of improving health and function. Additionally, as treatment progresses 
and tumors are either resected or eradicated, it is possible that fewer tumorkines 
were produced allowing for a decrease in myostatin production allowing for 
weight gain to occur. The decrease in tumorkines would also shift the body back 
to normal physiological homeostasis allowing for weight to be added. However, 
lower levels of IFN-y and increasing weight loss does not match the literature.  
 Higher levels of IFN-y have been strongly associated with cachexia in both 
mice and human models (Matthys et al., 1991) (Ito, et al., 2006).  However, 
within this study, this association only occurred at the month 12. It is possible that 
this association was spurious as at 6-months the Beta for this weight association 
was zero. However, a recent study indicated that patients with lower levels of 
IFN-y and higher levels of IL-10 with oral squamous cell carcinoma had worse 
long-term outcomes (Wang, et al., 2014). The Wang, et al., study did not explore 
an association with IFN-y, IL-10 and weight loss. Like IL-10, it is possible that 
within HNC patients, IFN-y levels may be a prognosticator of other clinical 
manifestations other than weight loss and cachexia. Overall, IFN-y and IL-10 
appear to associate with negative outcomes in HNC patients. Further studies 
differentiating these cytokines at the cellular and genetic level should occur.  
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AIM 3: To examine the association between cytokines, RBCs, albumin and 
reported symptoms in HNC patients? 
 
Question 3: Are initial cytokines, RBCs and albumin associated with 
changes in reported symptoms such as: depression, nutrition 
consumption, swallowing difficulties, mucositis, generalized pain, mouth 
pain, dental discomfort, hearing, xerostomia, taste, jaw movement and 
voice at 6- and 12-months? 
 
 A primary goal of this study was to assess how initial baseline cytokines 
correlated with long-term symptom development in patients post-treatment for 
HNC. Throughout the literature, most studies are conducted for a short-term 
duration of 3 to 6-months during cancer treatment. Furthermore, limited studies 
to date examine how baseline cytokines affect the development of long-term 
symptoms. Many patients within this study had advanced cancer at the time of 
diagnosis (Stage 3 or greater) therefore the inflammatory mediators responsible 
for the development of cachexia and symptoms were already promoting 
metabolic derangements at the time of enrollment. Due to the fact that cytokines 
have variable half-lives ranging from seconds to a few minutes, examining how 
these biomarkers influence long-term symptom development was important so 
that future research can target modalities that may interfere with cytokines that 
appear to promote worse symptoms. The caveat to understanding these 
cytokines is that the ability to understand the development of cytokines in human 
cancer patients during early stages is limited because cancers are generally not 
detected at the onset of the disease. Thus determining the progression of 
cytokine initiation from the tumor is difficult to elucidate. Presently, researchers 
must rely upon animal models to direct the understanding of cytokine progression 
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in early cancer states. Consecutively, animals cannot fill out forms in regards to 
their symptoms. Overall, associating symptoms and cytokines is a difficult 
endeavor. However, through identifying those cytokines that associate with 
symptoms, the goal is to further study these associations at the cellular and 
genetic levels in future animal studies in order to begin fully understanding the 
potential biological processes that cytokines influence upon each other. 
Depression  
Within this study two significant associations with increased levels of 
depression were lower baseline levels of TGF-β2 and higher initial levels of CRP. 
No similar associations of TGF-β2 have been found, in regards to depression, in 
previous research. With regards to CRP, an association with increased CRP 
levels and increased levels of depressive symptoms has previously been 
described in the literature (Archer, et al, 2014). A recent study comparing 
different alleles associated with CRP production found that elevated CRP was 
associated with increased risk of depression, but genetically elevated CRP was 
not concluding that CRP per se is not a causal risk factor for depression (Wium-
Andersen, Orsted, Nordestgaard, 2014).  
Depression is a common symptom that is associated with cancer, cancer 
cachexia and associated cytokines (Moubayed et al., 2014) (Archer et al., 2012) 
(Kamath, 2012). Several studies indicate an association between increasing 
cytokines and the development of depression in cancer patients. However, the 
association within this study is opposite of what has been consistently described 
in the literature. With the exception of CRP (which isn’t a cytokine) no other 
cytokine correlated with worsening symptoms of depression. It remains unclear 
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as to the possibility of why a growth factor would correlate with depression. The 
statistically significant association between TGF-β2 and depression only 
occurred at the 12-month interval, indicating that this may be a spurious finding. 
A further exploration of this possible connection will need to be conducted.  
CRP is a generic marker of inflammation within the body and has been 
linked with not only depressive symptoms, but that of fatigue and pain in cancer 
patients (Myers, 2008). Most studies report a negative association with outcomes 
and cancer when CRP levels are elevated (Chung & Chang, 2003) (Wallengren 
et al., 2013). Within this study, only elevated CRP levels at baseline was 
associated with depression. While this finding is not new, there was no 
association with any other symptom. However, this study did not examine the 
symptom of fatigue, and generally throughout the literature, depression and 
fatigue have correlated with elevated CRP.  
Nutrition consumption  
Several baseline cytokines were statistically significant at the 6-month 
point, which were significantly associated with the VHNSS nutrition cluster. They 
were IL-6, IL-10, MMP2A, TGF- β1 and IFN-y.  
Head and neck cancer patients are prone to developing difficulties 
obtaining adequate nutritional intake due to the location of their tumor. 
Furthermore, there is a direct link between lack of caloric intake and increased 
mortality (Jager-Wittenaar et al., 2011) (O’Neill & Shaha, 2011) and decreased 
quality of life (Caro et al., 2007). The role of cytokines and their mediation of 
caloric intake through influencing of the brain, specifically the hypothalamus, 
have become increasingly understood. Increased inducible nitric oxide synthase 
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production in the hypothalamus leads to severe anorexia, which is possibly a 
pathway through which pro-inflammatory cytokines produce anorexia (Morley & 
Farr, 2008). Various cytokines influence several neuropeptides that directly affect 
the desire to eat (Patra & Arora, 2012). Therefore, understanding the cytokines 
that are influential in potentially regulating these various neuropeptides is 
important in developing future interventional modalities that may be used to 
thwart the progression of cachexia.  
Individuals, who had higher levels of IL-6, IL-10, MMP2A, TGF-β1 and 
IFN-y at baseline, were prone to having greater difficulties with nutrition 
symptoms such as anorexia and losing weight. The precise role of IL-6, IL-10, 
MMP2A, TGF- β1 and IFN-y on the progression of anorexia and cachexia is not 
fully understood, but there are two hypotheses. 1) cytokines influence 
neuropeptide interaction through the blood brain barrier promoting early satiety 
and anorexia (Banks, 2001), 2) IL-6 specifically alters the JAK/STAT pathway 
promoting muscle catabolism and decreases muscle production through 
promoting an increase in circulating levels of myostatin which inhibits muscle 
regeneration.   
The role of IL-10 and MMP2 on cachexia is less clear than IL-6. In a large 
study of 203 patients examining multiple cytokine polymorphisms, only IL-10-
1082 polymorphism was linked to the development of cachexia in gastric cancer 
(Deans et al., 2009). Increased IL-10 serum expression was significantly 
associated with worse survival in early stage oral squamous cell carcinoma 
(Chen et al., 2013). However, this same association was not witnessed in 
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myelofibrosis. Another recent study indicates that certain IL-10 genotypes 
increase the susceptibility of oral cancer (Tsai, et al., 2014). What is additionally 
problematic is that IL-10 is generally considered an anti-inflammatory cytokine 
and it inhibits other cytokines such as TNF-α, which can promote cachexia. The 
association of IL-10 and worsening nutrition symptoms is perplexing and needs 
further exploration.  
MMP2 has generally been correlated with tumor promotion and 
progression as its role in the healthy individual is tissue repair and regulation of 
vascularization. An association with MMP2 and cachexia remains unclear 
presently. However, MMP2 may play a role in vascularization of tumors, which 
help them grow and subsequently enhances release of cachectic inducing 
cytokines.  
The TGF-Beta superfamily cytokine MIC-1/GDF15 circulates in all humans 
and when overproduced in cancer leads to anorexia/cachexia, by direct action on 
brain feeding centers, specifically the hypothalamus. However, within this study, 
lower levels of TGF- β1 was associated with worsening nutrition symptoms. This 
finding was only statistically significant at the 6 month mark. Additionally, lower 
levels of IFN-y were also associated with worsening nutrition symptoms at the 6-
month mark and not at the 12-month mark. Both higher levels of IFN-y and TGF-
β1 have been associated with worsening cachexia (Argiles, et al, 2005) (Bing, 
2011)(Blum et al, 2011)(Cahlin, 2000)(Donohoe, 2011)(Patra &Arora, 2012). The 
findings within this study are likely spurious in regards to TGF-β1 and IFN- y.   
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By the 12-month the effects of IL-6, IL-10, MMP2A, TGF-β1 and IFN-y 
were all less significant with only the association with IL-6 maintaining statistical 
significance. Additionally, at this same time the median weight began to increase, 
cytokine levels decreased as well as study participants reported less issues with 
nutrition symptoms. This is perhaps attributed to post-surgery patients beginning 
to improve their overall states of health and having less inflammation as the 
tumorkines production in these patients should theoretically be zero.  
   
Swallowing related symptoms  
Within this study, higher levels of 3 cytokines correlated with increased 
difficulty swallowing solids at both 6- and 12-months. They were IL-6, IL-10 and 
TNF-α. Lower levels of albumin at baseline were also associated with worsening 
ability to swallow. Additionally, lower levels of IL-12p70 at baseline were 
associated with worsening ability to swallow liquids at the 12-month.  
Difficulties swallowing are directly related to several factors such as the 
direct impact of the tumor, cancer resection, chemotherapy and radiotherapy 
(Raber-Durlacher et al., 2012). What is not well described in the literature is the 
association between cytokines and swallowing dysfunction in the HNC patient 
over time. Interestingly, IL-6 and IL-10 also correlated with difficulties in regards 
to nutrition consumption. However, in this case IL-6 and IL-10 were associated 
with difficulty swallowing at 12-months, but this was not the case when patients 
self-reported difficulties obtaining nutrition on the VHNSS. This perhaps indicates 
that some patients were able to adapt to their difficulty obtaining nutrition over the 
year by adapting to different foods. Their perception of obtaining nutrition may 
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have changed over the duration of their illness, but they still experienced 
“trouble” swallowing. IL-6 inhibits muscle production and promotes degradation of 
muscle mass through inhibition of the JAK/STAT pathway as well as altering the 
mitochondrial functioning of muscle (White et al., 2012). The body employs over 
fifty muscles when it produces the act of swallowing. Further studies quantifying 
muscle tissue degradation with IL-6 and other cytokines in the HNC patient 
should occur to determine if muscle wasting in the specific muscles of swallowing 
is occurring. IL-10 at the early stage of cancer has been associated with worse 
outcomes in HNC patients (Chen et al., 2013). The role of IL-10 in regards to 
muscle breakdown and dysfunction is not well understood. 
TNF-α has been implicated in the development of cachexia in several 
studies (Tisdale, 2005). TNF-α appears to be a stimulus for the production of 
other catabolic cytokines that subsequently cause the development of cachexia 
(Argiles, Busquets, Stemmler, & Lopez-Soriano, 2014). Additionally, TNF-α 
appears to affect the hypothalamus through pro-inflammatory signals that affects 
neurotransmitters and subsequent hunger signaling to patients perpetuating the 
cycle of cachexia by inducing anorexia (Amaral et al., 2006). TNF-α also 
promotes fat lipolysis and fat depletion (Tsoli & Robertson, 2013). TNF-α has 
also been recently identified to regulate lipolysis through the GO/G1 switch gene 
2 (GOS2). By inhibiting expression of GOS2, an increased level of lipolysis 
occurs (Yang, Zhang, Heckmann, Lu, & Liu, 2011). Presently, it appears that 
TNF-α directly relates to adipose tissue loss, but not directly to the loss of muscle 
protein (van Hall, 2012). With limited effects on muscle loss, the association with 
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decreased ability to swallow and increased TNF- α levels in the HNC is not clear. 
It is possible that the elevation of TNF- α promoted the metabolic effects that 
promoted muscle degradation through promotion of myostatin. 
 Lower levels of albumin at baseline are associated with worse swallowing 
symptoms. Low albumin is a marker of the inability to obtain adequate nutrition 
for approximately 12-weeks prior to the lab draw. Persons with lower albumin 
levels may have been sicker at baseline and perhaps did not recover by the 12th 
month. If the dysphagia was already problematic pre-treatment, this could have 
affected the patient’s albumin levels initially as the patient would have had 
difficulty consuming adequate calories prior to enrollment. Finding ways to 
optimize nutritional intake to combat many negative cachexia symptoms is 
complex and not fully understood. However, increasing caloric intake is not the 
solution to thwarting cancer cachexia. 
 
Mucositis, Generalized Pain and Mouth Pain  
Within this study, higher baseline IL-1β levels were associated with worse 
mucositis, generalized pain and mouth pain at 6-months but not at 12-months. 
Higher initial baseline RBC levels were associated with worse general and mouth 
pain at 6-months but not at 12-months. It should be noted that within this study, 
mucositis, generalized pain and mouth pain were measured on a 0-10 point scale 
with 10 being the most severe level of pain. At baseline, the median level of 
mucositis was 0.13, generalized pain was 0.83 and mouth pain was 0.25.  While 
mucositis and mouth pain are well-documented negative sequela of HNC cancer 
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treatment and progression, it is perplexing as to why the average pain scores 
remained low for this study population (Nicolatou-Galitis, et al., 2013).   
Inflammation has consistently been correlated with pain in several cancer 
studies (McClement, 2005) (Laird et al., 2011b) (Myers, 2008). IL-1β has been 
associated with worsening pain in patients through its up-regulation of pro-
nociceptive mediators (Ren & Torres, 2009). Through this action, this makes the 
body more prone to perceiving the presence of pain. Additionally, there appears 
to be an association with individuals with a genetic disposition towards producing 
IL-1β having increased pain during cancer (Oliveira et al., 2014). Oncologists and 
nurses treating pain could use the association between IL-1β to potentially 
anticipate or titrate pain medication needs. Further studies testing the validity of 
this idea should occur.  
Again, higher levels of RBCs at baseline were also associated with 
worsening generalized pain and mouth pain, but not mucositis. Interestingly, it is 
generally anemia that is associated with increased bone pain and angina due to 
lack of oxygen delivery.  It is possible that the ability of the body to deliver oxygen 
to the tissue and cellular level promotes free radical damage that perpetuates the 
demise of the IL-6 altered mitochondria. Most studies within cancer attribute an 
association between lower levels of RBCs and increased pain and other 
symptoms such as fatigue (Holzner, et al., 2002). This study did not examine a 
change in RBCs over the 12-month period. It is possible that patients with higher 
RBC levels at the start of the study had a greater decrease in their RBC levels, 
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which is associated with worsening pain. A further exploration of this result and 
HNC patients should occur.  
Xerostomia  
Similarly to swallowing and nutrition, increased levels of IL-6 and IL-10 
were associated with worse reports of xerostomia. However, IL-6 was only 
statistically significant at 6-months with a shared variance of less than 15. The IL-
6 results need to be interpreted cautiously. Higher RBCs were associated with 
worse xerostomia at the 6-month mark, but not the 12-month mark.  
Overall, these associations are not surprising in that it takes saliva in order 
to swallow and digest solid foods. It is known that xerostomia directly impacts the 
ability to swallow solids (Raber-Durlacher et al., 2012). Furthermore, the same 
association between elevated baseline RBCs was appreciated for xerostomia as 
it was for swallowing solids. This association indicates a plausible link between 
the two symptoms. The question that is not fully elucidated then is are the 
cytokines responsible primarily for inhibiting saliva production which then makes 
swallowing solids more difficult, or are their two distinct pathways that promote 
both a decrease in saliva production and a decrease in neck muscle functioning 
inhibiting the ability to swallow? Due to the fact that IL-10 also remained 
statistically significant for associating with increased issues with xerostomia at 
month-12, while it did not do so for swallowing solids at month-12, could suggest 
that two distinct pathways mediated by cytokines are responsible for a decrease 
in saliva as well as decreased muscle functioning. This notion should be explored 
further.  
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Taste dysfunction  
Higher levels of baseline IL-1β and IL-6 correlated with increased taste 
dysfunction at both 6- and 12- months. IL-1β is involved in olfactory abilities 
(Poretti et al., 2015). An examination of the influence of IL-1β on the influence of 
smell and taste in HNC patients has not been conducted. Increasing levels of IL-
1β may inhibit the ability to smell, which is the predominant sense that humans 
utilized for taste. In a recent study, an injury to the tongue correlated with higher 
IL-1β levels approximately 2-days after an initial injury (Shi, et al., 2012). This 
same process could also be occurring in the HNC population both through tumor 
mediation as well as through the negative sequela of treatment.  Additionally, 
increased IL-6 levels have been found in the plasma, saliva and nasal mucus of 
patients with hyposmia (Henkin, Schmidt & Velicu, 2013). Overall, the 
association with IL-6 and impaired taste and smell has not been well studied. 
However, it appears that increased IL-6 and IL-1β does negatively affect the 
symptom of decreased taste and smell.  
 
Voice dysfunction  
Within this study, no significant associations between cytokines and voice 
were found. However, a higher baseline level of RBCs significantly correlated 
with increased problems in voice at 6-months. This result is perplexing. Without 
An association for an inflammatory mediator, it is possible that there is some 
other untested cytokine that may be promoting inflammation of the vocal cords in 
conjunction with the presence of increased RBCs. A review of the literature has 
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not identified any other associations between RBCs and dysphonia in HNC 
patients.  
Non-significant findings  
There were no significant findings for either hearing impairment or 
jaw/trismus dysfunction. Conductive and sensorineural hearing impairment can 
occur in HNC patient due the region of the tumor as well as treatment modalities 
utilized to eradicate the disease (Hitchcock, Tward, Szabo, Bentz, & Shrieve, 
2009). However, within this study, the median hearing problem for the entire 12-
months was zero. While lower levels of TGF-β2 were associated with worsening 
hearing loss at 6-months, this did not hold true for 12-months when in fact higher 
levels of TGF-β2 were associated with worsening hearing though not 
significantly. It appears that these findings were spurious. This study was not a 
good representation of those patients with affected hearing secondary to their 
HNC. 
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AIM 4. To examine the Association between cytokines and changes in 
musculoskeletal function in HNC patients.  
 
Question 4: Are baseline cytokines associated with musculoskeletal 
impairment (neck and shoulder movement) as measured by shoulder and 
neck ranges of motion and neck disability at 12-months?  
 
Neck Disability Index  
The study group as a whole had high self-reported rates of neck 
movement dysfunction at baseline with a median score of 10. By the 12th month, 
the median score had dropped to 6. Higher levels of IL-β1, IL-6, IL-8, MMP9 and 
TNF-α at baseline associated with worsening scores on the NDI. Lower initial 
TGF-β2 levels were significantly associated with worse NDI scores at 12-months.  
Dysfunction of muscle movement of the head and neck is common in HNC 
patients (Teymoortash et al., 2010).  However, the relationships between 
cytokines and long-term abilities to move the head and neck over the long term 
have not been conducted. Within this study both the subjective, Neck Disability 
Index scale, and objective, Cervical Range of Motion test was utilized to evaluate 
and compare the associations with cytokines with long-term problems with head 
and neck movement.  
Higher levels of MMP9 have been correlated with worse prognosis for 
nasopharyngeal cancer patients and higher mortality (Liu et al., 2010). MMP9 
has also been associated with worsening myocardial muscle functioning (Chiao 
et al., 2012) (Pan et al., 2014). Under normal circumstances, MMP9 promotes 
muscle healing and tissue repair. An alteration of MMP9 however may be 
promoting muscle dysfunction at the cellular level that has not been identified 
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presently. Additionally, the body may be producing more MMP9 in order to 
promote tissue healing, specifically at the site of the muscle, but other metabolic 
processes are hindering the normal tissue repair that MMP9 orchestrates. 
However, it is possible that higher levels of MMP9 were directly related to the 
tumorgenesis that was occurring at the time of enrollment in the study. It is 
possible that higher levels of MMP9 were associated with tumor progression. 
However, this study lacks the ability to address that hypothesis. Overall, the 
association with cytokines and long-term muscle dysfunction in HNC is not well 
understood. Further studies of this finding will need to be made in the future; 
perhaps specifically examining the MMP9 within the tissue at the time treatment 
begins and looking for correlations among neck motility dysfunction over time.  
IL-6 inhibits muscle production and promotes degradation of muscle mass 
through inhibition of the JAK/STAT pathway as well as altering the mitochondrial 
functioning of muscle (White et al., 2012). An association with higher levels of IL-
6 and worsening neck movement over time correlates with the known 
degradation of muscle that IL-6 can produce. However, IL-6 was only significantly 
associated with worsening neck movement at the 6-month mark. This is likely 
attributed to the decreasing levels of IL-6 in general for this population and the 
likely decrease in the effects IL-6 would have on this patient population as they 
continued to recover in the post-treatment period.  
IL-1β had a similar pattern to that of IL-6 in that it was only statistically 
significantly associated with worse neck movement at the 6-month mark. 
However, the correlation with movement of muscle and IL-1β is not well 
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documented in the literature, what is documented is a strong correlation between 
IL-1β and increasing muscle pain (Willemen, et al., 2014) (Chen, et al., 2015). It 
is possible that neck movement was hindered by pain, which contributed to this 
association. The association with IL-1β with muscle dysfunction symptoms in 
HNC patients will need further research, specifically around movement of the 
head and neck in association with pain. It is possible that IL-1β is contributing to 
a potential symptom cluster.  
TNF-α also had a similar pattern to IL-6 and IL-1β in that it was only 
statistically significantly associated with decreased neck movement at 6-months. 
TNF-α was originally called cachectin and has been associated with a decrease 
in muscle mass in cancer patients. This decrease in muscle mass may be 
contributing to the difficulties HNC patients were reporting with neck movement 
within this study. However, this study did not directly examine muscle mass 
changes over time. As the patients continue to recover post-treatment, it is likely 
that the initial levels of TNF-α became less important. However, the correlation 
with TNF-α and neck movement does indicate that HNC patients with higher 
levels of TNF-α are likely to have increased neck disability immediately post-
treatment due to increased muscle mass loss. However, TNF-α has not 
consistently demonstrated a cause and effect on muscle wasting. Further studies 
should examine TWEAK in association to neck dysfunction as it appears that 
TWEAK is associated more strongly with overall muscle wasting (Kumar, 
Bhatnagar, & Paul, 2012) 
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Higher initial levels of IL-8 were associated with increased neck 
impairment at both 6- and 12-months post-treatment. The role of IL-8 in cancer 
appears to be one of promoting muscle wasting (Gioulbasanis, Patrikidou & 
Kitikidou, 2012). It is probable that increased IL-8 levels promoted some muscle 
wasting for patients in this study, however as stated previously, this study did not 
directly measure muscle mass changes. It is probable that any muscle wasting 
that did occur in turn likely promoted neck dysfunction. Within this study it 
appears that the effects of IL-8 had a longer-term effect compared to other 
cytokines. Studies about the effects of IL-8 on HNC patients are inconclusive 
presently (Mojtahedi, et al., 2014). Further research into IL-8 levels in HNC 
patients need to occur, specifically measuring muscle dysfunction and any 
wasting simultaneously.  
Lower levels of TGF-β2 and worsening muscle dysfunction of the neck 
correlates with other recent findings. When TGF-β2 is inhibited, muscle atrophy 
is worse (Ohsawa, et al., 2012). Further studies indicate that TGF-β2 is 
responsible for conduction at the nerve synaptic function (Kutsano, et al., 2010). 
Less TGF-β2 would cause a decrease in electrical conduction and theoretically 
would decrease muscle movement abilities. Lower levels of TGF-β2, in 
conjunction with location of tumor and treatment, would likely cause neck motility 
dysfunction in the HNC patient. In a recent mouse model study, providing TGF-
β2 helped increase muscular function and prevented muscle wasting. Exploring 
ways to increase TGF-β2 levels in the HNC patient may help to alleviate some of 
the muscle wasting and dysfunction that occurs within this population. 
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Lower albumin level at baseline is possibly indicative of overall poorer 
health at the beginning of the study. This may translate into worse muscle 
functioning in patients for several reasons. Lower albumin levels indicate 
decreased long-term caloric consumption, specifically of protein. For muscle to 
regenerate and heal, protein is required. Several studies indicate that lower 
albumin levels generally lead to worse outcomes in patients (Jiang et al., 2014) 
(Yang, Zhang, Hou, Xie, & Cao, 2014). Additionally, a recent study examining 
outcomes in association with serum albumin and CRP found that those with 
lower albumin and elevated CRP at the time of surgery had worse outcomes 
post-operatively (Farhan-Alanie, McMahon, & McMillan, 2015). Possibly, 
decreased albumin levels could affect musculoskeletal dysfunction. Further 
evaluation in cancer patients needs to occur to examine this association.  
Cervical Range of Motion 
Overall, this objective measurement provided inconsistent results. No 
clear patterns of associations were observed. The only biomarker with more than 
one statistically significant association among the 6 CROM measures was 
MMP2A. Higher pre-treatment levels of MMP2A were associated with greater 
decreases (relative to pre-treatment) in extension. In a recent study, the reliability 
and validity of measuring CROM in healthy volunteers demonstrated a wide 
range of intra-class-association coefficients, suggesting that its validity in healthy 
individuals is questionable, while it appeared valid for those with known neck 
movement disability (Wibault, Vaillant, Vuillerme, Dedering, & Peolsson, 2013). 
Perhaps in future studies determining who is having neck difficulty verses those 
who do not may need to be examined. Overall, a sound conclusion regarding 
 142 
cytokines and neck movement disability measured by the CROM cannot be 
made from this study. Furthermore, patients in this study received lymphedema 
therapy, physical therapy and corrective posture instruction as part of the parent 
study. This could have directly improved CROM as well as NDI scores. 
 
 
Synthesis of Findings 	  	  
 A primary goal of this dissertation research was to examine for the 
associations with cytokine production and weight loss as a marker of cachexia. 
Increasing levels of IL-10 was associated with both increasing weight loss at 6- 
and 12-months as well as worsening swallowing of solids and xerostomia at 6- 
and 12-months and worse nutrition symptoms as measured by the VHNSS at 6-
months. Additionally, patients who had higher albumin levels at the time of 
enrollment had lower IL-10 levels. It is possible that the inflammatory cascade 
promoted by IL-10 caused anorexia in patients prior to treatment. This anorexia 
would have theoretically resulted in albumin levels to decrease. IL-10 is involved 
in the regulation of the JAK-STAT signaling pathway. Through inhibition of this 
pathway, the body increases its consumption of muscle protein while at the same 
time begins to decrease muscle production through increased release of 
myostatin. This imbalance likely was exacerbated by the ensuing decrease in 
albumin levels, which was inhibited by xerostomia and difficulty swallowing.  The 
question and answer that is unknown is why would IL-10 remain elevated in 
some individuals? It is possible that there may be an unknown genetic 
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component influencing IL-10 production. Certain IL-10 genotypes appear to 
contribute to oral cancer susceptibility (Tsai, et al., 2014). What is less clear is 
what the IL-10 elevation means beyond the 12-month period of this study. 
Overall, it appears that IL-10 may be a potential cytokine that can help identify 
patients early during the course of their treatment that may be at greater risk for 
the development of cachexia and difficulties obtaining nutrition. Other cytokines, 
which were elevated at baseline also associated with difficulty obtaining nutrition, 
they were IL-β1, IL-6, TNF-α, MMP2A and TGF-β1. Of these, IL-6 matched 
similarly to that of IL-10. 
 Patients with higher IL-6 levels at baseline had greater decrease in weight 
through the study period than patients with lower IL-6 pre-treatment values. 
However, unlike IL-10, increasing levels of IL-6 did not associate with weight 
loss, but it did associate with worse ability to swallow solids and nutrition 
symptoms at 6- and 12-months as well as worse xerostomia at 6-months. Unlike 
IL-10, IL-6 baseline levels also associated with worse ability to taste and smell at 
6- and 12-months. The likely difference between IL-6 and IL-10 is the pattern in 
which IL-6 increases first in an acute illness. It is possible that the initial levels of 
IL-6 are most important in terms of long-term symptom development. In short, IL-
6 may be a marker for how acute a cancer is for a particular patient at the time 
treatment begins or more precisely at the initial stages of cancer. Therefore, the 
change overtime is not as important for a patient’s IL-6 levels in comparison to 
IL-10, which is likely a cytokine that is more indicative of how a patient is 
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progressing with their illness. Another cytokine that may be indicative of how a 
patient is progressing through their disease is IL-β1. 
IL-1β has been increasingly identified as an interleukin that is positively 
associated with worse pain levels in cancer patients. Within this study, 
generalized pain, mouth pain and worse mucositis associated with higher levels 
of this cytokine at baseline. Unlike IL-6, there was no association with weight 
loss. However, while there was an association with increased pain scores with IL-
β1, this did not associate with the inability to consume nutrition. It is likely that the 
IL-1β physiologically is responsible for pain signaling, but not with the 
physiological processes that IL-6 and IL-10 appear to associate with in terms of 
saliva production and swallowing. Furthermore, pain often times correlates with 
increased depression scores. IL-1β did not associate with worsening depressive 
symptoms. Within this study higher CRP levels and lower TGF-β2 levels 
correlated with depression. The association with lower TGF-β2 levels and less 
depressive symptoms is not completely understood presently. Interestingly, 
higher TGF-β2 levels associated with worse scores on the NDI.  It is possible that 
muscle dysfunction in general contributes to an overall decrease in quality of life 
for patients and increases their self-reporting of depression. Further studies 
regarding this finding are warranted. Another perplexing finding within this study 
is the association with higher RBC levels at baseline and worse generalized pain, 
mouth pain and xerostomia at 6-months. 
 It is possible that the ability of the body to deliver oxygen through 
hemoglobin to the tissue and cellular level promotes free radical damage that 
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perpetuates the demise of the IL-6 altered mitochondria. Most studies within 
cancer attribute an association between lower levels of RBCs and increased pain 
and other symptoms such as fatigue (Holzner, et al., 2002). A further exploration 
of this result and HNC patients should occur.  
 Overall, this study demonstrated some new results not previously reported 
in the literature as well as correlated with previous published results. While IL-10 
has generally been considered an anti-inflammatory cytokine, recent studies, in 
conjunction with results in this study, demonstrate that IL-10 may promote not 
only muscle wasting and weight loss, but also correlates with worse symptoms 
over 12-months specifically those symptoms surrounding nutrition and 
swallowing. Additionally, IL-1β appears to associate with worse pain symptoms 
over time. This association will need further research as a potential target for 
helping cancer patients manage their pain. Finally, IL-6 associated with weight 
loss within this study, and this finding while not new, highlights the fact that the 
IL-6 is integral to the metabolic derangements that promote cachexia.  
 
 
 
Strengths and Limitations 
  
 
Strengths  
This dissertation research is unique in the fact that it is the first known 
study to examine the relationship between cytokines and the development of 
long-term symptoms in head and neck cancer patients. The long-term 
development of symptoms and the effects on patient’s lives is not well 
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understood. A predominance of studies within the HNC literature are short term 
studies that examine how cytokines effect outcome and symptoms generally over 
three to six months during cancer treatment. Overall, the study population within 
this group matched other HNC cohorts in terms of age, gender and race. 
Furthermore, this study examined the relationship between RBCs, albumin and 
cytokines. No studies examining these correlates within HNC have been found. 
Several of the instruments utilized within this study demonstrated sound internal 
consistency and test-retest reliability. Overall, this was a unique study that will be 
able to inform several future studies.  
Limitations  
One of the paramount weaknesses of this study was the fact that it was a 
secondary analysis. While the parent study utilized in this secondary analysis 
examined the development, nature, progression and prevalence of late-effect 
fibrosis and/or lymphedema as well as biological correlates such as cytokines 
and genetic polymorphisms and psychological stressors in patients with head 
and neck cancer, this study analyzed data specific to cachexia and potential long 
term effects of cytokines on symptom development. A limitation of this study was 
that the original purpose of the study was not intended to specifically answer the 
questions posited in this dissertation. However, the original study evaluated HNC 
patients and this dissertation continued to focus on HNC patients. Another 
limitation of this study was the small number of participants (N=56). While this 
matches other HNC studies, it may not have been large enough to see the 
effects of cytokines on symptom development and musculoskeletal dysfunction. 
Furthermore, due to the multiple associations conducted during this study, it is 
 147 
possible that the findings were simply statistical “noise”. This is evident in that 
many scores overall had a low median baseline score, such as pain, without 
significant associations with pain and baseline cytokines and the changes in 
those cytokines over 6- and 12-months. Additionally, it appears that the CROM 
may not be the best measure of musculoskeletal dysfunction in this patient 
population. Due the nature of this secondary analysis, as well as understanding 
the fact that patients received physical therapy and corrective posture instruction, 
it will be difficult to interpret those results.   
 
 
 
Implications 
 
 
 Generally, the trend for patients within this study was improvement in their 
overall symptoms burden at both 6- and 12-months post-treatment. These overall 
findings indicate that eradication of the tumor burden appears to positively impact 
patients. This correlates with the theory that the tumor initiates the metabolic 
derangements that the body experiences. Through the removal of the tumor, this 
tumor burden decreases and the body is able to return to homeostasis. As the 
body returns to homeostasis, the body is able to heal and symptoms burden 
declines.  This knowledge can help nurses and providers work with their patients 
as they progress through the cancer treatment spectrum and enter into their 
post-treatment phase. 
 The association with IL-10 and IFN-y and negative outcomes within this 
study supports relatively new research indicating that these two cytokines 
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negatively affect cancer patients. This study demonstrates that there is also an 
association with symptoms even during the recovery period following treatment. 
These findings, in conjunction with other findings, could be utilized to specifically 
conduct animal studies to determine the biological processes that promote the 
interplay between these two cytokines. Through this research, it is possible that 
future translational research at the bedside could be conducted to help providers 
thwart the many negative symptoms that accompany cancer.  
Nurses are excellent patient advocates that utilize scientific evidence to 
implement holistic nursing care plans aimed at improving patient’s symptoms and 
quality of life. Understanding which patients are at the highest risk for having 
long-term difficulties with symptoms is a venue through which nurses can provide 
this important holistic care. While the applicability of cytokines and RBCs on 
long-term symptom development is not fully understood, this study demonstrated 
that low albumin levels at the time of enrollment generally correlated with more 
difficulty long-term with symptom problems surrounding nutrition and swallowing. 
These study findings correlate with other cancer studies (Gupta and Lis, 2010). 
Nurses can apply the knowledge of albumin directly to patient care today by 
identifying those patients with low albumin levels and initiating nursing care plans 
that may help promote healing with a focus on improving symptoms.  Through 
this endeavor it may be possible help HNC patients recover from their illnesses 
more effectively. Nurse practitioners may also utilize the knowledge from this and 
similar research to help treat cancer patients.  
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It is possible that nurse practitioners may someday be utilizing the 
measurement of some cytokines to help direct the care and treatment of their 
patients. For example, the result that IL-1β appears to drive pain over a 12-month 
period could potentially be utilized by the nurse practitioner to treat pain in the 
future once a further understanding of the biological processes that promote IL 
are further understood. This knowledge may help the nurse practitioner direct the 
prescribing of pain medications with the understanding that patients with higher 
IL-1β may actually have increased pain medication needs for a longer period 
when compared to those with lower IL-1β levels. It will be important to continue 
with studies of associations with cytokines and symptoms so that future 
translational research can be conducted at the bedside to help promote healing 
and recovery for patients with HNC.  
 
Recommendations for Future Research 
 
 
Presently, there are six domains that will require future research: 1) further 
evaluation of cytokines in a larger sample, 2) genetics, 3) cancer associations, 4) 
viral verses non-viral, 5) translational research, 6) the role of RBCs in cancer.   
Larger Sample: Several findings within this study were statistically 
significant. A larger sample size investigating initial cytokine levels and long-term 
symptom development is warranted based upon these results. Through such 
studies, it may be possible to further highlight the associations between cytokines 
and symptoms. This knowledge could ultimately direct laboratory research that 
examines the biological pathways and influences of these cytokines, which may 
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help to distinguish the pathways through which these cytokines influence 
symptom development. These studies may identify cytokines that can be 
targeted from a therapeutic perspective with the ultimate goal of helping to 
decrease symptom burden in the cancer patient.  
Genetics: The scientific understanding of the role that genetics have within 
health continues to increase. Future studies need to continue to examine the 
genetic differences within individuals’ production of cytokines under various 
illnesses including cancer. Through further understanding of these factors, it may 
be possible to highlight the cytokines that give survival advantage in some 
diseases and perhaps not in others.  
Cancer associations: Cancer by its very nature is heterogeneous. 
However, cancers cannot remain within their silos if we are to develop a sound 
understanding of cachexia and the role of cytokines in cancer. To understand the 
differences and similarities in symptom development, a study following cytokines 
and symptoms in other cancers over a long time period should occur. Through 
this research, it may be possible to identify the common links between negative 
and positive symptom development in all cancers.  
Viral verses non-viral: Evidence continues to increase that many cancers 
are virally mediated. Are there certain cytokine mediators that can attenuate the 
development of cancer and or the development of cachexia and other negative 
cancer symptoms in virally induced cancers? Further large-scale examinations of 
the differences in these cancers need to occur to inform our understanding of the 
pathways of not only cancer progression, but also the progression of cachexia.  
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Translational research: Throughout the research that comprised much of 
this dissertation, what became clear is that the many studies that have been 
conducted surrounding cachexia have not made its way to the nurse or medical 
provider at the bedside. While there is no curative modality available to stop 
cachexia, there are other ideas that could inform how patients are treated 
presently. Through better understanding of cytokines and cachexia by bedside 
providers it may be possible to provide better treatment.  
The role of RBCs in cancer: This study provided some very interesting 
associations with initial higher levels of RBCs and worse long-term symptoms. 
Future studies examining this association need to occur. It is possible that these 
findings were secondary to the multiple associations conducted during this 
analysis. However, these findings support recent recommendations to not 
transfuse chronically ill patients with hemoglobin levels greater than 7.  
 
Summary 	  	  
 This dissertation study was a secondary analysis of data from a four-year 
prospective longitudinal, descriptive study that was recently completed. The 
following assumptions guided this study: 1) many patients with HNC develop 
cachexia; 2) the physiological underpinnings of cachexia in this population are 
not well articulated; 3) inflammatory processes contribute to cachexia; 4) other 
symptoms besides weight loss can accompany cachexia; and 5) long-term 
associations between baseline cytokines and symptoms progression are not well 
understood. In order to examine these assumptions, this secondary analysis 
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examined cytokines, red blood cells (RBCs), albumin and changes in symptoms 
and weight over a 12-month period. It assessed how changes in cytokines over 
time correlated with variables of cachexia and cancer symptoms as well as 
changes in musculoskeletal functioning over the 12-month period. 
 Overall, symptom burden declined over the 6- and 12-month period in 
patients.  As cytokine levels decreased, so too did symptoms. However, a 
interesting finding was obtained with patients who had higher levels of RBCs at 
baseline. Higher RBCs were correlated with worse symptoms burden at 6- and 
12-month, such as with swallowing and pain.  A further exploration of these 
results will need to be conducted.  
 Cachexia and symptom burden in head and neck cancer patients is an 
understudied area of research. This study resulted in associations between 
cytokines, RBCs and albumin levels with changes in symptoms. Further studies 
and explorations of these results will need to be conducted to clarify these results 
to further the understanding of cachexia and cytokines in head and neck cancer 
patients.  
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Appendix 
Cervical Range of Motion (CROM)    
VISIT _____________ 
 
The subject’s CROM parameters: 
(1) Forward flexion________degrees  (normal: 0-45 degrees) 
(2) Extension ____________ degrees  (normal: 0-45 degrees) 
(3) Left lateral flexion_____  degrees  (normal: 0-45 degrees) 
(4) Right lateral flexion____  degrees  (normal: 0-45 degrees) 
(5) Left lateral rotation_____degrees  (normal: 0-80 degrees) 
(6) Right lateral rotation____degrees (normal: 0-80 degrees) 
______________________________________________________________ 
 
 (1) Forward flexion________degrees  (normal: 0-45 degrees) 
(2) Extension ____________ degrees  (normal: 0-45 degrees) 
(3) Left lateral flexion_____  degrees  (normal: 0-45 degrees) 
(4) Right lateral flexion____  degrees  (normal: 0-45 degrees) 
(5) Left lateral rotation_____degrees  (normal: 0-80 degrees) 
(6) Right lateral rotation____degrees (normal: 0-80 degrees) 
 
 
Please check the following symptoms if the subject has them: 
Pain____, weakness____, spasm____, tenderness____, lack of endurance____  
Postural abnormalities____, fixed deformity of cervical spine musculature__
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Head and Neck Disease and 
Treatment Additional Information 
Form 
 
 
Primary Specific Tumor Location  
_____   
____________________________ 
Secondary Specific Tumor 
Location  
_____   
____________________________ 
Tertiary Specific Tumor Location  
_____   
____________________________ 
 
Cancer Type  
(Type of Cancer according to 
Pathology) 
___(1) Squamous Cell Carcinoma   
___(2) Nasopharyngeal Carcinoma 
___(3) Salivary Duct Carcinoma 
___(4) Acinic Cell Carcinoma 
___(5) Spindle Cell Carcinoma 
___(6) Olfactory Neuroblastoma 
(esthesioneuroblastoma) 
___(7) Adenoid Cystic Carcinoma 
___(8) Buccal Cell Carcinoma 
___(9) Adenocarcinoma 
___(10) Mucoepidermoid Carcinoma 
___(11)Teratoma 
___(12) Carcinoma, Unknown Type  
___(13) 
Other_______________________  
______ 
Other_______________________ 
 
Local Metastasis 
___(0) No 
___(1) Yes 
Date of Diagnosis: ___/___/____ 
Type:  
___(1) Squamous Cell Carcinoma   
___(2) Nasopharyngeal Carcinoma 
___(3) Salivary Duct Carcinoma 
___(4) Acinic Cell Carcinoma 
___(5) Spindle Cell Carcinoma 
___(6) Olfactory Neuroblastoma 
(esthesioneuroblastoma) 
___(7) Adenoid Cystic Carcinoma 
___(8) Buccal Cell Carcinoma 
___(9) Adenocarcinoma 
___(10) Mucoepidermoid Carcinoma 
___(11)Teratoma 
___(12) Unknown  
___(13) 
Other_______________________  
______ 
Other_______________________ 
Location: 
___(1) Neck 
___(2) Lungs 
___(3) Bone  
___(4) Other 
_______________________ 
______ 
Other________________________ 
 
Distant Metastasis 
___(0) No 
___(1) Yes 
Date of Diagnosis: ___/___/____ 
Type:  
___(1) Squamous Cell Carcinoma   
___(2) Nasopharyngeal Carcinoma 
___(3) Salivary Duct Carcinoma 
___(4) Acinic Cell Carcinoma 
___(5) Spindle Cell Carcinoma 
___(6) Olfactory Neuroblastoma 
(esthesioneuroblastoma) 
___(7) Adenoid Cystic Carcinoma 
___(8) Buccal Cell Carcinoma 
___(9) Adenocarcinoma 
___(10) Mucoepidermoid Carcinoma 
___(11)Teratoma 
___(12) Unknown  
 2 
___(13) 
Other_______________________  
______ 
Other_______________________ 
Location: 
___(1) Neck 
___(2) Lungs 
___(3) Bone  
___(4) Other 
_______________________ 
______ 
Other________________________ 
 
Known Lymphatic Spread 
___(0) No 
___(1) Yes 
 
 
 
 
 
 
 
 
 
 
 
 
Tumor-Expressed Virus 
___(0) No known virus 
___(1) HPV 
___(3) EBV 
___(8) Other 
________________________ 
 
Known Viral Infection 
___(0) No known virus 
___(1) Human Papilloma Virus 
(HPV) 
___(2) HIV 
___(3) Epstein-Barr Virus (EBV) 
___(4) Cytomegalovirus (CMV) 
___(5) Herpes Simplex Virus (HSV) 
___(6) Hepatitis C (HCV) 
___(7) Other Herpes 
virus_____________ 
___(8) Other  
virus___________________ 
___(9) Hepatitis A (HAV) 
___(10) Hepatitis B (HBV) 
___(11) Hepatitis, Unknown type 
______ 
Other_______________________ 
 
Secondary Known Viral Infection 
___(0) No known virus 
___(1) Human Papilloma Virus 
(HPV) 
___(2) HIV 
___(3) Epstein-Barr Virus (EBV) 
___(4) Cytomegalovirus (CMV) 
___(5) Herpes Simplex Virus (HSV) 
___(6) Hepatitis C (HCV) 
___(7) Other Herpes 
virus_____________ 
___(8) Other  
virus___________________ 
___(9) Hepatitis A (HAV) 
___(10) Hepatitis B (HBV) 
___(11) Hepatitis, Unknown type 
______ 
Other_______________________ 
1 	  
 
 
Head and Neck Cancer 
Medical Record Extraction-To be used if unable to pull directly from 
electronic record. 
 
Date of diagnosis:  _________________ 
 
 
Medical History: 
 
Cardiovascular 
 
 
 
 
 
 
Excretory 
 
 
 
 
 
 
Digestive 
 
 
 
 
 
 
Respiratory 
 
 
 
 
 
 
Integumentary 
 
 
 
 
 
 
 2 
 
Nervous 
 
 
 
 
 
 
Skeletal 
 
 
 
 
 
 
Muscular 
 
 
 
 
 
 
Endocrine 
 
 
 
 
 
 
Reproductive 
 
 
 
 
 
 
 
Immune 
 
 
 
 
 
 
 
 
 3 
Type of treatment [check all that apply] 
 
q  Radiation  q   Chemotherapy  q   Biopsy      q  Surgery 
 
 
Date of 
Biopsy: 
 
 
Dates of 
Chemotherapy: 
 
 
Dates of 
Radiation: 
 
 
Stage HNC   Site of HNC 
q   1    q   Larynx 
q   2    q   Pharynx 
q   3    q   Oral Cavity 
q   4    q   Salivary Glands 
    q   Perinasal Sinus 
q   Other___________________   
 
 
Total Radiation 
Dose: 
 
 
Schedule of Radiation Therapy (days on/off, etc.) 
 
 
 
 
 
 
 
 
Structures within Radiation Field: (check all that apply) 
 
Structure Check Structure Check 
Base of Tongue    
Posterior Pharyngeal Wall    
Epiglottis    
Pharyngoepiglottic Folds    
Aryepiglottic  Folds    
 4 
Interarytenoid Space    
Cricopharyngeal 
Prominence 
   
Arytenoids    
False Vocal Folds    
True Vocal Folds    
Anterior Commissure    
Surgery 
 
Type Date 
  
  
  
  
 
Medication regimen at time of study enrollment and during study:  
 
Drug Dose Frequency 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
   
 5 
 
 
 
  
 
 
  
 
 
  
 
 
  
Performance Status at each study assessment 
 
 Notes Date 
Baseline   
EOT   
6wk   
12wk   
18wk   
24wk   
30wk   
36wk   
42wk   
15mth   
18mth   
 
Infection/Injury at each study assessment 
 
 
Notes Date 
Baseline 
 
  
EOT 
 
  
6wk 
 
  
12wk 
 
  
18wk 
 
  
24wk 
 
  
 6 
30wk 
 
  
36wk 
 
  
42wk 
 
  
15mth 
 
  
18mth 
 
  
Toxicity Criteria at Each Visit 
 
 Notes Date 
Baseline 
 
 
  
EOT 
 
 
  
6wk 
 
 
  
12wk 
 
 
  
18wk 
 
 
  
24wk 
 
 
  
30wk 
 
 
  
36wk 
 
 
  
42wk 
 
 
  
15mth 
 
 
  
18mth 
 
 
  
 7 
 
Comments  
 
 
 
 
 
 
CT Findings 
 
 
Date 
 
Findings 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Barium Swallow Results 
 
 
 
Notes Date 
Baseline 
 
 
 
 
 
 
  
48wk 
 
 
 
 
  
 8 
 
 
 
18mth 
 
 
 
 
 
 
  
 
 9 
Laryngoscopy Results 
 
  
Notes 
 
Date 
 
Baseline   
EOT   
6wk   
12wk   
18wk   
24wk   
30wk   
36wk   
42wk   
15mth   
18mth   
 
 
 
 
 
 
 
 
 10 
CESD 
 
Below is a list of ways you might have felt or behaved. Please tell me how often 
you have felt this way during the past week. 
  
 Hardly 
ever or 
none of 
the time 
(less than 
1 day) 
Some or a 
little of the 
time (1-2 
days) 
Occasionally 
or a moderate 
amount of the 
time (3-4 
days) 
Most or all 
of the time 
(5-7days) 
1. I was bothered by things that usually 
don’t bother me. 
 
0 1 2 3 
2. I did not feel like eating; my appetite 
was poor. 
 
0 1 2 3 
3. I felt that I could not shake off the 
blues even with help from my family 
or friends. 
0 1 2 3 
4. I felt I was just as good as other 
people. 
 
0 1 2 3 
5. I had trouble keeping my mind on 
what I was doing. 
 
0 1 2 3 
6. I felt depressed.  
 
 
0 1 2 3 
7. I felt that everything I did was an 
effort.  
 
0 1 2 3 
8. I felt hopeful about the future. 
 
 
0 1 2 3 
9. I thought my life had been a failure. 
 
 
0 1 2 3 
10. I felt fearful. 
 
 
0 1 2 3 
11. My sleep was restless.  
 
 
0 1 2 3 
12. I was happy.  
 
0 1 2 3 
 11 
 
 
 
 
13. I talked less than usual. 
 
 
0 1 2 3 
14. I felt lonely.  
 
 
0 1 2 3 
15. People were unfriendly.  
 
 
0 1 2 3 
16. I enjoyed life.  
 
 
0 1 2 3 
17. I had crying spells. 
 
0 1 2 3 
18. I felt sad.  
 
 
0 1 2 3 
19. I felt that people disliked me.  
 
 
0 1 2 3 
20. I could not get "going".  
 
 
0 1 2 3 
1 	  
Patient Interview; 
1. What is your birthdate?     ____/____/_______ (month/day/year) 
 
2. Gender:  
(1) Female___(2) Male____ 
(3) Other____(4) Do not care to respond___ 
 
3. What is your race? 
(1) American Indian/Alaskan Native____   
(2) Asian____   
(3) Native Hawaiian or Other Pacific Islander 
      _____ 
(4) Black or African American_____ 
(5) White_____ 
Nation of Origin: _______________ 
 
4. What is the highest grade of education you completed? (Please circle) 
 1      2     3     4     5     6    7    8    9   10   11 12 (high school) 13  14    15   16  
(college)      
17  18  (master)  19  20  (doctorate) 
 
5. What is your marital status?  
(1) Single____    
(2) Single, living with partner_____          
(3) Married_____ 
(4) Widowed____    
(5) Other____ 
 
6. What is your current employment status? 
(1) Employed full time____      
(2) Employed part time____     
(3) Homemaker____  
(4) Retired_____                         
(5) Unemployed_____                  
(6) Other____ 
Vocation_____________________________ 
 
7. What best describes your area of residence? 
(1) City___ (2) Country ___ (3) Other___ 
 2 
Chart Review 
 
 
8. Health Maintenance 
8.1 Smoking/Dipping/Chewing 
(1) No  ____ 
(2) Yes ___(Tobacco__or Marijuana__or ___) 
   _____years _____ cigarettes per day  
   _____ dips per day ____ plugs/chaw per day 
(3) Quit _____When____________ 
(4) Not Quit ______  
_____cigarettes per day (Current) 
 
 
8.2 Drinking Alcohol 
(1) No ____ 
(2) Yes ____ 
_____years _____ times per week 
(3) Quit ______When__________ 
(4) Not Quit ______ 
_____ times per week (Current) 
 
9. What is your insurance coverage? 
(1) Medicare____ (2) Medicaid____  
(3) TennCare____ (4) Private Insurance____ 
(5) HMO____         (6) None_____                      
(7) Other_____ 
 
10. Do you have any medical problems?  
(1) No 
(2) Yes (e.g., HBP, DM, Obesity, Injury History) 
_____________________________________ 
 
11. What is your yearly household income? 
(1) $10,000 or less____      
(2) $10,001 to $ 20,000____    
(3) $20,001 to $ 30,000____ 
(4) $30,001-$40,000___     
(5) $ 40,001 to $50,000____    
(6) $50,001 to $60,000 ____ 
(7) Over $60,000____         
(8) Do not care to respond____ 
 
 
 
 3 
The Vanderbilt Head and Neck Cancer Symptom Survey (version 2.0)  
Name:______________________- 
_________________________________Date:_______________  
Directions: Please answer the following questions by checking the appropriate box.  
1. I currently have a feeding tube in place. ⁮ Yes ⁮ No 2. I have teeth ⁮ Yes ⁮ No 
3. I use dentures ⁮ Yes ⁮ No  
Directions: Please read all questions and circle the number that best describes your 
symptoms over the past week. In general, a “0” indicates the least amount of problems 
with a particular symptom and “10” indicates the most problems.  
1. I have been losing weight  
0 1 2 3 4 5 6 7 8 9 None  
2. I have lost my appetite  
0 1 2 3 4 5 6 7 8 9 Normal  
10 
A lot  
10 
No appetite  
3. I have to use liquid supplements (like Ensure® or Boost®) to maintain my weight  
0 1 2 3 4 5 6 7 8 9 None  
supplements  
4. I have trouble maintaining my weight because of swallowing problems  
0 1 2 3 4 5 6 7 8 9 None  
10 
All liquid  
10 
A lot  
5. I have trouble eating certain solid foods (like hard to chew, crumbly, or sticky foods)  
0 1 2 3 4 5 6 7 8 9 None  
6. I have trouble drinking thin liquids (like water, tea and Ensure®)  
 4 
10 
A lot  
10 
A lot  
10 Always  
10 Always  
0 1 2 3 4 None  
7. Food gets stuck in my mouth  
0 1 2 3 4 Never  
8. Food gets stuck in my throat  
0 1 2 3 4 Never  
9. I choke or strangle on liquids  
5 6 7 8 9  
5 6 7 8 9  
5 6 7 8 9  
0 1 2 3 4 5 6 7 8 9 10  
Never  
10. I choke or strangle on solid foods  
0 1 2 3 4 Never  
11. I cough after I swallow  
0 1 2 3 4 Never  
12. Swallowing takes great effort  
0 1 2 3 4 Never  
Always  
5 6 7 8 9 10 Always  
5 6 7 8 9 10 Always  
 5 
5 6 7 8 9 10 Always  
13. It takes me longer to eat because of my swallowing problem  
0 1 2 3 4 5 6 7 8 9 10 Never Always  
14. I have problems with dry mouth  
0 1 2 3 4 5 6 7 8 9 10 Never Severe  
15. Problems with dry mouth make chewing and swallowing difficult  
0 1 2 3 4 5 6 7 8 9 10 Never Always  
16. Problems with dry mouth affect my ability to sleep  
0 1 2 3 4 5 6 7 8 9 10 Never Always  
17. Problems with dry mouth affect my ability to talk  
0 1 2 3 4 5 Never  
18. I have thick mucous or phlegm  
0 1 2 3 4 5 Never  
19. Mucous causes me to choke or gag  
0 1 2 3 4 5 Never  
20. Mucous causes difficulty swallowing  
0 1 2 3 4 5 Never  
21. Mucous causes difficulty sleeping  
0 1 2 3 4 5 Never  
6 7 8 9 10 Always  
6 7 8 9 10 Always  
6 7 8 9 10 Always  
6 7 8 9 10 Always  
6 7 8 9 10 Always  
22. I have sores in my mouth or throat that cause pain  
 6 
0 1 2 3 4 5 6 7 8 9 No Pain  
23. Mouth or throat pain causes difficulty swallowing  
0 1 2 3 4 5 6 7 8 9 Never  
24. Mouth or throat pain causes difficulty speaking  
0 1 2 3 4 5 6 7 8 9 Never  
10 
Severe pain  
10 Always  
10 Always  
10 
Severe pain  
10 
Severe pain  
25. My average pain level over the last week has been.....  
0 1 2 3 4 5 6 7 No pain  
26. My worst pain level over the last week has been....  
0 1 2 3 4 5 6 7 No pain  
27. The average relief from my pain medication is....  
pain medications  
0 1 2 3 4 5 6 7 No relief  
28. Pain causes difficulty sleeping  
0 1 2 3 4 5 6 7 Never  
29. I have trouble speaking  
0 1 2 3 4 5 6 7 Never  
30. My voice is hoarse  
0 1 2 3 4 5 6 7 Not at all  
 7 
8 9 8 9  
31. I have trouble being understood because of my speaking or hoarse voice  
0 1 2 3 4 5 6 7 8 9 Never  
32. I have trouble with my hearing  
0 1 2 3 4 5 6 7 8 9 None  
33. My taste is altered  
0 1 2 3 4 5 6 7 8 9 None  
34. I have less desire to eat due to taste change  
0 1 2 3 4 5 6 7 8 9 Never  
10 Always  
10 Severe  
10 
A lot  
10 Always  
⁮ Not Applicable, I am not on  
8 9  
8 9  
8 9  
8 9  
10 
Total relief  
10 Always  
10 Always  
10 
Very Hoarse  
35. My taste changes have altered the foods that I choose to eat  
0 1 2 3 4 5 6 7 8 9 Never  
 8 
36. My taste changes have caused me to decrease the amount of food I eat  
0 1 2 3 4 5 6 7 8 9 Never  
37. My sense of smell has changed  
0 1 2 3 4 5 6 7 8 9 Not at all  
38. I have altered what I eat due to a change in my sense of smell  
0 1 2 3 4 5 6 7 8 9 Not at all  
10 Always  
10 Always  
10 
Very much  
10 
Very much  
39. I have difficulty chewing because of my teeth or dentures...⁮ Not applicable, I do  
not have teeth or dentures  
0 1 2 3 4 5 6 7 8 9 10 None Severe  
40. My teeth are sensitive to hot, cold or sweet foods ⁮ Not applicable, I do not have  
teeth  
0 1 2 3 4 5 6 7 8 9 Not at all  
41. My teeth feel looser ⁮ Not applicable, I do not have teeth  
0 1 2 3 4 5 6 7 8 9 Not at all  
10 
Very Sensitive  
10 
Very Loose  
42. My teeth are cracking or chipping ⁮ Not applicable, I do not have teeth  
0 1 2 3 4 5 6 7 8 9 10 Not at all Severe  
43. I have trouble with my dentures ⁮ Not applicable, I do not have dentures  
 9 
0 1 2 3 4 5 6 7 8 9 None  
44. I have a burning sensation in the lining of my mouth and throat  
0 1 2 3 4 5 6 7 8 9 None  
10 
A lot  
10 
Very Painful  
45. The lining of my mouth and throat is sensitive to spicy, hot or acidic foods  
0 1 2 3 4 5 6 7 8 9 Not at all  
46. The lining of my mouth and throat is sensitive to dryness  
0 1 2 3 4 5 6 7 8 9 Not at all  
47. Burning pain in the lining of my mouth and throat changes what I eat  
10 
Very Sensitive  
10 
Very Sensitive  
0 1 2 3 4 5 6 7 8 9 10 Never Always  
48. Burning pain in the lining of my mouth and throat prevents me from brushing my 
teeth  
0 1 2 3 4 5 6 7 8 9 10 Never Always  
49. I have limitations in the ability to open or move my jaw  
0 1 2 3 4 5 6 7 8 9 10 Never Severe  
50. I have limitations in the ability to move my neck and shoulders  
0 1 2 3 4 5 6 7 8 9 10 Never Severe  
 
